





































































Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic 
Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human 
Services. 
 
This information is distributed solely for the purpose of pre dissemination public comment under 
applicable information quality guidelines.  It has not been formally disseminated by the Agency for Toxic 
Substances and Disease Registry.  It does not represent and should not be construed to represent any 
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This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary. 
 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is 
also presented, but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced. 
 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a public health statement that describes, in nontechnical language, a substance's relevant 
toxicological properties.  Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance's health effects is described in a health effects summary.  Data needs that are of 
significance to the protection of public health are identified by ATSDR and EPA. 
 
Each profile includes the following: 
 
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects; 
 
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and 
 
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans. 
 
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.  We plan to 
revise these documents in response to public comments and as additional data become available.  
Therefore, we encourage comments that will make the toxicological profile series of the greatest use. 
 
Electronic comments may be submitted via: www.regulations.gov. 
Follow the on-line instructions for submitting comments. 
 
Written comments may also be sent to:  
 Agency for Toxic Substances and Disease Registry 
 Division of Toxicology and Human Health Sciences 
 Environmental Toxicology Branch 
 
Regular Mailing Address: Physical Mailing Address: 
1600 Clifton Road, N.E. 4770 Buford Highway 
Mail Stop F-57 Building 102, 1st  floor, MS F-57 



























The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute. This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the 
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for 
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA 
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise 
necessary to support the site-specific response actions conducted by ATSDR.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel 
and is being made available for public review.  Final responsibility for the contents and views expressed 
in this toxicological profile resides with ATSDR.
Patrick N. Breysse, Ph.D., CIH
 
Director, National Center for Environmental Health and
 
Agency for Toxic Substances and Disease Registry 

Centers for Disease Control and Prevention 







QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances may find the following information helpful for fast 
answers to often-asked questions. 
 
 
Primary Chapters/Sections of Interest 
 
Chapter 1:  Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
 
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
 
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (e.g.,death, systemic, immunologic, reproductive), by route of exposure, and by 
length of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies 
are reported in this section.  
 NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting.  Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
 
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues: 
 Chapter 1 How Can (Chemical X) Affect Children? 
 
 Chapter 1 How Can Families Reduce the Risk of Exposure to (Chemical X)? 
 
 Section 3.8 Children’s Susceptibility 
 
 Section 6.6 Exposures of Children 
 
 
Other Sections of Interest: 
 Section 3.9  Biomarkers of Exposure and Effect 
 Section 3.12  Methods for Reducing Toxic Effects 
 
 
ATSDR Information Center  
 Phone:   1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)   
 Internet:  http://www.atsdr.cdc.gov 
 
The following additional materials are available online: 
 
Case Studies in Environmental Medicine are self-instructional publications designed to increase primary 
health care providers’ knowledge of a hazardous substance in the environment and to aid in the 














Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident (see https://www.atsdr.cdc.gov/MHMI/index.asp).  Volumes I and II are planning guides 
to assist first responders and hospital emergency department personnel in planning for incidents 
that involve hazardous materials.  Volume III—Medical Management Guidelines for Acute 
Chemical Exposures—is a guide for health care professionals treating patients exposed to 
hazardous materials. 
 




Other Agencies and Organizations 
 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 
30341-3724 • Phone:  770-488-7000 • FAX:  770-488-7015 • Web Page:  
https://www.cdc.gov/nceh/. 
 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 395 E Street, S.W., Suite 9200, 
Patriots Plaza Building, Washington, DC 20201 • Phone:  202-245-0625 or 1-800-CDC-INFO 
(800-232-4636) • Web Page: https://www.cdc.gov/niosh/. 
 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 




Clinical Resources (Publicly Available Information) 
 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:  
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266 • Web Page:  
http://www.acoem.org/. 
 
The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with 


















    
 
 
    
 
     
   
 
   
 
     
 
ixMOLYBDENUM
Suite 200-111, Phoenix AZ 85028 • Phone: 844-226-8333 • FAX:  844-226-8333 • Web Page:
http://www.acmt.net.
The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists 
who respond to questions from public health professionals, clinicians, policy makers, and the
public about the impact of environmental factors on the health of children and reproductive-aged
adults.  Contact information for regional centers can be found at http://pehsu.net/findhelp.html.
The American Association of Poison Control Centers (AAPCC) provide support on the prevention and 
treatment of poison exposures.  Contact:  AAPCC, 515 King Street, Suite 510, Alexandria VA
22314 • Phone: 701-894-1858 • Poison Help Line: 1-800-222-1222 • Web Page:
http://www.aapcc.org/.
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
 
 
1.	  Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
 
2.	  Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
 
3.	  Data Needs Review.  The Environmental Toxicology Branch reviews data needs sections to 
assure consistency across profiles and adherence to instructions in the Guidance. 
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A peer review panel was assembled for molybdenum.  The panel consisted of the following members:  
 
1.	  John Meeker, Sc.D., C.I.H., Professor, Environmental Health Sciences, Associate Dean for 
Research, School of Public Health, University of Michigan, Ann Arbor, Michigan; 
 
2. 	 Alexander V. Lyubimov, M.D., Ph.D., D.A.B.T., Toxicology Research Laboratory, Chicago, 
Illinois; and 
 
3. 	 Dagobert Heijerick, ARCHE consulting, Gent, Belgium. 
 
These experts collectively have knowledge of molybdenum’s physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.   
 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
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1MOLYBDENUM
1. PUBLIC HEALTH STATEMENT FOR MOLYBDENUM
This Public Health Statement summarizes the Agency for Toxic Substances and Disease Registry’s 
(ATSDR) findings on molybdenum, including chemical characteristics, exposure risks, possible health
effects from exposure, and ways to limit exposure.
The U.S. Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the
nation. These sites make up the National Priorities List (NPL) and are sites targeted for long-term federal
clean-up activities.  The EPA has found molybdenum in at least 86 of the 1,832 current or former NPL
sites.  The total number of NPL sites evaluated for molybdenum is not known.  But the possibility
remains that as more sites are evaluated, the sites where molybdenum is found may increase. This 
information is important because these future sites may be sources of exposure, and exposure to 
molybdenum may be harmful.
If you are exposed to molybdenum, many factors determine whether you’ll be harmed.  These include
how much you are exposed to (dose), how long you are exposed (duration), how often you are exposed 
(frequency), and how you are exposed (route of exposure).  You must also consider the other chemicals
you are exposed to and your age, sex, diet, family traits, lifestyle, and state of health.
WHAT IS MOLYBDENUM?
Molybdenum is a chemical element with the symbol Mo.  Pure molybdenum exists as a dark-gray or
black powder with a metallic luster or as a silvery-white mass.  It does not occur naturally in the pure 
metallic form.  It is principally found as oxide or sulfide compounds.  Therefore, almost all exposure is to 
a molybdenum compound rather than the actual metal alone.  Important naturally occurring molybdenum
compounds are the minerals molybdenite, powellite, wulfenite, ferrimolybdite, and ilsemannite.  
Molybdenum has a very high melting point and it is used widely in industry to make steel alloys.
Molybdenum occurs naturally in all plants and animals.  Low levels of molybdenum are required for good 
health in humans and animals.  
WHAT HAPPENS TO MOLYBDENUM WHEN IT ENTERS THE ENVIRONMENT?
Molybdenum can enter the environment through releases from mining, milling, and smelting operations
and coal-fired power plants. The primary source of molybdenum in air is from coal combustion.  
***DRAFT FOR PUBLIC COMMENT***
   
 










       
 
       
   
 
 






     
  
 




    
    
       
     
 
    
  
     
    
 
2MOLYBDENUM
1.  PUBLIC HEALTH STATEMENT
Molybdenum released to the air will settle to the ground by gravity or in rain and snow.  Molybdenum
can also be directly released into surface water. When molybdenum is released into soil or water, it can 
become attached to the organic material and other components (such as clay, sand, etc.) in the top layers 
of the soil or in the water and may not move far from where it is released. The soil conditions, especially
the acidity of the soil, will influence the binding of molybdenum to soil and sediment.  Molybdenum does
not break down in the environment.  
HOW MIGHT I BE EXPOSED TO MOLYBDENUM?
Molybdenum is common in the environment.  The primary way that you may be exposed to molybdenum
is by eating food containing molybdenum.  Grains, legumes, nuts, and dairy products have the highest
levels of molybdenum.  You may also be exposed to molybdenum in some nutritional supplements.  You 
may be exposed to small amounts of molybdenum by breathing air, by drinking water, and by skin 
contact with soil and water. You may be exposed to higher levels of molybdenum in drinking water if
you live near industries using molybdenum and the industries release molybdenum into the waterways.
HOW CAN MOLYBDENUM ENTER AND LEAVE MY BODY?
Molybdenum can enter your body when you breathe air, drink water, or eat food containing molybdenum.  
When you breathe air containing molybdenum, molybdenum particles can be deposited in your lungs.  
Some of these particles can be coughed up and swallowed.  Particles deposited deeper in the lungs are
likely to pass through the lining of the lungs and enter the bloodstream.  Some of the molybdenum in the
lungs may stay there for years. At least half of ingested molybdenum will enter the bloodstream. The
amount of molybdenum absorbed depends on what other food and beverages are ingested. We do not
have any information on whether molybdenum can enter the body through the skin.  Molybdenum in the
blood will be distributed throughout the body, with the highest amounts found in the liver and kidneys.  
Molybdenum leaves your body in urine and feces, mostly in urine.  Generally, the amount of
molybdenum in your body remains constant (the amount that enters your body equals the amount that
leaves).  More information on how molybdenum enters and leaves the body is presented in Chapter 3.
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1.  PUBLIC HEALTH STATEMENT
HOW CAN MOLYBDENUM AFFECT MY HEALTH?
Molybdenum is essential for good health.  An intake of 45 micrograms of molybdenum per day (μg/day)
is recommended for adults.  On average, adults in the United States ingest 76–109 μg molybdenum per
day.  
Exposure to high levels of molybdenum can be harmful.  Long-term exposure of rats and mice to 
molybdenum dust in the air can cause damage to the nasal cavity, epiglottis, and lungs. Studies in 
animals suggested that ingesting large amounts of molybdenum, at least 1,000 times higher than needed 
for health may damage the male and female reproductive system and might cause kidney and liver
damage.
A study in mice provides some evidence that exposure to inhaled molybdenum can result in lung cancer.
Molybdenum has not been classified as to carcinogenicity by the Department of Health and Human 
Services (HHS), the International Agency for Research on Cancer (IARC), or EPA.
More detailed information on the health effects of molybdenum in humans and animals can be found in 
Chapter 3.
HOW CAN MOLYBDENUM AFFECT CHILDREN?
This section discusses potential health effects of molybdenum exposure in humans from when they’re 
first conceived to 18 years of age.
Children need small amounts of molybdenum to maintain good health.  It is likely that the adverse health 
effects observed in adults exposed to higher than normal levels of molybdenum would also be observed in 
children.  We do not know if children would be more susceptible to the toxicity of molybdenum than 
adults.  We do not have enough information to determine whether molybdenum can cause birth defects or
affect growth.  Studies in humans and laboratory animals show that molybdenum is transferred from the 
mother to the fetus.  Molybdenum has also been found in breast milk.
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1.  PUBLIC HEALTH STATEMENT
HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO MOLYBDENUM?
If your doctor finds that you have been exposed to significant amounts of molybdenum, ask whether your
children might also be exposed.  Your doctor might need to ask your state health department to 
investigate.  You may also contact the state or local health department with health concerns.
Molybdenum is part of the natural environment and you need some molybdenum in your diet to maintain 
good health.  Families can be exposed to more molybdenum than is needed for health if they live near
natural or industrial sources of molybdenum, such as mining sites.  If you live in an area with high levels 
of molybdenum in drinking water, you may consider using bottled drinking water.
If you are exposed to molybdenum at work, you can wear protective equipment and can remove
contaminated clothing before going home.
ARE THERE MEDICAL TESTS TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
MOLYBDENUM? 
Molybdenum is normally found in all tissues of the body, as well as in blood, urine, and feces.  High 
levels of molybdenum in the blood or urine can show that you have been exposed to higher than normal
levels of molybdenum.  Measuring blood molybdenum levels may only tell you if you have been very
recently exposed to molybdenum.  Urinary molybdenum levels are more likely to give information on 
long-term exposure to molybdenum.  Tests to measure molybdenum levels in the body are not usually
available at a doctor’s office because they require special equipment.  Although these tests can show that
you have been exposed to higher than normal molybdenum levels, they cannot be used to predict how
much molybdenum you have been exposed to or whether the exposure will result in an adverse health
effect.  More detailed information on the measurement of molybdenum is provided in Chapters 3 and 7.
WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT
HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  Regulations
can be enforced by law.  Federal agencies that develop regulations for toxic substances include the
Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA),
and the Food and Drug Administration (FDA).  Recommendations provide valuable guidelines to protect
public health but are not enforceable by law.  Federal organizations that develop recommendations for
***DRAFT FOR PUBLIC COMMENT***
   
 









   
 
 
    




   









    
  
  
   
 
  
   
 
 
    
   
   
 
    
5MOLYBDENUM
1.  PUBLIC HEALTH STATEMENT
toxic substances include the Agency for Toxic Substances and Disease Registry (ATSDR) and the 
National Institute for Occupational Safety and Health (NIOSH).
Regulations and recommendations can be expressed as “not-to-exceed” levels; that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value usually based on levels that affect
animals; levels are then adjusted to help protect humans.  Sometimes these not-to-exceed levels differ
among federal organizations.  Different organizations use different exposure times (e.g., an 8-hour
workday or a 24-hour day), different animal studies, or emphasize some factors over others, depending on 
their mission.
Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that issued the regulation
or recommendation.
The Institute of Medicine has made recommendation of the amount of molybdenum that is needed for 
good health; these values are called Recommended Dietary Allowances (RDAs). The RDAs are specific 
for different age groups:
• 17 μg/day for children aged 1–3 years
• 22 μg/day for children aged 4–8 years
• 34 μg/day for children aged 9–13 years
• 43 μg/day for teens aged 14–18 years
• 45 μg/day for adults
• 50 μg/day for pregnant and nursing women
EPA has determined that exposure to drinking water containing 0.08 milligrams per liter (mg/L) is not 
expected to cause effects that are harmful to children exposed for 1 or 10 days.  Lifetime exposure to 
drinking water containing 0.04 mg/L is not likely to cause adverse health effects.
OSHA has set a limit of 5 milligrams per cubic meter (mg/m3) for soluble molybdenum compounds and 
15 mg/m3 for insoluble molybdenum compounds and total dust in workroom air to protect workers during
an 8-hour work shift (40-hour work week).  NIOSH has not established a guideline for exposure to
molybdenum to protect workers exposed up to 10 hours per workday.  However, NIOSH has established
a level of 5,000 mg/m3 for insoluble molybdenum compounds and 1,000 mg/m3 for soluble molybdenum
***DRAFT FOR PUBLIC COMMENT***
   
 








      

























1.  PUBLIC HEALTH STATEMENT
compounds that it considers immediately dangerous and likely to cause death or immediate or delayed
permanent adverse health effects, or to prevent escape.
Further information on regulations and guidelines pertaining to molybdenum is provided in Chapter 8.
WHERE CAN I GET MORE INFORMATION?
If you have any questions or concerns, please contact your community or state health or environmental
quality department, or contact ATSDR at the address and phone number below.  You may also contact
your doctor if experiencing adverse health effects or for medical concerns or questions.  ATSDR can also
provide publicly available information regarding medical specialists with expertise and experience 
recognizing, evaluating, treating, and managing patients exposed to hazardous substances.






Agency for Toxic Substances and Disease Registry

Division of Toxicology and Human Health Sciences
 






Toxicological profiles and other information are available on ATSDR’s web site:
http://www.atsdr.cdc.gov.
***DRAFT FOR PUBLIC COMMENT***












    
   
 
     
 
    




    
   
   
  
 




       
 
   




    




    
 
7MOLYBDENUM
2. RELEVANCE TO PUBLIC HEALTH
 
2.1  	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO MOLYBDENUM IN THE
UNITED STATES
Molybdenum (Mo) is a naturally occurring trace element that can be found extensively in nature.
Molybdenum is a metal that exists as a dark-gray or black powder with a metallic luster or as a silvery-
white mass.  It does not occur naturally in the pure metallic form, but principally as oxide or sulfide
compounds.  Therefore, almost all exposure is to a molybdenum compound rather than the actual metal.  
Important naturally occurring molybdenum compounds are the minerals molybdenite, powellite,
wulfenite, ferrimolybdite, and ilsemannite.
Biologically, molybdenum plays an important role as a micronutrient in plants and animals, including
humans.  It is used widely in industry for metallurgical applications; some of these applications include
high temperature furnaces, as a support wire for tungsten filaments in incandescent light bulbs, and as a
component of steel used in solar panels and wind turbines.
Molybdenum is more abundant in areas of natural mineral deposits and can be found in all environmental
media.  Higher concentrations in air, water, and soil can be found near industrial operations due to
contamination.  Molybdenum concentrations in ambient air have been reported to range from below
detection limits to 0.03 mg/m3. Concentrations of molybdenum in ambient air of urban areas, 0.01– 
0.03 µg/m3, are higher than those found in rural areas, 0.001–0.0032 µg/m3. It has been reported that
concentrations of molybdenum in surface waters are generally <1.0 µg/L and drinking water and 
groundwaters contain about 1.0 µg/L.  Near industrial sources, surface water molybdenum concentrations
can reach 200–400 μg/L and groundwater concentrations can reach 25,000 μg/L.  Concentrations as high 
as 1,400 µg/L have been detected in drinking waters in areas impacted by mining and milling operations, 
far exceeding the U.S. Geological Survey (USGS) health-based screening level of 40 µg/L.  Globally, 
most soils contain molybdenum at concentrations between 0.6 and 3.5 ppm, although total concentrations
in soils can vary widely depending on geological composition or industrial contamination.  The average
concentration of soils is generally 1–2 ppm.  In the United States, it has been reported that the median
concentration of molybdenum in soils is 1.2–1.3 ppm, with a range of 0.1–40 ppm.
The exposure to molybdenum to the general population is almost entirely through food.  Foods derived
from above-ground plants, such as legumes, leafy vegetables, and cauliflower, generally have a relatively
higher concentration of molybdenum in comparison to food from tubers or animals.  Beans, cereal grains, 
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8MOLYBDENUM
2. RELEVANCE TO PUBLIC HEALTH
leafy vegetables, legumes, liver, and milk are reported as the richest sources of molybdenum in the 
average diet.  Drinking water coming from sources close to areas with high molybdenum contamination 
from industrial effluents may contain a higher concentration of molybdenum.  The primary source of
dietary molybdenum intake among children in the United States is milk.  Exposure to molybdenum in an 
industrial setting such as mining can be significant.
2.2  SUMMARY OF HEALTH EFFECTS 
Molybdenum, as a component of pterin-based cofactor, is an essential element.  Historically, three
molybdenum cofactor-containing enzymes have been identified: sulfite oxidase, xanthine oxidase, and 
aldehyde oxidase. These enzymes are involved in the degradation of sulfur-containing amino acids and
sulfatides, purine degradation pathway catalyzing the oxidation of hypoxanthine to xanthine and of
xanthine to uric acid, and oxidation of aromatic and nonaromatic heterocycles and aldehydes to 
carboxylic acids. Within the last 10 years, a fourth enzyme, mitochondrial amidoxime reducing
component (mARC), has been identified in mammals. Clear signs of molybdenum deficiency have not
been found in healthy humans. However, a deficiency in molybdenum cofactor has been observed in 
individuals with a severe metabolic defect. The lack of molybdenum cofactor and subsequent
deficiencies in molybdoenzymes is manifested in central nervous system effects. The effects that
typically occur shortly after birth include intractable seizures and feeding difficulties; the patients develop
severe psychomotor retardation due to progressive cerebral atrophy and ventricular dilatation.  The
nutritional requirements for molybdenum are based on maintaining molybdenum balance; the Institute of
Medicine has established the following age-specific RDAs:
• 17 μg/day for 1–3 year olds,
• 22 μg/day for 4–8 year olds,
• 34 μg/day for 9–13 year olds,
• 43 μg/day for 14–18 year olds,
• 45 μg/day (0.64 μg/kg/day) for adults, and 
• 50 μg/day in pregnant and lactating women.
A small number of studies have investigated the toxicity of molybdenum following inhalation exposure.  
Decreases in lung function, dyspnea, and cough were reported in workers exposed to fine or ultrafine
molybdenum trioxide dust.  Another study of workers at a molybdenite roasting facility exposed to 
molybdenum trioxide and other oxides did not have alterations in lung function. However, this study did 
***DRAFT FOR PUBLIC COMMENT***
   
 








      
  
  




      
    
   
      
 
  
   
    
   
   
      
     
   
   
    
    
     
   
 
 
   
 
      
   
     
      
    
9MOLYBDENUM
2. RELEVANCE TO PUBLIC HEALTH
find an increase in serum uric acid levels.  In studies of rats and mice exposed to molybdenum trioxide for
2 years, hyaline degeneration of the nasal epithelium, squamous metaplasia of the epiglottis, and chronic 
inflammation (rats only) were observed.  However, no effects were observed following a 13-week
exposure to similar concentrations. No other alterations were observed in the intermediate- or chronic-
duration studies.
The oral toxicity of molybdenum has been well-established in ruminants, particularly cows and sheep.  
The toxicity is likely due to an interaction between molybdenum and sulfate in the rumen, resulting in the
formation of thiomolybdates.  In the absence of adequate copper in the rumen, the thiomolybdate is
absorbed through the rumen or small intestine and can bind to copper-containing compounds such as
ceruloplasmin and cytochrome oxidase, resulting in symptoms resembling copper deficiency (a condition 
often referred to as molybdenosis).  The observed effects can include decreases in weight gain, alterations 
in hair/wool texture and pigmentation, delayed puberty, and reduced conception rates. Molybdenum also 
interacts with copper in monogastric animals; however, the mode of interaction differs between the
species.  Exposure to molybdenum results in decreases in blood and liver copper levels in ruminants,
which is in contrast to the higher relative levels of liver and kidney copper in rats fed a copper-deficient
diet, as compared to those fed a copper-adequate diet.  Exposure to a molybdenum excess and copper-
deficient diet also resulted in higher relative levels of liver molybdenum and lower relative levels of
kidney molybdenum.  Exposure of rats to thiomolybdate compounds can result in effects that mimic
copper deficiency.  These data suggest that the findings in ruminants do not appear to be relevant to 
humans or monogastric animals. Additionally, studies in which laboratory animals were fed a copper-
deficient diet may not be relevant to evaluating the risk of molybdenum toxicity to the general population
with adequate copper intake.  A human study showed that a 24-day exposure to high molybdenum levels
in the diet (1,490 μg/day, approximately 21 mg/kg/day) did not result in any significant alterations in 
copper metabolism.  In the United States, the average copper intake is 1.0–1.6 mg/day and the copper
recommended dietary allowance is 0.9 mg/day.
A small number of studies have evaluated the toxicity of molybdenum in humans following oral
exposure.  An increased occurrence of gout and increased blood uric acid levels were observed in 
residents living in an area of high molybdenum levels in the soil; no alterations in urinary uric acid levels
were found in a 10-day experimental study in men.  Several studies have used the National Health and 
Nutrition Examination Survey (NHANES) dataset to evaluate potential associations between urinary
molybdenum levels and several diseases; statistically significant associations were found for the
occurrence of high blood pressure, self-reported liver conditions, and decreased triiodothyronine or
***DRAFT FOR PUBLIC COMMENT***
   
 








     
    
  
  
   
   
 
 
   
    
   
    
   
    
      
    
  
        
    
    
 
   
     
    
  
    
   
 
   
 
    
     
      
   
10MOLYBDENUM
2. RELEVANCE TO PUBLIC HEALTH
thyroxine.  Although the studies did not specifically evaluate copper intake, it is likely to be adequate 
based on a NAS finding that copper intake in the United States is greater than or equal to the dietary
requirement.  Other population studies have found significant associations between blood molybdenum
levels and sperm concentration and morphology or testosterone levels and between urinary molybdenum
levels and the psychomotor index in infants.  Although the observational epidemiology studies have 
found statistically significant associations, they do not establish causality and it is possible that the effects 
are not due to molybdenum exposure.
A number of studies have examined the oral toxicity in laboratory animals.  Studies in which the basal 
diet provided an adequate amount of copper have identified a number of end points including hepatic
effects, renal effects, reproductive effects, and possibly developmental effects. Based on the available 
animal data, the reproductive effects appear to be the most sensitive targets. Consistent with the findings
in an epidemiology study, decreases in sperm motility and concentration and increases in sperm
morphological changes have been observed in rats exposed to ≥4.4 mg molybdenum/kg/day as 
ammonium tetrathiomolybdate or sodium molybdate. Degeneration of the seminiferous tubules was also
observed at similar molybdenum doses.  Effects have also been observed in the female reproductive
system (oocyte morphological alterations, abnormal rate of ovulation, and irregularities in the estrous
cycle) at ≥1.5 mg molybdenum/kg/day in rats. Mixed results have been observed in animal
developmental toxicity studies. Decreases in the number of live fetuses and fetal growth were observed
in rats administered 14 mg molybdenum/kg as sodium molybdate; however, no developmental effects
were observed in rats at 4.4 or 38 mg/kg/day as ammonium tetrathiomolybdate or sodium molybdate, 
respectively.  Several studies have reported renal effects in rats exposed to ≥60 mg/kg/day.  The effects
included hyperplasia of the renal proximal tubules, degeneration, increases in total lipid levels in the
kidney, and diuresis and creatinuria. The liver effects, which consisted of decreases in glycogen content,
increases in aminotransferase activities, and increases in lipid content, have been observed at higher doses 
(≥300 mg/kg/day) that are often associated with body weight losses.  No hepatic effects have been
observed at lower (≤60 mg/kg/day) doses.
2.3  MINIMAL RISK LEVELS (MRLs)
As summarized in Table 2-1, an inhalation MRL has been derived for chronic-duration exposure to 
molybdenum and oral MRLs have been derived for acute- and intermediate-duration exposure to 
molybdenum.  The chronic-duration inhalation MRL is based on squamous metaplasia of the epiglottis in 
female mice exposed to molybdenum trioxide 6 hours/day, 5 days/week for 2 years (NTP 1997).  Acute-
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2. RELEVANCE TO PUBLIC HEALTH
and intermediate-duration inhalation MRLs were not derived because the available studies did not
identify adverse effects in rats or mice exposed for 14 days or 13 weeks (NTP 1997); the acute-duration 
study did identify a no-observed-adverse-effect level (NOAEL) and lowest-observed-adverse-effect levels 
(LOAELs) for decreases in body weight gain, but this was not considered a primary effect.  The acute-
and intermediate-duration oral MRLs for molybdenum were based on reproductive effects in female mice 
and rats, respectively.  The data were considered inadequate for derivation of a chronic-duration oral
MRL for molybdenum.  Refer to Section 3.6.2 and Appendix A for detailed information regarding MRL
derivation for molybdenum.
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2. RELEVANCE TO PUBLIC HEALTH
Table 2-1.  Minimal Risk Levels (MRLs) for Molybdenuma 
Exposure Point of Uncertainty
duration MRL Critical effect departure factor Reference
Inhalation exposure
Acute Insufficient data for derivation of an MRL
Intermediate Insufficient data for derivation of an MRL
Chronic 0.0004 mg 
Mo/m3 
Squamous metaplasia in 
female mice exposed to 
≥6.7 mg Mo/m3 
Oral exposure
Acute 0.05 Mg Increase rate of abnormal
Mo/kg/day MII oocytes in mice
Intermediate 0.008 mg Increased estrous cycle
Mo/kg/day length in rats
Chronic Insufficient data for derivation of an MRL
BMCLHEC of 30 NTP 1997
0.012 mg 
Mo/m3 










aThe respective exposure durations for acute, intermediate, and chronic MRLs are ≤14 days, 15–364 days, and 
≥1 year.
BMCL = benchmark concentration lower confidence limit; HEC = human equivalent concentration; NOAEL = no-
observed-adverse-effect level
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3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of molybdenum.  It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (e.g., death, systemic, immunological, neurological, 
reproductive, developmental, and carcinogenic effects).  These data are discussed in terms of three 
exposure periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
***DRAFT FOR PUBLIC COMMENT***
   
 















   
 
    
     
 
    
 
  




      
   
 




     
 
 
   
   
 
        
    
14MOLYBDENUM
3. HEALTH EFFECTS
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix C).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure 
The highest NOAEL values and all LOAEL values from each reliable study for each end point in each 
species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.1.1  Death 
No deaths were reported in rats or mice exposed to ≤200 mg molybdenum/m3 for 14 days (NTP 1997) or
≤67 mg molybdenum/m3 for 90 days or 2 years (NTP 1997).
3.2.1.2  Systemic Effects
No information was located regarding cardiovascular, gastrointestinal, hematological, muscular/skeletal,
hepatic, renal, endocrine, dermal, ocular, or body weight effects in humans following inhalation exposure
to molybdenum. No information was located regarding dermal or ocular effects in animals following
inhalation exposure to molybdenum.
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.
Respiratory Effects. Limited data are available on the toxicity of molybdenum to the respiratory
tract of humans.  A study of workers exposed to molybdenum trioxide and other oxides at a molybdenite
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Table 3-1. Levels of Significant Exposure to Molybdenum – Inhalation 
Less 

























No histological alterations were 




0, 2, 6.7, 20, 67, 
200 mg Mo/m3 
Decreased body weight gain in males 
exposed to 67 mg/m3 (10%) and 
females exposed to 200 mg/m3 (13%); 
weight loss was observed in males 
exposed to 200 mg/m3 . 
2 Mouse 6 hours/day; CS, BW, HP Resp 200 No histological alterations were NTP 1997
5M, 5F 5 days/week; Bd Wt 200 observed in the nasal cavity.  Body (molybdenum trioxide)
(B6C3F1) 14 days weight loss in males and decrease in 
0, 2, 6.7, 20, 67, 
200 mg Mo/m3 













No alterations in organ weights, 
hematology or clinical chemistry
NTP 1997
(molybdenum trioxide)
(F344/N) 13 weeks Gastro 67 parameters, or histological alterations 
0, 0.67, 2, 6.7, 20, Hemato 67 were found.




Bd Wt 67 









hematology or clinical chemistry
parameters, or histological alterations 
(molybdenum trioxide)
0, 0.67, 2, 6.7, 20, Hemato 67 were found.
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Table 3-1. Levels of Significant Exposure to Molybdenum – Inhalation 
Less 






















67 No significant alterations in sperm
counts or motility were found
NTP 1997
(molybdenum trioxide)
(F344/N) 13 weeks 
0, 0.67, 2, 6.7, 20, 
67mg Mo/m3 
6 Mouse 6.5 hours/day; CS, BW,OW, 67 No significant alterations in sperm NTP 1997
10M, 10F 5 days/week; HP counts or motility were found (molybdenum trioxide)
(B6C3F1) 13 weeks 








CS, BW, HP Resp 
Cardio 67 
6.7 Concentration-related increasing 
incidence of hyaline degeneration of 
NTP 1997 
(molybdenum trioxide)
(F344/N) 105 weeks Gastro 67 nasal respiratory and olfactory






epithelium (females only), squamous 





lung inflammation (only significant at 20 
and 67 mg/m3 concentrations)
Bd Wt 67 









incidence of squamous metaplasia of 
the epiglottis, histiocytic cellular 
(molybdenum trioxide)








infiltration in the lungs, and alveolar 
epithelial metaplasia were observed at 





respiratory effects were nasal 
supprative inflammation in males at 20 
or 67 mg/m3 and hyaline degeneration 
of nasal respiratory and olfactory 
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Table 3-1. Levels of Significant Exposure to Molybdenum – Inhalation 
Less 






















CS, BW, HP 6.7 Increased incidences of 
alveolar/bronchiolar carcinoma in males 
at ≥6.7 mg/m3; increased incidence of 
NTP 1997 
(molybdenum trioxide)
0, 6.7, 20, 67mg 
Mo/m3 
alveolar/bronchiolar adenoma in 
females at ≥20 mg/m3 . An increase in 
alveolar/bronchiolar adenoma or
carcinoma were also observed in male 
mice exposed to 6.7 or 20 mg/m3 . 
aThe number corresponds to entries in Figure 3-1.
BC = biochemistry; BW = body weight; Cardio = cardiovascular; CI = confidence interval; CS = clinical signs; d = day(s); Endocr = endocrine; F = female(s); FI = food intake; 

Gastro = gastrointestinal; GC = gas chromatography; GN = gross necropsy; HE = hematology; Hemato = hematology; HP = histopathology; hr = hour(s); LC50 = lethal concentration, 50% kill; 

LE = lethality; M = male(s); min = minute(s); MRL = Minimal Risk Level; NS = not specified; OP = ophthalmology; OW = organ weight; RD50 = concentration resulting in a 50% reduction in 
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Human - NOAEL Animal - NOAEL 
Human - LOAEL, Less Serious Animal - LOAEL, Less Serious 
Human - LOAEL, More Serious Animal - LOAEL, More Serious 
Human - Cancer Effect Level Animal - Cancer Effect Level 
Animal - LD50/LC50 Minimal Risk Level for effects other than cancer 
C-Cat K-Monkey J-Pigeon O-Other D-Dog M-Mouse E-Gerbil 
R-Rat  H-Rabbit S-Hamster 
P-Pig    A-Sheep G-Guinea Pig 
Q-Cow F-Ferret N-Mink 
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Figure 3-1. Levels of Significant Exposure to Molybdenum - Inhalation
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Figure 3-1. Levels of Significant Exposure to Molybdenum - Inhalation (Continued)
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Figure 3-1. Levels of Significant Exposure to Molybdenum - Inhalation (Continued)
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roasting plant reported normal lung function test results in 20/25 workers (Walravens et al. 1979).  Some
alterations in lung function (forced expiratory volume in 1 second, FEV1) was observed in the remaining
five workers; the decrease in FEV1 was characterized as mild in three of the workers and “more marked” 
in two workers, which may be indicative of mild obstructive lung disease. The study did not provide lung
function data for a reference group. The estimated 8-hour time-weighted average (TWA) molybdenum
concentration in total dust was 9.46 mg molybdenum/m3; the molybdenum content of the respirable dust
ranged from 1.02 to 4.49 mg molybdenum/m3. Another study of workers exposed to fine and ultrafine
molybdenum trioxide dust reported dyspnea and cough in symptomatic workers (Ott et al. 2004).  
Radiographic abnormalities were noted in the lungs of most of the symptomatic workers and in half of the
asymptomatic workers, although none of the radiographs showed evidence of interstitial lung disease.  
Significant alterations in lung function (increased predicted FEV1 and forced vital capacity) were also
observed in the workers, as compared to a control group.  In symptomatic workers, alterations in 
bronchioalveolar lavage cytology suggestive of subclinical alveolitis were noted. This study (Ott et al.
2004) has several limitations including the lack of monitoring data, minimal information on the control
group, which does not appear to be comprised of workers at this facility, and differences in the mean and 
ranges of ages of the different groups (40.0 years [range of 24–58 years], 30.5 years [22–45 years], and
30.0 years [14–72 years] in the symptomatic workers, asymptomatic workers, and controls, respectively),
which were not adjusted for in the statistical analyses.
The database on the respiratory toxicity of molybdenum in laboratory animals is comprised of acute-, 
intermediate-, and chronic-duration studies conducted by the National Toxicology Program (NTP 1997).  
No histological alterations were observed in the nasal cavity of rats and mice exposed to 200 mg
molybdenum/m3 as molybdenum trioxide for 14 days (NTP 1997); no other regions of the respiratory 
tract were examined. Similarly, no histological alterations were observed in the respiratory tract of rats or 
mice exposed to ≤67 mg molybdenum/m3 as molybdenum trioxide for 13 weeks (NTP 1997).  In contrast, 
chronic exposure has resulted in lesions in the nose, larynx, and lungs in rats and mice exposed to 
molybdenum trioxide for 2 years (NTP 1997).  In the nose, hyaline degeneration of the respiratory and 
olfactory epitheliums were observed in rats exposed to ≥6.7 mg molybdenum/m3 and in mice exposed to
67 mg molybdenum/m3; other nasal lesions observed in mice included suppurative inflammation at 
≥20 mg molybdenum/m3 and olfactory epithelial atrophy at 67 mg molybdenum/m3. Squamous
metaplasia of the epiglottis was observed in rats and mice exposed to ≥6.7 mg molybdenum/m3. In the
lungs, chronic inflammation was observed in rats exposed to ≥20 mg molybdenum/m3.and alveolar
epithelial metaplasia and histiocytic cellular infiltration were observed at ≥6.7 mg molybdenum/m3.
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Cardiovascular Effects. No histological alterations were observed in the hearts of rats or mice
exposed to molybdenum trioxide concentrations as high as 67 mg molybdenum/m3 for 13 weeks or
2 years (NTP 1997).
Gastrointestinal Effects. Intermediate- or chronic-duration exposure to ≤67 mg molybdenum/m3 as 
molybdenum trioxide did not result in histological alterations in the gastrointestinal tract (NTP 1997).
Hematological Effects. No significant alterations in hematological parameters were observed in rats 
or mice following exposure to molybdenum trioxide concentrations as high as 67 mg molybdenum/m3 for 
13 weeks (NTP 1997).
Musculoskeletal Effects. No histological alterations were observed in the bone of rats or mice 
exposed to 6.7–67 mg molybdenum/m3 as molybdenum trioxide for 13 weeks or 2 years (NTP 1997).
Chronic molybdenum exposure also did not affect femoral bone density or curvature in groups of 10 rats
exposed to concentrations as high as 67 mg molybdenum/m3 (NTP 1997).
Hepatic Effects. No significant alterations in serum clinical chemistry parameters or liver weights 
were observed in rats or mice exposed to molybdenum trioxide concentrations as high as 67 mg
molybdenum/m3 for 13 weeks (NTP 1997).  No significant alterations in the incidence of hepatic lesions
were observed following 13 weeks or 2 years of exposure (NTP 1997).
Renal Effects. Intermediate- or chronic-duration inhalation exposure to molybdenum trioxide
(highest concentration tested was 67 mg molybdenum/m3) did not result in histological alterations in the
kidney of rats or mice (NTP 1997).
Endocrine Effects. Based on histopathology findings, the adrenal, pituitary, pancreas, parathyroid,
and thyroid glands were not affected by exposure of rats and mice to ≤67 mg molybdenum/m3 as 
molybdenum trioxide for 13 weeks or 2 years (NTP 1997).
Body Weight Effects. Decreases in body weight gain and weight loss were observed in rats and mice 
exposed to molybdenum trioxide for 14 days (NTP 1997).  Terminal body weights were 10% lower in
male rats exposed to 67 mg molybdenum/m3 than in the controls, and weight loss was observed in male 
rats and mice exposed to 200 mg molybdenum/m3. In female rats and mice exposed to 200 mg
molybdenum/m3, the terminal body weights were 13 and 10%, respectively, lower than the control
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groups.  No significant alterations in body weight gain were observed in rats or mice exposed to
molybdenum trioxide concentrations as high as 67 mg molybdenum/m3 for 13 weeks or 2 years (NTP
1997).
Other Systemic Effects. Slight, but significant increases in serum uric acid levels were observed in
molybdenite roasting facility workers exposed to a TWA concentration of 9.47 mg molybdenum/m3 as 
molybdenum trioxide and other oxides (Walravens et al. 1979). The serum uric acid levels were 
5.90 mg/dL in the exposed workers and 5.01 mg/dL in the controls; these levels are within the normal 
range.  No significant associations between serum molybdenum levels and serum uric acid levels were 
found, and none of the workers reported gout-like symptoms.
3.2.1.3  Immunological and Lymphoreticular Effects 
No studies have examined immune function following inhalation exposure to molybdenum.  
Intermediate- and chronic-duration studies in rats and mice did not report histological alterations in the
thymus or spleen at molybdenum trioxide levels as high as 67 mg molybdenum/m3 (NTP 1997).
3.2.1.4  Neurological Effects 
No histological alterations were observed in the brain of rats and mice exposed to ≤67 mg
molybdenum/m3 as molybdenum trioxide for 13 weeks or 2 years (NTP 1997); the study did not evaluate
neurological function.
3.2.1.5  Reproductive Effects
Following a 13-week exposure to molybdenum trioxide, no alterations in sperm count or motility were
observed in rats or mice at concentrations as high as 67 mg molybdenum/m3 (NTP 1997).  No histological
alterations were observed in male or female reproductive tissues following exposure to ≤67 mg
molybdenum/m3 for 13 weeks or 2 years (NTP 1997).
3.2.1.6  Developmental Effects 
No studies were located regarding developmental effects in humans and animals following inhalation 
exposure to molybdenum.
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In a case-control study examining the potential association between lung cancer and exposure to 
16 potential carcinogens, Droste et al. (1999) did not find a significant increase in lung cancer among
workers who self-reported exposure to molybdenum.  However, an increased risk of lung cancer was
found in workers who self-reported working in industries that could involve exposure to molybdenum
(odds ratio of 2.1, 95% confidence interval of 1.2–3.7); the job most often related to molybdenum
exposure was processing of stainless steel in the manufacture of metal goods, which could also involve
exposure to other carcinogens including chromium, nickel, and arsenic.  Limitations of this study,
including self-reported exposure and the potential exposure to other lung carcinogens, preclude its use in 
assessing the potential carcinogenicity of molybdenum.
In the 2-year NTP rat study (NTP 1997), an increase in the combined incidence of alveolar/bronchiolar
adenoma or carcinoma was observed in male rats exposed to 67 mg molybdenum/m3; however, the
incidence was within the range of historical controls and NTP considered this to be equivocal evidence of
carcinogenic activity.  No other concentration-related increases in neoplastic lesions were observed in the
rats. In mice, there were significant increases in the incidences of alveolar/bronchiolar carcinoma in 
males at ≥6.7 mg molybdenum/m3, alveolar/bronchiolar adenoma or carcinoma in males at 6.7 and 20 mg
molybdenum/m3, alveolar/bronchiolar adenoma in females at 20 and 67 mg molybdenum/m3, and 
alveolar/bronchiolar adenoma or carcinoma in females at 67 mg molybdenum/m3 (NTP 1997).  NTP
(1997) concluded that the male and female mouse data provided some evidence of molybdenum
carcinogenicity.
3.2.2 Oral Exposure
The highest NOAEL values and all LOAEL values from each reliable study for each end point in each 
species and duration category are recorded in Table 3-2 and plotted in Figure 3-2.
A number of studies have examined the oral toxicity of molybdenum; most were conducted in laboratory
animals and most had a limited scope (examined one or two potential targets); the studies evaluated the 
toxicity of several molybdenum compounds, predominantly sodium molybdate, ammonium
heptamolybdate, and ammonium tetrathiomolybdate.  Studies have also been conducted in ruminants, 
particularly cows and sheep; however, these species are not considered suitable models for humans due to
differences in interactions between molybdenum, copper, and sulfate in the rumen (see Section 3.5.2 for
more information). Studies in rats provide evidence that copper status, particularly the copper content of
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Table 3-2. Levels of Significant Exposure to Molybdenum – Oral 
Less 





















10 days (F); 
0.00237, 0.00771, 
0.022 mg/kg/day 
UR Other 0.022 No alterations in urinary uric acid levels Deosthale and Gopalan 1974 
(ammonium molybdate)




0 or 50 mg/kg/day
BW, HP Musc/Skel 
Bd Wt 50 
50 Increased buccal and sulcal enamel 
lesions following pre-eruptive exposure 
to molybdenum and administration of a 
caries promoting diet. 






14 day (F);  
0, 1.2 mg/kg/day 





1.2 A 60% increase in serum triglyceride 
levels was found; no significant 
alterations in liver or kidney
histopathology were found.
Bersenyi et al. 2008  
(ammonium heptamolybdate)
4 Rabbit 14 day (F);  BW, HP Hepatic 0.58 No histological alterations in the liver or Bersenyi et al. 2008  
(New Zealand 0, 0.58 mg/kg/day Renal 0.58 kidneys or alterations in serum clinical (ammonium heptamolybdate)
White) Bd Wt 0.58 chemistry parameters were observed. 
5 M The molybdenum in the diet came from 
carrots grown in molybdenum rich soil.
Reproductive 
5 Mouse (ICR) 
25 F
14 days (W); 
0, 1.3, 2.6, 5.3,
and 11 mg/kg/day 
HP 5.3b 11 Significant increase in the rate of 
abnormal MII oocytes and decrease in 
ovarian weights were observed at 11 
mg/kg/day. Ovarian hyperemia was 
observed at 5.3 and 11 mg/kg/day 
(incidence and statistical significance 
were not reported).
Zhang et al. 2013  
(sodium molybdate)
6 Mouse (ICR) 
10 M 
14 days;
0, 3, 6, 12, 25, 
and 49 mg/kg/day 
OF 12 25 Significant decreases in relative 
epididymis weight, sperm 
concentration, and sperm motility and 
increase in rate of sperm abnormalities. 







0, 1.2 mg/kg/day 
BW, HP 1.2 No histological alterations were 
observed in the ovaries. 
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8 Rabbit (New 14 days (F); BW, HP 0.58 Reduction in germ cells and mature Bersenyi et al. 2008  
Zealand 0, 0.58 mg/kg/day spermatocytes (incidence andr (ammonium heptamolybdate)









8 weeks (GW); 
0, 40, 80 
mg/kg/day 















Increases in diuresis and creatinuria, 
decreases in creatinine clearance, 
increases in urinary kallikrein (distal 
tubule enzyme) levels, and increases in 
relative and absolute kidney weights.  
Decrease in body weight gain; terminal 
body weight was 26% lower than in 
controls 
Bompart et al. 1990  
(ammonium heptamolybdate)
No alterations in mean hemoglobin 
levels were found.   










(GW); 0, 0.4, 1.5,
4.4 mg/kg/day 





0 or 74 mg/kg/day






Decreases in body weight gain in males 
starting at day 50.  Decreases in 
erythrocyte count, hemoglobin 
concentration, and hematocrit in males. 
Lyubimov et al. 2004  
(ammonium tetrathiomolybdate)
36% decrease in body weight gain Mills et al. 1958 
(sodium molybdate)




(F); 0, 5, 17, or 60
mg/kg/day 
CS, BW, BC, 




















15.2% lower terminal body weight in 
males; slight diffuse hyperplasia in the 
renal proximal tubules in 2/10 female 
rats exposed to 60 mg/kg/day.
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Table 3-2. Levels of Significant Exposure to Molybdenum – Oral 
Less 
Species Exposure serious Serious
Figure (strain) parameters/ Parameters NOAEL LOAEL LOAEL Reference
keya No./group concentrations monitored System (mg/kg/day) (mg/kg/day) (mg/kg/day) Results (compound)
14 Rat 5 days/week BW Bd Wt 24 No significant alterations in body weight Pandey and Singh 2002 
(Druckery) 60 days gain were observed (sodium molybdate)
10M (GW); 0, 4.7, 14, 
24 mg/kg 
15 Rat (Wistar) 9 weeks (W); 0 or BW, BI, OW Cardio 100 Slight decrease (approximately 4%) in Peredo et al. 2013  
6M 100 mg/kg/day Bd Wt 100 systolic blood pressure.  No significant (sodium molybdate)
Metab 100 alterations in blood triglyceride, 
glucose, or insulin levels.
16 	Rat (Wistat) 4-5 weeks (F); BW, EA Bd Wt 110 46-48% decrease in body weight gain; Van Reen and Williams 1956 
10M or 5M, 0 or 110 no feed intake data were provided. (sodium molybdate)
5F mg/kg/day 
17 Rat (NMRI-D) 5 weeks; 0, 2, 4, HP Musc/Skel 8 No significant alterations in the number Van Reen et al. 1962 
17-18 NR and 8 mg/kg/day of carious teeth and the severity of (sodium molybdate)
carious lesions 
18 Rat (Wistar) 6 weeks; 0, or 85 BW, EA Bd Wt 85 No alteration in body weight gain was Williams and Van Reen 1956 
8 (sex not mg/kg/day observed and there was no effect on (sodium molybdate)
reported  the ability to acetylated p-aminobenzoic 
acid. An increase in liver alkaline 
phosphatase levels was observed. 
Feed intake of control group was 
matched to molybdenum group.
19 Rat (Wistar) 6 weeks; 0, 90, BW, EA Bd Wt 90 Decreases in body weight gain of 22, Williams and Van Reen 1956 
8 (sex not 144, and 185 44, and 60% were observed in the 90, (sodium molybdate)
reported) mg/kg/day 144, and 185 mg/kg/day groups; 
decreases in feed intake were also 
observed in these groups.
20 Rat (Sprague 8 weeks (W); BW, EA, OW Bd Wt 1.5 No significant differences in terminal Yang and Yang 1989  
Dawley) 0,0.015, 0.076, body weights were observed. (sodium molybdate)
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Table 3-2. Levels of Significant Exposure to Molybdenum – Oral 
Less 
Species Exposure serious Serious
Figure (strain) parameters/ Parameters NOAEL LOAEL LOAEL Reference
keya No./group concentrations monitored System (mg/kg/day) (mg/kg/day) (mg/kg/day) Results (compound)
21 Rabbit 30-84 days CS, LE, BW, Hemato 25 54 
(Dutch) (F); 0, 7.1, 25, 54, HE Dermal 25 54 
2-5 M,F 120, 240 Bd Wt 25 120 
mg/kg/day 
Weight loss was observed in the 120 Arrington and Davis 1953  
and 240 mg/kg/day groups.  Anemia (sodium molybdate)
was observed in 2/5, 5/5, and 4/5 
rabbits in the 54, 120, and 240
mg/kg/day groups and in no rabbits at 
lower doses.  Alopecia was observed in 
4/5 and 4/5 rabbits in the 54 and 120 
mg/kg/day groups; not observed at 
lower doses or in the 240 mg/kg/day
group.
Reproductive Effects 




(W); 0, 0.76, 1.5,
7.6, and 15 
mg/kg/day 
BW, WI, OF 0.76c 1.5 Prolonged estrus phase (6-12 hours) of 
the estrous cycle observed at ≥1.5 
mg/kg/day.  No effect on fertility was 
observed.
Fungwe et al. 1990  
(sodium molybdate)
23 Rat (Long 
Evans) 
4M, 4F
At least 8 weeks
(F); 0 or 7 
mg/kg/day 
BW, HE 7 All rats produced litters; rats were 
maintained on a high copper diet..








(GW); 0, 0.4, 1.5,
4.4 mg/kg/day 
OF, HP 1.5 4.4 Decreases in sperm motility and sperm 
count, and increased sperm 
morphological alterations; histological 
alterations in spermatogenesis in 25/25 
males. No alterations in female 
reproductive parameters.
Lyubimov et al. 2004  
(ammonium tetrathiomolybdate)




(F); 0, 5, 17, or 60
mg/kg/day 
CS, BW, BC, 
HE, FI, GN, 
HP, OW
17 60 Significant decrease in the percentage 
of progressively motile sperm; no 
alterations in overall percentage of
motile sperm, spermatid or sperm
counts, or sperm morphology. No
alterations in vaginal cytology, estrus 
cycle, or histopathology of male or
female reproductive organs 
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(GW); 0, 4.7, 14, 
motility and increases in sperm 
abnormalities were observed at 14
(sodium molybdate)
24 mg/kg mg/kg and higher.  Degeneration of 
seminiferous tubules were observed in 
the testesat 24 mg/kg (incidence and 
statistical significance were not 
reported.  
27 Rat 5 days/week DX, FX 14 Decrease in fertility (60% versus 80% Pandey and Singh 2002 
(Druckery) 60 days in controls) and increased pre- (sodium molybdate)
20M (GW); 0 or 14 implantation losses 
mg/kg 
Developmental Effects
28 Rat (long 
Evans) 
4M, 4F
At least 14 weeks 
(F); 0 or 7 
mg/kg/day 
BW, HE 7 All rats produced litters and there were 
no alterations in birth weight or average 
weight at weaning. 








(GW); 0, 0.4, 1.5,
4.4 mg/kg/day 
DX 4.4 No effects on resorptions, pre- or post-
implantation losses or viable fetuses 
Lyubimov et al. 2004  
(ammonium tetrathiomolybdate)




(F); 0, 2.8, 9.8, 
20.0, and 37.5 
mg/kg/day 
DX 37.5 No effects on resorptions, post-
implantation losses, fetal body weights, 
or occurrence of fetal malformations. 







(GW); 0 or 14
mg/kg 
DX, FX 14 Increased post-implantation losses, 
increased resorptions, decreased 
number of live fetuses, and decreases 
in fetal weight and crown-rump length. 
Males mated with unexposed females 
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aThe number corresponds to entries in Figure 3-2.

bUsed to derive an acute-duration oral minimal risk level (MRL) of 0.053 m molybdenum/kg/day based on the NOAEL of 5.3 mg molybdenum/kg/day and an uncertainty factor of 100 (10 for 

extrapolation from animals to humans and 10 for human variability). 

cUsed to derive an intermediate-duration oral MRL of 0.0076 mg molybdenum/kg/day based on the NOAEL of 0.76 mg molybdenum/kg/day and an uncertainty factor of 100 (10 for extrapolation 

from animals to humans and 10 for human variability).  

BC = biochemistry; BW = body weight; Cardio = cardiovascular; CS = clinical signs; d = day(s); DX = developmental; EA = enzyme activity; Endocr = endocrine; F = female(s); F = food; FI = 

feed intake; FX = function testing; Gastro = gastrointestinal; GN = gross necropsy; GW = gavage in water; HE = hematology; Hemato = hematology; HP = histopathology; hr = hour(s; MRL = 
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Figure 3-2.  Levels of Significant Exposure to Molybdenum - Oral
Acute (≤ 14 days) 
 






      
     
     
    
           
Figure 3-2.  Levels of Significant Exposure to Molybdenum - Oral (Continued) 
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the diet, can influence the toxicokinetics of molybdenum and possibly its toxicity.  The current
recommended dietary copper concentrations of 5, 6, and 3 ppm have been set for rats, mice, and rabbits, 
respectively (NAS 1977, 1995); for rats and mice, a copper dietary level of 8 ppm has been established to 
support gestation and lactation (NAS 1995).  Administration of 150 and/or 500 mg/kg molybdenum in the
diet for up to 6 weeks to rats fed a copper-deficient or copper-adequate diet resulted in profound 
differences in the distribution of copper and molybdenum in the plasma, liver, and kidneys (Nederbragt
1980, 1982).  For example, at a molybdenum dietary concentration of 150 mg/kg, molybdenum levels in 
the liver and kidneys were 3.5 and 9 times higher, respectively, in the copper-adequate rats as compared
to 6 and 4 times higher in the copper-deficient rats.  Additionally, the relative increase in copper levels in
the liver and kidneys was greater in the rats fed the copper-deficient diet, as compared to those fed the 
copper-adequate diet.  Administration of tetrathiomolybdate compounds, as compared to molybdate
compounds, results in more dramatic shifts in copper levels in rats fed copper adequate diets (Mills et al. 
1981a).  Since it is not known whether the differences in the distribution of copper and molybdenum
influence the molybdenum toxicity, studies in which the laboratory animals were fed a basal diet with 
inadequate copper levels are clearly identified in the text, are discussed separately from studies in which
there was adequate dietary copper levels, and are not included in the LSE table or figure. Additionally,
laboratory animal studies in which the diet provided an inadequate amount of copper are not likely to be a 
good model for the U.S. population since the median copper intake of adults in the United States exceeds 
the nutritional requirement (RDA) for copper (NAS 2001).
3.2.2.1  Death 
Several oral studies have reported deaths in rabbits exposed to molybdenum.  Mortality rates of 42–100% 
were observed in rabbits exposed to 59–120 mg molybdenum/kg/day for intermediate durations
(Arrington and Davis 1953; Robinson et al. 1969; Valli et al. 1969; Widjajakusuma et al. 1973).  
Although the causes of death were not reported, anorexia, body weight loss, and anemia were observed in 
most of the studies at the lethal concentrations, suggesting that the deaths may be related to a functional
copper deficiency.  The copper content of the diet was adequate in the Arrington and Davis (1953) study
and was not reported in the Widjajakusuma et al. (1973), Robinson et al. (1969), and Valli et al. (1969)
studies.  No deaths have been reported in rat studies (e.g., Lyubimov et al. 2004; Murray et al. 2013, 
2014; Pandey and Singh 2002).
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3.2.2.2  Systemic Effects
Respiratory Effects. Only one animal study examined the respiratory tract following oral exposure
to molybdenum.  No lesions were observed in the lungs of rats exposed to ≤60 mg molybdenum/kg/day as
sodium molybdate in the diet for 90 days (Murray et al. 2013).
Cardiovascular Effects. Using the NHANES dataset (2009–2012), Shiue and Hristova (2014) found 
a significant positive association between urinary molybdenum levels and high blood pressure among
adults after adjusting for potential confounders (adjusted odds ratio of 1.45; 95% confidence interval of
1.04–2.02).  The investigators estimated that molybdenum accounted for 6.3% of the variance in the
population risk and significant associations were also found for other metals including cesium, lead, 
platinum, antimony, arsenic, and tungsten and industrial pollutants including phthalates, bisphenol A, and 
parabens.  In a population-based study examining the possible association between municipal water
constituents and cardiovascular mortality in residents of 94 large cities in the United States, Schroeder
and Kraemer (1974) found a weak negative correlation between arteriosclerotic heart disease deaths and
molybdenum levels among white males, but not white females or nonwhite males or females. The mean
concentration of molybdenum in the municipal water samples was 1.25 µg/L (0.00003 mg
molybdenum/kg/day, assuming a water intake of 2 L/day and body weight of 70 kg) with a range of 0– 
16 µg/L. These studies appear to provide conflicting results, with one study suggesting a beneficial effect
of increased molybdenum (Schroeder and Kraemer 1974) and the other a detrimental effect (Shiue and
Hristova 2014).  However, a number of etiological factors contribute to the overall risk of both diseases
and the contribution of molybdenum to the overall risk was low in both studies.
No alterations in heart weight or histopathology were observed in rats ingesting ≤60 mg
molybdenum/kg/day as sodium molybdate for 90 days (Murray et al. 2013).  Peredo et al. (2013) reported
a slight decrease (approximately 4%) in systolic blood pressure in rats exposed to 100 mg
molybdenum/kg/day as sodium molybdate in drinking water for 9 weeks; this slight decrease in blood 
pressure was not considered biologically relevant.
Gastrointestinal Effects. No histological alterations were observed in the gastrointestinal tract of
rats exposed to ≤60 mg molybdenum/kg/day as sodium molybdate in the diet for 90 days (Murray et al. 
2013).  In contrast, Fell et al. (1979) reported soft feces and diarrhea and a number of histological
alterations in the gastrointestinal tract of rats exposed for up to 21 days to 0.5 mg molybdenum/kg/day as
ammonium tetrathiomolybdate in the diet (diet provided an inadequate amount of copper).  The
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alterations included shortening of the gastric pits with a reduction in the amount of mucin in the stomach, 
an increase in the crypt to villus ratio in the small intestine due to a lengthening of the crypts, edema of
the lamina propria in the ileum, and submucosal edema of the cecum resulting in a thickening of the
cecum but no effect on the brush border.  However, the investigators did not provide incidence data,
which limits the assessment of these alterations.
Hematological Effects. In general, the hematological system does not appear to be a target of
molybdenum toxicity when the basal diet contains adequate levels of copper.  In rats exposed to sodium
molybdate or ammonium heptamolybdate, the highest NOAEL values for hematological alterations 
ranged from 3.35 to 150 mg molybdenum/kg/day for intermediate-duration exposure (Brinkman and 
Miller 1961; Franke and Moxon 1937; Gray and Daniel 1954; Hunt and Navia 1973; Jeter and Davis
1954; Johnson et al. 1969; Murray et al. 2013).  One study reported decreases in erythrocyte counts,
hemoglobin, and hematocrit in rats exposed to 4.4 mg molybdenum/kg/day as ammonium
tetrathiomolybdate administered via gavage for 59–61 days (Lyubimov et al. 2004).  Although the basal
diet contained the NRC’s recommended amount of copper (NAS 1995), hematological effects were not
observed in rats exposed to the same molybdenum dose receiving a diet containing additional copper
(110 ppm), suggesting that the hematological effects may have been secondary to a molybdenum-induced 
copper deficiency (anemia is a sign of copper deficiency).  In young rabbits, exposure to 54 mg
molybdenum/kg/day as sodium molybdate in the diet resulted in anemia (Arrington and Davis 1953). 
Even though the reported copper concentration in the diet exceeded the more recently recommended 
standard of 3 ppm (NAS 1977), administration of additional copper resulted in increases in hemoglobin 
levels. In a similar study using mature rabbits, anemia was observed in one of two rabbits exposed to 
30 mg molybdenum/kg/day as sodium molybdate in the diet (Arrington and Davis 1953).  Decreases in
hemoglobin levels and packed cell volume were also observed in two other rabbit studies (Valli et al.
1969; Widjajakusuma et al. 1973) in which rabbits were exposed to 77 or 59 mg molybdenum/kg/day in 
the diet for approximately 4 weeks. Mortality was observed in both studies and neither study reported the
copper levels of the basal diet; Valli et al. (1969) did note that the rabbits were fed a diet with a low
copper content.  In pigs, no hematological alterations were observed following dietary exposure to 20– 
100 ppm molybdenum as sodium molybdate or ammonium heptamolybdate in the diet for at least 
8 weeks (Gipp et al. 1967; Kline et al. 1973); the studies did not provide sufficient information to allow
for an estimation of the molybdenum dose.
Musculoskeletal Effects. A number of animal studies have examined the effect of molybdenum on 
bone growth and strength and on the promotion of dental caries.  Musculoskeletal effects were observed
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in two studies in which the diet contained at least the recommended level of copper.  In a study by
Johnson et al. (1969) in which rats were exposed to 150 mg molybdenum/kg/day as sodium molybdate in 
the diet for 6 weeks (the basal diet contained copper levels that were 3 times higher than the 
recommended amount), decreases in femur breaking strength (22% less than controls) and tail ring
rupture strength (32% less than controls) were observed.  Young rabbits exposed to ≥54 mg
molybdenum/kg/day as sodium molybdate for 30–84 days exhibited a front limb abnormality
characterized by weakness progressing to an inability to “maintain weight and legs spread outward”
(Arrington and Davis 1953).  This was not observed in mature rabbits exposed to ≤120 mg
molybdenum/kg/day as sodium molybdate for at least 54 days (Arrington and Davis 1953).  The
investigators noted that in three of the seven affected animals, one or both feet bent inward at the carpus
joint, the articular surface of the radius was exposed, and the tendon slipped out of normal position.  It
should also be noted that increases in mortality were also observed in the young rabbits exposed to 54 mg
molybdenum/kg/day, and in two of the rabbits with limb abnormalities, administration of additionally
copper did not reverse the skeletal effect, although there was improvement of other effects including
anemia and body weight gain.  
In an acute-duration study, femurs were significantly shorter in rats exposed to 0.6 mg
molybdenum/kg/day as ammonium heptamolybdate or ammonium tetrathiomolybdate for 13 days (Parry
et al. 1993).  No alterations in the width of the growth plate or the bone composition (dry matter content, 
ash content, or percentage of calcium or phosphorus) were found.  Similar findings were found in a
26-day study conducted by Parry et al. (1993); significant decreases in femur length were noted in rats 
exposed to 0.6 mg molybdenum/kg/day as ammonium heptamolybdate or ammonium tetrathiomolybdate
in the diet. Although no direct comparisons were made between the two molybdenum groups, the
magnitude of the decrease in femur length, as compared to the controls, was greater in the 
tetrathiomolybdate group.  Increases in growth plate width were also observed in the rats exposed to 
ammonium tetrathiomolybdate, but not in rats exposed to ammonium heptamolybdate.  In both 
experiments, the rats were fed a basal diet with inadequate copper levels (60% of the recommended 
concentration); in the ammonium tetrathiomolybdate study, plasma and liver copper levels indicated that
the animals were extremely copper deficient.  Spence et al. (1980) examined the development of
widening of the epiphyseal growth plate over time in rats exposed to 1 mg molybdenum/kg/day as
ammonium tetrathiomolybdate in the diet for 2–21 days.  The study found cartilaginous dysplasia at the
epiphyseal growth plate with impaired or arrested endochondral ossification, increases in periosteal
osteogenesis and production of large amounts of disorganized bone, resorption of most trabecular bone,
hemorrhaging within and tearing of tendons and ligaments, rotation and slipping of the distal epiphysis in 
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the femur without fracture, and impaired fibrogenesis at ligamentous attachments to bone.  A thickening
and widening of the epiphyseal growth plate was observed in the distal femur and proximal and in the
epiphyses of the humeral head, distal radius, and ulna; these effects were observed within the first
2 weeks of the study. Other morphological alterations in the bone were observed after 7 days of
exposure; these included loss of alignment of hypertrophic cells at the periphery of the epiphyseal
cartilage and localized increases in cell numbers. In rats allowed to recover for 39 days following the
21-day exposure period, osteogenesis and fibrogenesis returned to normal, and remodeling and growth 
returned (although some abnormal cartilage and bone were present).  As with the Parry et al. (1993)
study, the rats in the Spence et al. (1980) study were fed a basal diet containing an inadequate amount of
copper (60% of the recommended level). Fejery et al. (1983) found an increase in femur breaking
strength in rats exposed to 0.17 or 1.7 mg molybdenum/kg/day (copper content of the diet was not
reported), which was considered a beneficial effect; at 17 mg molybdenum/kg/day, breaking strength was
similar to controls.  However, if the rats were maintained on a protein-deficient diet, decreases in
breaking strength were observed at 1.7 and 17 mg molybdenum/kg/day.  In rabbits exposed to a lethal
concentration of sodium molybdate (77 mg molybdenum/kg/day) in the diet for 4 weeks, fractures of the
humeral bone epiphyses were observed in 50% of the animals (Valli et al. 1969).  Other effects included
longitudinal widening of the epiphyseal cartilage, marked reduction in trabecular bone, irregularly
arranged spicules, and irregular metaphyseal calcification.  In addition, the investigators noted that there
was marked muscular degeneration in the pelvic limbs in 25% of the rabbits.  The copper content of the
basal diet was not reported in this study, although the investigators noted that the diet had a low copper
content.
Alterations in tooth enamel and caries formation have also been observed in laboratory animals exposed 
to molybdenum.  In rat pups administered 50 mg molybdenum/kg/day as sodium molybdate via gavage
on postnatal days (PNDs) 4–17 (prior to tooth eruption) and fed a caries-promoting diet on PNDs 18–35, 
a 25% increase in buccal enamel lesion and 85 and 12.5% increases in lesions penetrating to the buccal
and sulcal dentine-enamel junctions, respectively, were observed in the mandibular molars (Hunt and 
Navia 1975).  Fejery et al. (1983) reported biphasic alterations in incisor tooth enamel microhardness in 
rats exposed to sodium molybdate in drinking water for 6 weeks (the copper content of the basal diet was
not reported).  At 1.7 mg molybdenum/kg/day, there were increases in microhardness (6–7% increases in
surface and deep enamel microhardness), which was considered a beneficial effect.  However, at 17 mg
molybdenum/kg/day, tooth surface and deep enamel microhardness was decreased by 14.5 and 7.5%, 
respectively.  The study also examined the possible effect of a low protein diet (3% in the low-protein 
groups compared to 18% in the protein-adequate groups) and found that the beneficial effect of 1.7 mg
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molybdenum/kg/day did not occur in the rats in the low-protein diet; a 4–5% reduction in microhardness
was found at 1.7 mg/kg/day.  Van Reen et al. (1962) did not find increases in dental caries in weanling
NMRI-D rats (a caries susceptible strain) exposed to 8 mg molybdenum/kg/day as sodium molybdate for
5 weeks (the basal diet provided adequate copper levels).
Hepatic Effects. There are limited data on the hepatotoxicity of molybdenum in humans.  Using the
NHANES 2007–2008 data, Mendy et al. (2012) found a significant association between urinary
molybdenum levels and the risk of having a self-reported liver condition (odds ratio of 3.09; 95%
confidence interval of 1.24–7.73).  The geometric mean urinary molybdenum level of the population was
43.8 μg/g creatinine (95% confidence interval of 42.61–45.19); the investigators did not report the urinary 
concentration associated with the increased risk of liver conditions. This study does not establish
causality between molybdenum exposure and liver damage, and significant associations were also found 
between uranium and cesium levels and liver conditions.
The liver does not appear to be a sensitive target of molybdenum toxicity in laboratory animals, although 
effects have been observed at higher doses.  No histological alterations were observed in livers of rabbits
exposed to 1.2 mg molybdenum/kg/day as ammonium heptamolybdate in the diet for 14 days (Bersenyi et
al. 2008), rabbits exposed to 0.58 mg molybdenum/kg/day from carrots grown in ammonium
heptamolybdate rich soil, or rats exposed to 60 mg molybdenum/kg/day in the diet for 90 days (Murray et
al. 2013); these are the only studies that included histological examination of the liver. The Bersenyi et
al. (2008) female rabbit study did not find alterations in serum alanine or aspartate aminotransferases 
levels, γ-glutamyl transferase, alkaline phosphatase, or cholesterol levels; however, a 60% increase in
serum triglyceride levels was found at 1.2 mg molybdenum/kg/day.  In contrast, the Murray et al. (2013)
study examined similar serum clinical chemistry parameters (including triglyceride levels) and did not
find any significant alterations. A series of studies conducted by Rana and associates have also reported
some liver alterations in rats exposed to 300–490 mg molybdenum/kg/day as ammonium molybdate. The
reported alterations included increases in total lipid levels (Rana et al. 1980; Rana and Kumar 1980b, 
1980c), decreases in “total carbohydrate” (Rana and Kumar 1980c), decreases in glycogen content (Rana 
et al. 1985), and increases in serum alanine aminotransferase and aspartate aminotransferase activities 
(Rana and Chauhan 2000).  The addition of 100 mg/kg body weight/day copper to the basal diet
(approximately 5 ppm) appeared to reverse the effects of molybdenum on hepatic lipid and carbohydrate
levels (Rana and Kumar 1980c). There was low confidence in these studies due to the poor reporting of
the study design (including route of oral administration, whether the dose was reported in terms of
molybdenum or ammonium molybdate, and copper content of the diet), the lack of histological
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examination of the liver, and the reported body weight losses (Rana et al. 1980; Rana and Chauhan 2000); 
body weight was not assessed in every study.
Renal Effects. The available data from laboratory animal studies suggest that the kidney may be a 
target of molybdenum toxicity.  Most of these studies involved exposure to ammonium molybdate or
ammonium heptamolybdate and it is possible that the renal effects may be due to the ammonium ion 
rather than the molybdate.  In the only available acute-duration study, no histological alterations were
observed in the kidneys of female rabbits exposed to 1.2 mg molybdenum/kg/day as ammonium
heptamolybdate in the diet for 14 days (Bersenyi et al. 2008) or male rabbits exposed to 0.58 mg
molybdenum/kg/day from carrots grown in ammonium heptamolybdate-rich soil for 14 days (Bersenyi et
al. 2008). Murray et al. (2013) reported a slight diffuse hyperplasia in the renal proximal tubules in
2/10 female rats exposed to 60 mg molybdenum/kg/day as sodium molybdate in the diet for 90 days; no 
renal lesions were observed in females exposed to 60 mg molybdenum/kg/day for 90 days and allowed to 
recover for 60 days.  No alterations were observed in the male rats. Although the incidence was low, the
investigators considered it to be treatment-related because it is an uncommon finding in female rats of this
age.  Degenerative changes in the kidneys were noted in male rats exposed to 240 mg
molybdenum/kg/day as ammonium molybdate (Bandyopadhyay et al. 1981).  It should be noted that the
food intake in the molybdenum group was paired to another group of rats fed a low-protein diet and 
exposed to molybdenum; the basal diet likely provided adequate copper levels.  No other studies included 
histological examination of the kidneys.
Several studies reported alterations in serum and urinary parameters that could be suggestive of altered 
renal function.  Diuresis and creatinuria and a decrease in creatinine clearance were observed in rats 
administered via gavage 80 mg molybdenum/kg/day as ammonium heptamolybdate for 8 weeks (Bompart
et al. 1990).  The study did not find significant alterations in urinary protein or glucose levels.  Studies by
Rana and associates have reported increases in total lipid levels in the kidneys (Rana et al. 1980; Rana 
and Kumar 1980c), decreases in “total carbohydrate” levels in the kidney (Rana and Kumar 1980c),
increases in serum urea and urinary albumin levels (Rana and Kumar 1983), and increases in urine
specific gravity (Rana and Kumar 1983) in rats exposed to high doses of ammonium molybdate (300– 
490 mg molybdenum/kg/day).  The addition of copper (approximately 5 ppm) to the basal diet appeared 
to reverse the increased lipid and decreased carbohydrate levels (Rana and Kumar 1980c). As noted in 
the hepatic effects section, there is low confidence in these studies and the results should be interpreted
cautiously.
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Endocrine Effects. The possible association between molybdenum and thyroid effects was 
investigated in adults (subjects did not report having thyroid disease, thyroid cancer, or taking thyroid 
medication on a medical questionnaire completed at the blood sampling) using the NHANES 2007–2008 
data set (Yorita Christensen 2013). Significant associations between decreased levels of triidothyronine 
(free and total) and thyroxine (free) and higher urinary molybdenum levels were found.  Although the
study found associations, these data are inadequate for establishing causality. A study of men at a fertility
clinic found a significant inverse relationship between blood molybdenum levels and prolactin levels
(Meeker et al. 2009); the men were categorized into three groups based on blood molybdenum levels
(<70th percentile, 70th–85th percentile, and >85th percentile). The study did not find a significant
association with thyroid stimulating hormone and blood molybdenum levels.
In animal studies, increases in serum cortisol, prolactin, and follicle stimulating hormone levels were
found in male rats administered 240 mg molybdenum/kg/day as ammonium molybdate for 4 weeks
(Bandyopadhyay et al. 1981); as noted in the renal effects section, food intake was matched to a low-
protein molybdenum group.  Murray et al. (2013) did not find increases in histological alterations in the
adrenal glands, pituitary gland, or thyroid of rats exposed to 60 mg molybdenum/kg/day as sodium
molybdate in the diet for 90 days. Several thyroid effects were reported in rabbits exposed to 59 mg
molybdenum/kg/day as sodium molybdate in the diet for 25–31 days (Widjajakusuma et al. 1973). The
investigators did not report the copper content of the diet; it is likely to be low based on the severe
decreases in body weight, hematological parameters, and increased mortality. The effects included 
decreases in thyroxine secretion rates; decreases in follicle size (height and diameter); atrophy of the 
follicular epithelium, colloids, and stroma; and degenerative alterations in the follicular epithelium and 
interfollicular connective tissue. With the exception of the degenerative changes, similar, but less
prominent, thyroid effects were also observed in pair-fed controls, suggesting that the resulted decreases 
in food intake and body weight contributed to the thyroid toxicity.
Dermal Effects. There are limited data on the dermal toxicity of molybdenum following oral
exposure.  In the first study of weanling rabbits (Arrington and Davis 1953), alopecia and slight
dermatosis were observed in four of five rabbits exposed to 54 mg molybdenum/kg/day as sodium
molybdate in the diet for 84 days; no dermal effects were observed at 25 mg molybdenum/kg/day.  In 
another study by this group, alopecia and slight dermatosis were observed in one of two mature rabbits
exposed to 30 mg molybdenum/kg/day as sodium molybdate. Anemia was also observed at these doses.
In the study of weanling rabbits, administration of additional copper resulted in a return to a normal hair
coat, suggesting that copper insufficiency, possibly molybdenum induced, was a contributing factor to the
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dermal toxicity. Johnson et al. (1969) reported decreases (25% lower than controls) in skin rupture
strength in rats exposed to 150 mg molybdenum/kg/day as sodium molybdate in the diet for 6 weeks.
Ocular Effects. No ocular lesions were observed in rats exposed to 60 mg molybdenum/kg/day as
sodium molybdate in the diet for 90 days (Murray et al. 2013); no other studies examined ocular end
points.
Body Weight Effects. A large number of animal studies have reported alterations in body weight
following acute- or intermediate-duration exposure to molybdenum.  Large differences in terminal body
weights between controls and molybdenum-exposed groups and weight loss have been reported in many
studies in which the basal diet did not provide adequate levels of copper (Brinkman and Miller 1961; Fell
et al. 1983; Johnson and Miller 1961; Ostrom et al. 1961; Sasmal et al. 1968; Van Reen 1959).  In one
study, exposure to 500 mg molybdenum/kg/day as sodium molybdate resulted in weight loss in rats 
(Sasmal et al. 1968); no alterations in weight loss were observed at 50 or 100 mg molybdenum/kg/day.  
The weight loss began early in the study; the animals weighed about 35% less than at the start of the 
study after 1 week of exposure. In another study by this group (Sasmal et al. 1968), exposure to 50 mg
molybdenum/kg/day as ammonium molybdate resulted in weight loss.  Although the study suggests
differences between the two molybdenum compounds, the very low copper content of the diet (no 
additional copper was added to the purified diet) precludes extrapolating these data to other conditions.  
In another study comparing molybdenum compounds, a 10-day dietary exposure to 0.6 mg
molybdenum/kg/day as ammonium tetrathiomolybdate resulted in a 10% decrease in body weight in rats;
however, no alterations in body weight gain were observed in rats exposed to 0.6 mg molybdenum/kg/day
as ammonium heptamolybdate under the same exposure conditions (Parry et al. 1993). The copper
content of the diet was 3 ppm, which is lower than the recommendation of 5 ppm in the diet (NAS 1995).
Decreases in body weight gain have been observed in studies in which the basal diet provided a
nutritionally adequate level of copper (Arrington and Davis; 1953; Bompart et al. 1990; Jeter and Davis 
1954; Johnson 1969; Lyubimov et al. 2004; Mills et al. 1958; Murray et al. 2013; Van Reen and Williams
1956).  Studies in rats in which the basal diet contained at least twice the amount of copper recommended 
by the NAS (1995) reported significant decreases in body weight gain at 60–110 mg molybendum/kg/day
as sodium molybdate or ammonium heptamolybdate in intermediate-duration studies (Bompart et al. 
1990; Mills et al. 1958; Murray et al. 2013; Van Reen and Williams 1956; Williams and Van Reen 1956).  
The magnitude of the decrease in body weight gain appeared to be related to the dose, with approximately
15% decreases observed at 60 mg molybdenum/kg/day and 48% decreases observed at 110 mg
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molybdenum/kg/day.  Administration of ammonium tetrathiomolybdate resulted in a very low LOAEL of
4.4 mg molybdenum/kg/day for decreases in body weight gain (Lyubimov et al. 2004); there are 
insufficient data to assess whether this is evidence of differences between molybdenum compounds.
Decreases in food intake have also been reported in dietary exposure studies (Murray et al. 2013;
Williams and Van Reen 1956) and a gavage study (Lyubimov et al. 2004). Williams and Van Reen
(1956) found that when the control group food intake was matched to the molybdenum group, body
weight was not adversely affected after 5 weeks of exposure to 85 mg molybdenum/kg/day as sodium
molybdate.  However, when the control group had ad libitum access to food, exposure to 90 mg
molybdenum/kg/day as sodium molybdate resulted in a 22% decrease in body weight gain. In contrast, 
Murray et al. (2013) found a decrease in food conversion efficiency suggesting that factors other than the
reduction in feed intake resulted in the decreased body weight gain. Similarly, in a study by Johnson and 
Miller (1961) in which the basal diet contained 3.2 ppm copper, large differences (50–60% less) in food 
intake were observed between the control group and the group exposed to 20 ppm molybdenum/kg/day as
sodium molybdate.  However, when the control intake was matched to the molybdenum group’s intake, 
significant decreases in body weight gain were still observed.
Metabolic Effects. The potential of molybdenum to induce metabolic alterations has not been fully
investigated. Two studies in rats did not find significant alterations in serum glucose levels following
intermediate-duration exposure to 60 or 100 mg molybdenum/kg/day (Murray et al. 2013; Peredo et al. 
2013); additionally, serum insulin levels were not altered by exposure to 100 mg molybdenum/kg/day
(Peredo et al. 2013).  Prakash (1989) reported decreases in glycogen levels in the hind limb muscles of
rats administered 490 mg molybdenum/kg/day as ammonium molybdate via gavage for 30 days.  The
significance of this effect is difficult to determine since the study did not provide information on body
weight gain.
Other Systemic Effects. Koval’skiy et al. (1961) reported a significant increase in blood uric acid 
levels and symptoms of gout in residents living in an area of Armenia with high levels of molybdenum in 
the soil and food, as compared to residents living outside of this area. The mean uric acid levels in a 
subset of the examined population (n=52) was 6.2 mg/dL, as compared to levels in five control subjects 
who had a mean level of 3.8 mg/dL; the mean uric acid levels were 8.1 mg/dL among the subjects with 
gout symptoms and 5.3 mg/dL among the exposed subjects without symptoms.  The investigators 
reported that copper intakes (5–10 mg/day) were lower in the high molybdenum area as compared to
copper intake for residents outside of this area (10–15 mg/day).  It was also noted that gout-like
symptoms have not been observed in other high molybdenum areas that have higher copper intakes
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(Koval’skiy et al. 1961).  Interpretation of the result of this study is limited by the small control group, as
compared to the exposed group; lack of information on the selection of controls, particularly if they were 
matched to the exposed group; and lack of information on diet and alcohol exposure, which could 
influence uric acid levels. Based on the levels of molybdenum in the foodstuff, the investigators
estimated a daily dose of 10–15 mg (0.14–0.21 mg/kg/day assuming a 70-kg body weight). Deosthale
and Gopalan (1974) did not find significant increases in urinary uric acid levels in four subjects exposed
to a low molybdenum diet for 10 days followed by a high molybdenum diet with an ammonium
molybdate supplement for 7 days (TWA molybdenum intake was 0.014 mg molybdenum/kg/day), as
compared to uric acid levels when the subjects were fed a low molybdenum diet.  A series of studies in
Colorado investigated uric acid levels in communities with high molybdenum levels in the drinking water
from mine tailings pollution (EPA 1979).  Comparisons between subjects living in areas with high 
molybdenum in the drinking water (80–200 μg/L; approximately 0.002–0.006 mg/kg/day) to those living
in areas with lower levels (<40 μg/L; <0.001 mg/kg/day) did not result in any significant differences in
serum uric acid levels or urinary molybdenum levels. Another study (EPA 1979) noted that serum uric
acid levels were within the normal range in students with an estimated molybdenum intake of 500 μg/day
(0.007 mg/kg/day) (EPA 1979). A third study found significant increases in uric acid levels in residents 
with low molybdenum (20 μg/L; 0.0006 mg/kg/day) levels in the water and in residents with high 
molybdenum levels (150–200 μg/L; 0.004–0.006 mg/kg/day) in the drinking water; as compared to 
residents with drinking water levels of 0–50 μg/L (0–0.001 mg/kg/day). The inconsistencies in the results 
could be explained by the lack of control of several variables including age, sex, alcohol intake, dietary 
habits, and altitude.
Murray et al. (2013) found a statistically significant decrease in serum uric acid levels in female rats 
exposed to ≥5 mg molybdenum/kg/day as sodium molybdate in the diet for 90 days; no alterations were 
observed in male rats exposed to up to 60 mg molybdenum/kg/day.  Other statistically significant
alterations in serum clinical chemistry parameters noted in the Murray et al. (2013) study include
decreases in total protein and calcium at 60 mg molybdenum/kg/day in males and decreases in serum
creatinine at ≥5 mg molybdenum/kg/day in females.  The investigators noted that the changes in serum
clinical chemistry (including uric acid levels) were not considered treatment-related because the 
alterations were of small magnitude, not dose-related, due to outliers in the controls, and/or were
consistent with normal variability.  Quantitative data for the serum clinical chemistry parameters were not
provided in the published paper.
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3.2.2.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and lymphoreticular effects in humans and animals 
following oral exposure to molybdenum.
3.2.2.4  Neurological Effects 
There are limited data on the neurotoxicity of molybendum; no human or animal studies were designed to 
assess sensitive neurological end points. No overt signs of neurotoxicity were observed in laboratory
animal studies (e.g., Murray et al. 2013); Murray et al. (2013) did not report any histological alterations in 
the brain.
3.2.2.5  Reproductive Effects
There are limited data on reproductive effects of molybdenum in humans.  The available studies have
evaluated correlations between ambient molybdate exposure and reproductive health measures, including
semen quality (Meeker et al. 2008) and sex hormone levels (Meeker et al. 2010).  Meeker et al. (2008)
reported a negative significant association between higher molybdenum blood levels (>85th percentile, 
based on molybdenum levels in blood) and sperm concentration (adjusted odds ratio of 3.48, 95%
confidence interval of 1.12–10.8) after adjustment for potential confounders and other metal exposures.
No significant associations were found for sperm morphology (adjusted odds ratio of 2.61, 95%
confidence interval of 0.97–7.0) or sperm motility (adjusted odds ratio of 2.24, 95% confidence interval
of 0.77–6.49).  In another study, Meeker et al. (2010) reported a negative correlation between higher
molybdenum blood levels (≥70th percentile) and testosterone and free androgen index (molar ratio of total
testosterone sex hormone-binding globulin) levels.  The men in these studies, who were recruited from
Michigan infertility clinics and were not all considered to be infertile (i.e., their partners may have been 
infertile), were only exposed to molybdenum from their surroundings. A significant negative association
between a biomarker of molybdenum exposure (urinary levels) and serum testosterone levels was also
observed in a study of males participating in NHANES (2011–2012) (Lewis and Meeker 2015). The
study found a 3.82% decrease in serum testosterone levels when urinary molybdenum levels doubled
(after adjustment for age, body mass index [BMI], income, race, and smoking). Although these studies
found statistically significant associations, they do not establish causality and the alterations in 
reproductive parameters may be due to multiple factors rather than only to molybdenum exposure. 
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Several studies have evaluated the reproductive toxicity in male laboratory animals. Decreases in sperm
motility and concentration and increases in sperm morphological changes were observed in rats
administered via gavage 4.4 mg molybdenum/kg/day as ammonium tetrathiomolybdate for 59–61 days
(Lyubimov et al. 2004) or 14 mg molybdenum/kg/day as sodium molybdate for 60 days (Pandey and 
Singh 2002), and in mice exposed to 25 mg molybdenum/kg/day as sodium molybdate in the drinking
water for 14 days (Zhai et al. 2013). These studies also found decreases in epididymis, seminal vesicle,
and/or prostate gland weights (Lyubimov et al. 2004; Pandey and Singh 2002; Zhai et al. 2013).  
Degeneration of the seminiferous tubules was found in rats at 7 mg molybdenum/kg/day as sodium
molybdate, which was administered in the diet from weaning age through sexual maturity (Jeter and 
Davis 1954); although this study provided an adequate amount of copper, there was evidence of copper
deficiency (achromotrichia) at ≥7 mg molybdenum/kg/day.  Degeneration of the seminiferous tubules was 
also reported by Pandey and Singh (2002) for intermediate-duration (60 days) exposures in rats
administered molybdenum at doses up to 24 mg molybdenum/kg/day (sodium molybdate); however, the
dose(s) producing the effects are unclear and incidence data were not reported.  Lyubimov et al. (2004)
reported delayed spermiation, increased sperm and seminal fluid concentration, and increased sloughing
of epididymal tail epithelial cells at 4.4 mg molybdenum/kg/day as ammonium tetrathiomolybdate.  
Although the basal diet in the Lyubimov et al. (2004) study provided 11 ppm of copper, which is above
the NAS (1995) recommended amount for rats (5 ppm), dietary copper supplementation (110 ppm)
prevented testicular toxicity. It is likely that the tetrathiomolybdate interfered with the absorption of
dietary copper, resulting in a secondary effect of copper insufficiency.  In contrast to these findings, 
Murray et al. (2013) did not find any alterations in spermatid, sperm counts, sperm motility, or sperm
morphology in rats exposed to 60 mg molybdenum/kg/day as sodium molybdate in the diet.  Although the
study found no alterations in the percentage of motile sperm, a significant decrease in the percentage of
progressively motile sperm was observed at 60 mg molybdenum/kg/day (59.0% compared to 69.4% in 
controls).  The investigators noted that the decrease was likely attributable to the control group having a
value that approached the upper end of the range for historical controls (mean of 59.8%). Given the
results of the Lyubimov et al. (2004), Pandey and Singh (2002), and Zhai et al. (2013) studies, the 60 mg
molybdenum/kg/day dose level was considered a LOAEL for male reproductive effects. It should be
noted that the basal diet in this study exceeded the NAS (1995) recommendation; the copper content was
14.23 ppm.
Effects have also been observed in female laboratory animals.  An increase in the rate of M II oocyte 
morphological abnormalities and decreases in relative ovarian weights were observed in mice exposed to
11 mg molybdenum/kg/day as sodium molybdate in drinking water for 14 days (Zhang et al. 2013).  The
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investigators also reported ovarian hyperemia in mice exposed to 5.3 and 11 mg molybdenum/kg/day;
however, the incidence and statistical significance were not reported.  Irregularities in the estrous cycle 
were reported in rats administered 1.5 mg molybdenum/kg/day in the drinking water from weaning
through sexual maturity (Fungwe et al. 1990).  Murray et al. (2013) did not find any alterations in vaginal
cytology or estrus cycle in female rats exposed to ≤60 mg molybdenum/kg/day as sodium molybdate and 
Bersenyi et al. (2008) did not find histological alterations in the ovaries of rabbits exposed to 1.2 mg
molybdenum/kg/day as ammonium heptamolybdate in the diet for 14 days.
Several intermediate-duration studies evaluated fertility.  No alterations in fertility were observed in
female rats exposed to ≤15 mg molybdenum/kg/day as sodium molybdate in drinking water (Fungwe et
al. 1990) or in male and female rats exposed to 7 mg molybdenum/kg/day as sodium molybdate in the
diet when a high copper diet was administered (Jeter and Davis 1954).  In contrast, Pandey and Singh 
(2002) reported decreases in fertility in males exposed to 14 mg molybdenum/kg/day and mated to 
unexposed females.  Another study conducted by Jeter and Davis (1954) in which rats were exposed to
7 mg molybdenum/kg/day from weaning to maturity also found impaired male fertility; in this study, 
there is some indication that the diet did not provide an adequate level of copper.
3.2.2.6  Developmental Effects 
There are limited data on the developmental effects of molybdenum in humans from two population 
studies.  Vazquez-Salas et al. (2014) found an association between third trimester maternal urinary
molybdenum levels (mean level of 54.0 µg/g creatinine) and infant psychomotor development indices, 
including gross and fine motor coordination, during the first 30 months of life in a study of women in 
Mexico participating in a prospective study of neurodevelopment in children.  A doubling of creatinine
corrected urinary molybdenum levels resulted in significant decreases in psychomotor development index
scores. No association was found between maternal urinary molybdenum levels during pregnancy (mean 
levels ranged from 45.6 to 54.6 µg/g creatinine during the first, second, and third trimesters) and newborn
body weight or infant mental development indices (sensory ability, memory, learning, problem solving, 
and verbal ability).  Shirai et al. (2010) found no association between maternal urinary molybdenum
levels and newborn body weight, length, or head circumference in women in Japan with mean urinary 
molybdenum levels of 79.0 µg/g creatinine. As noted elsewhere in this document, these observational
epidemiology studies do not establish causality between molybdenum and developmental effects, and 
other factors are likely to have contributed to the risk.
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Several studies have examined the effect of molybdenum on development in laboratory animals.  No 
developmental effects were reported in three studies of rats exposed to molybdenum in the presence of
adequate copper concentrations in the basal diet (Jeter and Davis 1954; Lyubimov et al. 2004; Murray et
al. 2014).  Murray et al. (2014) reported no effects on litter size, embryofetal survival, sex ratio, fetal
body weight, or fetal malformations and variations in rats exposed to 38 mg molybdenum/kg/day as
sodium molybdate in the diet on gestation days 6–20.  Similarly, Lyubimov et al. (2004) found no effects
on litter size or fetal survival in rats administered molybdenum daily via gavage at 4.4 mg
molybdenum/kg/day as ammonium tetrathiomolybdate for 59–61 days (for 29 days prior to mating, 
during mating, and thereafter until sacrifice) in males or for 22–35 days (for 15 days prior to mating, 
during mating, and during gestation days 0–6) in females. No alterations in birth weights were observed
in the offspring of male and female rats exposed to 7 mg molybdenum/kg/day as sodium molybdate for at
least 14 weeks (Jeter and Davis 1954). However, a fourth study found decreases in the number of live 
fetuses, fetal crown-rump length, and fetal body weight in the offspring of male rats administered 14 mg
molybdenum/kg as sodium molybdate via gavage for 60 days prior to mating to untreated females
(Pandey and Singh 2002).  The copper content of the commercial diet was not reported, but was assumed 
to be adequate. Two studies only available as abstracts provide additional information on the potential
developmental toxicity of molybdenum.  Lyubimov et al. (2002) found no developmental effects in rats
exposed to 6 mg/kg/day as tetrathiomolybdate on gestation days 6–17.  Exposure on gestation days 7–20, 
resulted in an increase in carpal/tarsal flexure in the offspring of dams exposed to 20 mg/kg/day
ammonium tetrathiomolybdate (Lyubimov et al. 2003).  Although neither study provided information on 
the copper content of the diet, it is assumed to be adequate based on Lyubimov et al. (2004).
Developmental effects have also been reported in studies in which the copper content of the diets were 
lower than the NAS recommended standard of 8 ppm for pregnant rats (NAS 1995).  Fungwe et al. (1990)
reported increases in fetal resorptions and decreases in litter weights in female rats exposed to 1.3 mg
molybdenum/kg/day as sodium molybdate in the drinking water for 8 weeks prior to mating through 
gestation day 21; the copper content in the basal diet was 6.3 ppm.  Decreased maternal body weight gain
was also observed at doses resulting in developmental toxicity.  Decreased weaning weights were 
observed in the offspring of rats exposed to ≥2 mg molybdenum/kg/day as sodium molybdate; the copper
content of the diet was 5 ppm (Jeter and Davis 1954).  
***DRAFT FOR PUBLIC COMMENT***
   
 




























    
 
  
   
    
 
    
  
  






No studies were located regarding cancer in humans and animals following oral exposure to
molybdenum.
3.2.3 Dermal Exposure 
3.2.3.1  Death 
No studies were located regarding death in humans and animals following dermal exposure to 
molybdenum.
3.2.3.2  Systemic Effects
No studies were located regarding systemic effects in humans and animals following dermal exposure to
molybdenum.
3.2.3.3  Immunological and Lymphoreticular Effects 
There are limited data on the immunotoxicity of molybdenum in humans.  Studies of patients with 
stainless steel stents (which contain nickel, chromate, and molybdenum) or in patients prior to hip or knee
replacements found a low rate of positive results in patch tests with molybdenum (Koster et al. 2000;
Menezes et al. 2004; Zeng et al. 2014).  In patients with stainless steel stents, 3% had a positive delayed-
type contact hypersensitivity reaction to molybdenum chloride (Koster et al. 2000).  In the other studies, 
exposure to an unspecified molybdenum compound did not result in any positive hypersensitivity results.
Guinea pigs showed contact sensitization to a topical challenge with molybdenum pentachloride after
induction via intradermal injection with 0.03% molybdenum and topical exposure to 5.2% molybdenum
and an epicutaneous challenge with ≥0.35% molybdenum as molybdenum pentachloride (Boman et al. 
1979).  Similarly, guinea pigs were sensitized to 3.2% molybdenum as sodium molybdate following
intradermal (3.2% molybdenum) or topical (8% molybdenum) induction (Boman et al. 1979).
***DRAFT FOR PUBLIC COMMENT***
   
 













   
 





   
 
 





   
 
   
  
  
    
 
   
  
    
    
  
   
   
49MOLYBDENUM
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3.2.3.4  Neurological Effects 
No studies were located regarding neurological effects in humans and animals following dermal exposure 
to molybdenum.
3.2.3.5  Reproductive Effects
No studies were located regarding reproductive effects in humans and animals following dermal exposure
to molybdenum.
3.2.3.6  Developmental Effects 
No studies were located regarding developmental effects in humans and animals following dermal
exposure to molybdenum.
3.2.3.7 Cancer
No studies were located regarding cancer in humans and animals following dermal exposure to
molybdenum.
3.3  GENOTOXICITY
No studies were available regarding genotoxic effects of molybdenum compounds in humans following
environmental or occupational exposure to these compounds.  The genotoxicity of molybdenum
compounds has been studied mostly in in vitro assays utilizing prokaryotic organisms and in mammalian
cells.  Limited information is available regarding the in vivo genotoxicity of molybdenum.
As shown in Table 3-3, sodium molybdate induced a modest, but statistically significant, increase in
micronucleated bone marrow cells (polychromatic erythrocytes, PCE) from male C57BL/6J mice 
following two intraperitoneal injections of 200 or 400 mg/kg sodium molybdate on two consecutive days
(Titenko-Holland et al. 1998).  The increase in micronucleated cells per 1,000 PCE or in micronuclei per
1,000 PCE were about half of those produced by colchicine, the positive control. The same group of
investigators reported that sodium molybdate induced a positive response in the dominant lethal assay in 
mice.  In these experiments, male C57BL/6J mice were treated with 200 or 400 mg/kg sodium molybdate
and were mated with non-treated female C3H/J mice at various times after dosing.  Sodium molybdate
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Table 3-3.  Genotoxicity of Molybdenum Compounds In Vivo
Species Compound End point Results Reference
Mouse (male C57BL/6J) Sodium Micronuclei in bone (+) Titenko-Holland 
molybdate marrow cells et al. 1998
Mouse (male C57BL/6J) Sodium Dominant lethal assay (+) Titenko-Holland 
molybdate et al. 1998
Drosophila melanogaster Molybdenum Gene mutation + Ogawa et al.
wing spot test chloride 1994
+ = positive result; (+) = weakly positive result
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did not significantly affect pregnancy rate, but induced a significant dose-related increase in post-
implantation loss, which was attributed to an effect on post-meiotic male germ cells.
Assessment of the activity of molybdenum chloride in the Drosophila melanogaster wing spot test
showed that the compound induced spots with one or two mutant hairs (small spots) (Ogawa et al. 1994).  
Almost all of the spots detected were mutant clones expressing the mwh phenotype which, according to 
the investigators, suggested a nonlethal genetic change such as gene mutation or mitotic recombination
occurring at a late developmental stage, or a semi-lethal change such as partial aneuploidy for a 
chromosomal region containing the mwh locus.
Table 3-4 summarizes studies of genotoxic effects of molybdenum compounds in in vitro systems.
Results of gene mutation and DNA tests performed in prokaryotic organisms, almost all conducted
without metabolic activation, were mixed, but negative results outnumbered positive results.  It is worth
noting the positive results reported for potassium molybdate and ammonium molybdate in the DNA
repair assay (Nishioka 1975). The investigator speculated that because molybdenum has a valence of +6
in both compounds, molybdate is an oxidizing agent and the positive effect might reflect an oxidation
capacity.
The few studies that tested molybdenum compounds in mammalian cells provided mixed results
(Table 3-4).  Different results were reported by NTP (1997) and Gibson et al. (1997) in experiments with 
molybdenum trioxide: negative in the former study for chromosomal aberrations, and positive in the
latter for micronuclei formation.  Aside from the differences in end point tested, it should be noted that
NTP (1997) tested concentrations of molybdenum trioxide of up to 10 µg/mL, whereas Gibson et al. 
(1997) tested concentrations of molybdenum trioxide ranging from 250 to 750 µg/mL.  Titenko-Holland 
et al. (1998) reported positive results for micronuclei formation in human peripheral lymphocytes
incubated with sodium or ammonium molybdate.  However, because blood was collected from only two 
donors, the results should be interpreted with caution.
In summary, the limited information regarding effects in vivo of molybdenum compounds is insufficient
to infer possible outcomes of exposure in human populations.  In vitro studies in prokaryotic organisms
provided mixed results, but there is suggestive evidence that molybdenum valence +6, as in molybdate
compounds (MoO4-2), could induce genotoxicity due to its oxidative capacity. Too few studies were 
available regarding effects of molybdenum compounds in mammalian cells in vitro to draw a meaningful
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Table 3-4.  Genotoxicity of Molybdenum Compounds In Vitro
Results
With Without







Gene mutation No data – Arlauskas
et al. 1985
S. typhimurium, TA97,




















No data – Arlauskas
et al. 1985




No data + Nishioka 
1975




No data – Nishioka 
1975
E. coli PQ37 Molybdenum
chloride
DNA damage No data – Olivier and
Marzin 
1987
E. coli WP2s(ƛ) Sodium
molybdate
DNA damage No data (+) Rossman 
et al. 1984
E. coli WP2s(ƛ) Sodium
molybdate
DNA damage No data (+) Rossman 
et al. 1991
Bacillus subtilis, H17 and
M45
Molybdic acid DNA repair assay No data – Kanematsu 
et al. 1980
B. subtilis H17 and M45 Molybdenum
disulfide
DNA repair assay No data – Kanematsu 
et al. 1980
B. subtilis H17 and M45 Molybdenum
chloride
DNA repair assay No data – Nishioka 
1975
B. subtilis H17 and M45 Potassium
molybdate
DNA repair assay No data + Nishioka 
1975
B. subtilis H17 and M45 Ammonium
molybdate
DNA repair assay No data + Nishioka 
1975


















No data + Titenko-
Holland et
al. 1998
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Table 3-4.  Genotoxicity of Molybdenum Compounds In Vitro
Results
With Without
Species (test system) Compound End point activation activation Reference
Syrian hamster embryo	 Molybdenum Micronucleus No data + Gibson et
(SHE) cells trioxide assay al. 1997
Chinese hamster ovary Molybdenum Chromosomal – – NTP 1997
(CHO) cells trioxide aberrations
CHO cells	 Molybdenum Sister chromatid – – NTP 1997
trioxide exchanges
+ = positive result; (+) = weakly positive result; – = negative result; ± = equivocal result
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3.4.1.1  Inhalation Exposure 
Inhaled molybdenum particles that deposit in the respiratory tract are subject to three general distribution
processes:  (1) bronchial and tracheal mucociliary transport to the gastrointestinal tract; (2) transport to
thoracic lymph nodes (e.g., lung, tracheobronchial, mediastinal); or (3) absorption into blood and/or
lymph and transfer to other tissues (e.g., peripheral lymph tissues, liver, kidney).  The above processes
apply to all forms of deposited molybdenum, although the relative contributions of each pathway and 
rates associated with each pathway vary with the physical characteristics (e.g., particle size, solubility).
Particles having diameters >5 µm are deposited primarily in the upper airways (extrathoracic,
tracheobronchial regions) and are cleared from the respiratory tract primarily by mucociliary transport to 
the gastrointestinal tract (Bailey et al. 2007; ICRP 1994).  Smaller particles (≤5 µm) are deposited
primarily in the pulmonary region (terminal bronchioles and alveoli).  Particles are cleared from the
pulmonary region primarily by absorption, lymph drainage, macrophage phagocytosis and migration, and
upward mucociliary flow.
Dissolved molybdenum is absorbed into blood.  The rate of absorption will depend on solubility.  ICRP
(2012) assigns molybdenum sulfide, oxides, and hydroxides to a “slow” classification in their absorption,
which equates to an expected terminal absorption half-time of approximately 19 years (Baily et al. 2007;
ICRP 1994). More soluble forms of molybdenum, such as molybdenum trioxide (MoVIO3), would be
expected to undergo more rapid dissolution and absorption.
Quantitative estimates of absorption following inhalation exposure to molybdenum in humans or animals
were not identified.  Evidence for absorption of molybdenum trioxide is available from inhalation studies
on molybdenum trioxide conducted in rodents (Fairhall et al. 1945; NTP 1997).  Fairhall et al. (1945)
showed distribution to several tissues following inhalation exposure of guinea pigs to molybdenum
trioxide.  In rats and mice exposed to inhaled molybdenum trioxide (6.7–67 mg molybdenum/m3, 
6 hours/day, 5 days/week for 2 years), exposure-dependent increases in blood molybdenum were
observed (NTP 1997). The respectively blood molybdenum levels in the 0, 6.7, 20, and 67 mg
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molybdenum/m3 groups were 0.221, 0.800, 1.774, and 6.036 μg/g in male rats, 0.059, 0.355, 0.655, and 
2.411 μg/g in female rats, 0.102, 0.208, and 0.770 μg/g in male mice (no data were available for controls), 
and 0.043, 0.066, 0.198, and 0.523 μg/g for female mice.
3.4.1.2  Oral Exposure
Absorption of ingested molybdenum has been studied in human adults and infants (Cantone et al. 1993, 
1997; Engle et al. 1967; Giussani et al. 1998, 2006, 2007; Novotny and Turnlund 2006, 2007; Robinson 
et al. 1993; Sievers et al. 2001a, 2001b; Turnlund et al. 1995a, 1995b; Werner et al. 1998; Yoshida et al.
2006). These studies fall into two general categories: mass balance studies and bioavailability studies.
Mass balance studies estimate the absorption fraction from measurements of the difference between the 
ingested dose of molybdenum and fecal excretion (the difference being net absorption).  Bioavailability
studies estimate the absorption fraction from measurements of the plasma concentration of molybdenum
following the oral dose. These methods provide estimates of net absorption in that absorbed molybdenum
that is excreted into the gastrointestinal tract (e.g., biliary excretion) may not be accurately quantified 
from mass balance or bioavailability estimates. However, both approaches have been facilitated by the
use of stable isotopes of molybdenum (95Mo, 96Mo), which allow measurement of plasma and excretion
kinetics following concurrent intravenous and oral dosing. The use of stable isotopes also allows 
measurement of the administered molybdenum in plasma and excreta, distinct from background sources
of molybdenum derived from other sources and preexisting body stores.  By incorporating elimination 
kinetics data into mathematical models that include parameters representing absorption and fecal
excretion of absorbed molybdenum, the absorption fraction can be estimated. In most reported stable
isotope studies, the exact form of molybdenum administered was not reported. However, typically, the
isotope dosing material was prepared from an acid dissolution of metallic molybdenum (Mo[0]).  The
resulting material dissolved in water most likely was a mixture of soluble molybdate anion (Mo[VI]O42-) 
and other soluble molybdenum oxide hydrates.
Balance and bioavailability studies conducted in humans have shown that the fraction of ingested 
molybdenum that is absorbed depends on numerous factors, including molybdenum dose level, fasting, 
diet, and nutritional status.  Absorption was estimated to be 80–100% in replete fasted adults who 
ingested molybdenum dissolved in water or in a beverage (Giussani et al. 2006; Novotny and Turnlund 
2006, 2007; Turnlund et al. 1995a).  Absorption was 80–100% following a single dose of 20–40 μg 
Mo/kg dissolved in water and decreased with increasing dose level; absorption was 60% after a dose of
60 μg Mo/kg (Giussani et al. 2006).  Absorption was lower when molybdenum was ingested with a meal
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(40–60%), when dissolved in black tea (20%), or when incorporated into vegetables cultivated with 96Mo 
(30–60%), compared to when ingested without a meal (80–100%) (Giussani et al. 2006; Werner et al. 
1998). Absorption was lower when molybdenum was incorporated into the diet (83%) compared to when 
it was administered in a beverage (90–94%) (Novotny and Turnlund 2007). Absorption appears to be
affected by dietary molybdenum intake and molybdenum nutritional status. The absorption fraction was
90% in adults fed a diet containing 22 µg/day (approximately 0.3 µg Mo/kg/day), compared to 94% when 
fed a diet containing 467 µg Mo/day (approximately 7 µg Mo/kg/day) (Novotny and Turnlund 2007).  
Absorption in infants (gestational age 30–39 weeks) was 96–99% when a stable isotope of molybdenum
was mixed with breast milk or infant formula (Sievers et al. 2001a, 2001b).
Long-term diet mass balance studies, without the aid of stable isotopes, have been conducted in adults and
children (Engel et al. 1967; Robinson et al. 1973; Tipton et al. 1966).  Because these studies cannot
distinguish between the ingested dose of molybdenum and molybdenum excreted from body stores, these
studies will underestimate the absorption fraction. A 50-week balance study conducted in two adult
males (age 23 and 25 years) found absorption to range from 60 to 80% (Tipton et al. 1966). A 3-week
balance study conducted in women (age 19–21 years) found absorption to range from 40 to 70%
(Robinson et al. 1973). An 8-day balance study conducted in women (age 18–23 years) found absorption 
to range from 72 to 84% (Yoshida et al. 2006). Balance studies (18–30 days) conducted in female 
children (age 6–10 years) estimated the absorption fraction from diet to range from 67 to 85% (Engel et
al. 1967).
Measurements of the time course of plasma molybdenum following oral doses of molybdenum indicate
that absorption is relatively rapid, with peak concentrations in plasma attained within 100 minutes of
dosing (Giusanni et al. 2006; Novotny and Turnlund 2007).
Studies of absorption and elimination kinetics conducted in swine provide estimates of absorption of
ingested molybdenum. Based on cumulative urinary and fecal excretion measurements in swine dosed
with a stable isotope of molybdenum, absorption was estimated to be between 80 and 90% (Bell et al. 
1964). Studies conducted in rats have shown that tetrathiomolybdate (MoVIS42-) is more poorly absorbed 
when ingested in the diet; approximately 21% was absorbed when the copper content of the diet was
8 ppm (Mills et al. 1981b).
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3.4.1.3  Dermal Exposure 
Studies evaluating the absorption of molybdenum following dermal exposure were not identified.
3.4.2 Distribution 
3.4.2.1  Inhalation Exposure 
Very little information on the distribution on molybdenum following inhalation exposure is available.  
Following exposure of guinea pigs to inhaled molybdenum trioxide (150–300 mg/m3, 1 hour/day, 
5 days/week for 5 weeks), molybdenum was distributed to the lungs, liver, kidneys, and bone (Fairhall et
al. 1945).  Tissue levels decreased by approximately 20% in the 2-week postexposure period.  
3.4.2.2  Oral Exposure
Absorbed molybdenum distributes to various tissues.  Human autopsy studies have found that the kidney
and liver have the highest amounts of molybdenum (Iyengar et al. 1978; Schroeder et al. 1970; Sorensen 
and Archambault, 1963; Sumino et al. 1975; Tipton and Cook 1963; Tipton et al. 1965; Yoo et al. 2002; 
Zeisler et al. 1988).  Based on a review of these data, Giussani (2008) estimated liver and kidney
molybdenum concentrations to be approximately 0.5–1.5 µg Mo/g wet in liver (700–2,700 µg) and 0.2– 
0.4 µg Mo/g wet in kidney (55–120 µg). Coughtrey and Thorne (1983) reported relatively high 
concentrations (56 µg Mo/g) in bone, based on their recalculation of measurements of molybdenum in 
bone ash reported in Nusbaum et al. (1965) and Iyengar et al. (1978).  However, these results are not
supported by other studies (previously cited) and have been attributed to overestimation of tissue
concentrations measured by arc emission spectrometry in the Nusbaum et al. (1965) and Iyengar et al. 
(1978) studies (Giussani 2008).
Results of studies in rats and guinea pigs exposed to oral molybdenum show that molybdenum is widely
distributed (Bibr et al. 1977; Howell et al. 1993; Murray et al. 2014; Pandey et al. 2002). Generally, the
highest molybdenum tissue concentration is observed in the kidney. Molybdenum also is distributed to 
liver, spleen, brain, lung, heart, bone, muscle, testis, epididymis, seminal vesicles, prostate, blood cells, 
and plasma. Studies conducted in rats have shown that molybdenum absorbed following ingestion of
tetrathiomolybdate from the diet distributes to the kidneys and liver (Mills et al. 1981a).
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Maternal-Fetal Transfer. Results of studies in humans and animals show that molybdenum is distributed
to the fetus.  In humans, maternal and fetal cord blood levels obtained from 33 maternal-fetal pairs at
parturition show similar molybdenum levels (maternal: 1.44±0.75 µg/L, mean±standard deviation [SD]; 
fetal: 1.44±0.89 μg/L) (Bougle et al. 1989).  Molybdenum concentrations in venous cord blood (flowing
from the placenta to the fetus; 0.7±0.2 µg/L, mean±SD) were slightly higher than in arterial cord blood 
(flowing from the fetus to the placenta; 0.6±0.2 µg/L), indicating fetal retention of molybdenum (Krachler
et al. 1999).
Gestational exposure of rats to ammonium molybdate and thiomolybdate shows distribution of
molybdenum to fetal liver, kidney, bone, and brain (Howell et al. 1993). Levels in liver, kidney, and bone
were similar, with lower levels in brain.  In rats, dose-dependent increases in placental and maternal liver
content of molybdenum were observed following gestational exposure to molybdenum (sodium
molybdate) in drinking water (5–100 mg Mo/L; equivalent to approximately 0.76–15 mg/kg/day, based 
on intermediate exposure to nonpregnant female rats) over the full dose range (Fungwe et al. 1989).
However, neonatal whole-body levels of molybdenum reached a plateau at drinking water concentrations
≥50 mg/L (Fungwe et al. 1989).  Results suggest that molybdenum levels in the fetus reach steady state 
more rapidly than in dams.
Maternal-Infant Transfer. Several studies have measured molybdenum in breast milk (Anderson 1992;
Aquilio et al. 1996; Biego et al. 1998; Bougle et al. 1988; Casey and Neville 1987; Dang et al. 1984; Friel
et al. 1999; Krachler et al. 1998; Wappelhorst et al. 2002); the mean concentrations ranged from 0.02 to 
24 µg/L.  Breast milk concentrations are highest at the start of breast feeding and then decline (EFSA
2013).  In the only study comparing maternal intake to breast milk levels, Wappelhorst et al. (2002) did
not find a correlation between breast milk concentrations of molybdenum (mean concentration of
72 μg/L) and maternal molybdenum intake (mean intake of 132 μg/day).
3.4.2.3  Dermal Exposure 
Studies evaluating the distribution of molybdenum following dermal exposure were not identified.
3.4.3 Metabolism
Molybdenum exists in several valence states and may undergo oxidation and reduction.  Although 
molybdenum can exist in biological systems in several different valence states (3+, 4+, 5+, and 6+), the
primary form of molybdenum that interacts with enzyme systems is Mo[VI], as the molybdate anion 
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(Mo[VI]O22-) (Nakanishi et al. 2013).  After molybdate is taken into a cell, it is incorporated into a
molybdopterin to form molybdenum cofactor (Moco).  Moco is a sulfur-molybdate complex that forms
the prosthetic group in molybdenum-dependent enzymes (Mendel and Kruse 2012; Schwarz et al. 2009).  
Given that Moco is extremely sensitive to oxidation, it is believed that it is bound to a Moco binding
protein in the cell (Mendel and Kruse 2012).  This stored Moco would be readily available to meet the 
cell’s demand for molybdenum enzymes.  Molybdate forms complexes with copper and binds to plasma
proteins as a copper-molybdenum-sulfur (Cu-Mo-S) complex (Nederbragt 1980, 1982).
3.4.4 Elimination and Excretion 
3.4.4.1  Inhalation Exposure 
Studies investigating the elimination and excretion of molybdenum following inhalation exposure were
not identified.
3.4.4.2  Oral Exposure
Absorbed molybdenum is excreted in urine and feces in humans.  Urine is the dominant excretion route, 
accounting for approximately 75–90% of the absorbed dose (Giussani 2008; Novotny and Turnlund
2007).  The fraction excreted in urine increases with increasing dietary intake (Novotny and Turnlund
2007).  Urine also is the dominant excretory route for absorbed molybdenum in swine.  Following an oral
dose, approximately 90% of the dose was excreted in urine (Bell et al. 1964). To measure urinary and 
fecal excretion of molybdenum, Turnlund et al (1995a, 1995b) exposed four healthy adult males to 
various doses of a radioactive isotope of molybdenum (24–1,378 μg 100Mo/day) and administered 
intravenous doses of stable isotope of molybdenum (33 µg 97Mo).  Six days after exposure to 100Mo in the
diet, 17.8% of the 100Mo label was excreted in the urine at the lowest dose tested (total molybdenum dose
of 24 μg/day).  As the molybdenum dose increased, the amount excreted in the urine also increased; at the 
highest dose (1488 μg/day), 82.1% of the 100Mo was excreted in the urine.  A similar pattern of urinary
excretion was found when 97Mo was measured: 32.7% of the label at 24 μg/day and 86.7% at
1,488 μg/day.  The percentage of the molybdenum dose excreted in the feces decreased with increasing
doses.  At the lowest dose tested, 9.4% of the 100Mo dose was excreted in the feces; at the highest dose,
7.5% of the 100Mo dose was excreted in the feces.  In contrast, no consistent pattern of fecal 97Mo 
excretion was found.  When total molybdenum excretion was measured, the study found that 41% was
excreted in feces and 59% was excreted in urine at the lowest dose tested and 6% was excreted in feces 
and 94% was excreted in urine at the highest dose tested. Fecal excretion of absorbed molybdenum is
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thought to result from biliary secretion. Studies conducted in rats have shown that, following an 
intravenous dose of Mo[V] or Mo[VI], approximately 1% of the molybdenum dose was secreted into bile in
a period of 4 hours (Lener and Bibr 1979).
The rate of elimination of molybdenum from plasma has been studied in human clinical studies (Cantone
et al. 1997; Rosoff and Spencer 1964; Thompson et al. 1996; Werner et al. 2000).  Elimination is
approximately biphasic, with mean half-times of 30 minutes and 6.6 hours (Giussani 2008).
The whole-body elimination rate in rats is dose-dependent (Bibr and Lener 1973).  Following oral
administration of Mo[VI] at doses <3 µg Mo/kg, elimination was mono-phasic with a half-time of
approximately 47 hours.  Following doses >3 µg Mo/kg, the rate of elimination increased, with an 
increasing proportion of elimination contributed by a fast phase having a half-time of 6 hours.
3.4.4.3  Dermal Exposure 
Studies evaluating the elimination and excretion of molybdenum following dermal exposure were not
identified.
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
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PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  However, if the uptake and disposition of the chemical substance(s)
are adequately described, this simplification is desirable because data are often unavailable for many
biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-3 shows a conceptualized representation of a PBPK model.
If PBPK models for molybdenum exist, the overall results and individual models are discussed in this
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations.
Several multi-compartmental models of the kinetics of molybdenum in humans have been developed 
(Giussani 2008; Giussani et al. 1998, 2000; Novotny and Turnlund 2007; Thompson et al. 1996).  The
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Figure 3-3.  Conceptual Representation of a Physiologically Based
 

















































Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  Krishnan and Andersen 1994
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latest of these are the Giussani (2008) and Novotny and Turnlund (2007) models.  Both models yield 
similar predictions when applied to the same dosing scenarios (Giusanni 2008).  The Giussani (2008)
model has been adopted for use by the International Commission on Radiological Protection (ICRP) and 
is described in this section.
Giussani (2008) Model.
Giussani (2008) developed a model of molybdenum kinetics in humans.  The structure of the model is
shown in Figure 3-4 and parameter values are presented in Table 3-5.  Data used to derive and evaluate 
the model are described in Giusanni (2008) and included human clinical studies in which subjects were 
administered intravenous or oral doses of stable isotopes of molybdenum (Giusanni et al. 2006, 2007;
Novotny and Turnlund 2006, 2007; Turnlund et al. 1995a; Werner et al. 1998, 2000). The Giussani
(2008) model has been adopted for use by the ICRP and is described in this section.
The model consists of two central compartments representing extracellular fluids (ECF) and
compartments representing liver, kidney (two subcompartments), and a lumped compartment representing
all other tissues.  All transfers of molybdenum between compartments are first order and governed by
first-order rate coefficients (day-1).  The two ECF compartments represent fast and slow transfer pathways 
out of the ECF and were based on studies conducted in humans, which provide evidence for multi-phasic 
clearance of molybdenum from plasma (Giussani et al. 2007; Werner et al. 2000).  The half-times for the 
two ECF compartments are approximately 30 minutes for ECF1 and 280 minutes for ECF2.  Transfers
from the fast compartment (ECF1) are to liver, kidney, and urine.  Transfers from the slow compartment
(ECF2) are to urine, kidney, and other tissues; the slow compartment also receives molybdenum from the
liver.  Retention half-times in tissues are 41 days for liver, 14.5 days for kidney, and 21.5 days for the
other tissue compartment.  Excretion of absorbed molybdenum occurs in urine (88%) and transfer from
liver to the gastrointestinal tract (12%).
The model can simulate absorption from the gastrointestinal tract and respiratory tract. The absorption 
fraction for the gastrointestinal pathway uses an absorption fraction of 0.9 for molybdenum ingested in 
liquids and 0.6 for molybdenum ingested in the diet.  The model predicts a steady state for constant
dietary intake of molybdenum in adults, in which approximately 52% of the molybdenum body burden is
in liver, 3% is in kidney, 45% is in other tissues, 53% of the daily dose is excreted in urine, and 47% of
the daily dose is excreted in feces (Giussani 2008). The model is constructed to be able to interface with
output from the ICRP Human Respiratory Tract Model (HRTM) (ICRP 1994; Baily et al. 2007). The
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Figure 3-4.  The Proposed Systemic Model for Molybdenum Radionuclides
From alimentary tract, 









ECF = extracellular fluid
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Table 3-5.  Transfer Rates (Day-1) for the Molybdenum Model
Transfer rate Value (day-1)
ECF1 to ECF2 12.5
ECF1 to liver 14.2
ECF1 to urinary bladder contents 6.5
ECF2 to urinary path 1.7
ECF2 to other kidney tissues 0.115
ECF2 to other tissues 1.73
Liver to alimentary tract 0.0048
Liver to ECF2 0.0122
Other kidney tissues to ECF2 0.0474
Other tissues to ECF2 0.0323
Urinary path to urinary bladder contents 1.40
Urinary bladder contents to urine 12
Modified parameters of the alimentary tract
Stomach to small intestine (liquid form) 100
Stomach to small intestine (diet) 40
Small intestine to right colon (liquid form) 10
Small intestine to right colon (diet) 16
ƒA (liquid form)a 0.9
ƒA (diet)a 0.6
aDimensionless number.
ECF = extracellular fluid
Source:  Reprinted from Giussani (2008) with permission from Elsevier.
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inputs to the Giussani (2008) model from the HRTM would be simulated transfers of molybdenum to the
gastrointestinal tract (mucociliary transfer) and to blood (absorption from the respiratory tract), depending
on the particle size and solubility of the inhaled molybdenum, and other physiological factors (e.g., age, 
activity).
Novotny and Turnlund (2007) Model.
The major difference between the structures of the Giussani (2008) and Novotny and Turnlund (2007)
models is that the Novotny and Turnlund (2007) model has a single lumped compartment representing all
tissues outside of the vasculature. The Novotny and Turnlund (2007) model has two configurations: an 
intravenous configuration, which has two plasma compartments, representing fast and slower clearance,
and an oral configuration, which has a single plasma compartment.  Molybdenum exchanges between
plasma and a lumped tissue compartment. Urinary excretion is represented as a direct transfer from
plasma.  Absorbed molybdenum is also transferred to the gastrointestinal tract.
Novotny and Turnlund (2006, 2007) conducted mass balance studies with subjects who ingested stable
isotopes of molybdenum in the context of varying dietary intakes of molybdenum (22–1,490 µg Mo/day)
and found that certain model parameters were dependent on dietary intake. These included, in association 
with increasing dietary intake, an increase in the first-order rate coefficients for gastrointestinal
absorption, and urinary excretion, and a decrease in the rate coefficients for transfer from plasma to 
tissues. The largest adjustments were needed to simulate molybdenum kinetics in subjects who consumed
>121 µg Mo/day and included a 70% decrease in the coefficient for transfer of molybdenum from plasma
to tissues and a 660% increase in the rate coefficient for transfer from plasma to urine. These results 
suggest that high molybdenum intakes (>121 µg Mo/day) result in physiological adaptations that increase
excretion of absorbed molybdenum (Novotny and Turnlund 2007).
3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
Absorption. Mechanisms that participate in absorptive transport of molybdenum in the
gastrointestinal tract have not been characterized.  Molybdate (MoO42-) and sulfate (SO42-) show mutually
competitive inhibition for absorptive transport in rat small intestine, suggesting involvement of a common 
transporter for both anions (Cardin and Mason 1975, 1976).  This transporter may be the Na+/SO42-
symporter (NaS1 or SLC13A1) expressed in rodent small intestine and renal proximal tubule (Markovich 
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and Aronson 2007; Murer et al. 1994).  In humans, NaS1 is expressed in kidney but not small intestine,
suggesting that mechanisms of absorptive transport in humans may be different from that of rodents (Lee
at al. 2000).
Distribution. Bacteria and eukaryotes express cell membrane molybdate transporters, one of which 
(MoT2) also appears to be expressed in humans (Tejada-Jimenez et al. 2007, 2011).  In eukaryotes, this
transporter participates in the delivery of molybdate into cells for incorporation into molybdopterin-
cofactor (Moco), the biologically active prosthetic group in molybdenum-dependent enzymes (Schwarz et
al. 2009).  MoT2 transport of molybdate is inhibited by sulfate, suggesting a common carrier for
molybdate and sulfate.  A sulfate-insensitive oxalate-sensitive molybdate transporter has been described
in mammalian MEK-293T cells grown in culture (Nakanishi et al. 2013).  Uptake of molybdate into 
human red blood cells involves participation of the Cl-1/HCO3-1 anion exchanger (Gimenez et al. 1993).
Metabolism. Molybdenum-dependent enzymes contain a molybdopterin cofactor (Moco), which is
formed in a series of enzymatically catalyzed steps (Mendel and Bittner 2006). The final step, insertion 
of molybdate into Moco, may involve displacement of copper from of the molybdate binding site, which 
may provide a mechanism for copper-molybdenum interactions in regulating Moco synthesis and copper-
induced deficiency in molybdenum-dependent enzymes (Mendel and Bittner 2006).  Binding of
molybdenum to plasma proteins involves formation of a Cu-Mo-S complex (Nederbragt 1980, 1982).
Excretion. Mechanisms that participate in the renal excretion of molybdenum have not been 
characterized.  In sheep, reabsorption of filtered molybdate (MoO42-) is saturable, which results in an
increase in the fraction of filtered molybdate excreted as the plasma molybdate concentration increases 
and approaches or exceeds the tubular maximum (Ryan et al. 1987). In sheep and rat kidney, sodium-
dependent reabsorptive transport of molybdate (MoO42-) and sulfate (SO4-2) exhibit mutual inhibition
(Ryan et al. 1987).  This is consistent with participation of the Na+/SO42- symporter (NaS1 or SLC13A1)
in the reabsorption of molybdate.  This symporter is also expressed in the human renal proximal tubule
(Markovich and Aronson 2007; Murer et al. 1994). 
3.5.2 Mechanisms of Toxicity
The mechanism of molybdenum toxicity has not been well-established.  There are some indications that
the mode of action may involve altered copper utilization; however, it is likely that other mechanisms, 
including direct molybdenum alterations, are involved.  Support of the mode of action involving impaired 
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copper utilization comes from toxicology studies demonstrating more severe effects when animals are 
maintained on a copper-deficient diet; molybdenum induced alterations in copper levels in the plasma,
liver, and kidneys; and apparent reversal of adverse effects following administration of high doses of
copper.  A number of the effects observed in animals orally exposed to molybdenum, particularly
decreases in body weight and anemia (Arrington and Davis 1953; Brinkman and Miller 1961; Franke and 
Moxon 1937; Gray and Daniel 1954; Johnson et al. 1969), are similar to those observed in copper-
deficient animals.  Administration of high levels of copper results in a fairly rapid improvement or
prevents the effect from occurring (Arrington and Davis 1953; Lyubimov et al. 2004).  In rats fed a
copper-adequate diet, exposure to high levels of molybdenum in the diet resulted in significant increases
in plasma copper levels (Nederbragt 1980, 1982), most of which were in a “tightly bound form” that did 
not appear to be associated with ceruloplasmin (major copper-carrying protein in the blood), as evidenced
by the lack of an increase in ceruloplasmin levels (Nederbragt 1980).  Significant increases in liver and 
kidney copper levels were also observed in rats exposed to molybdenum in the diet and maintained on a
copper-adequate diet.
In ruminants, which appear to be very sensitive to molybdenum toxicity, it is believed that molybdenum
reacts with sulfate generated in the rumen to form thiomolybdates; copper can bind to these
thiomolybdates, which impairs its absorption.  There is also some indication that cupric thiomolybdates
can form in the blood if dietary copper levels are inadequate (Telfer et al. 2004). The copper in these
cupric thiomolybdates is unavailable to ceruloplasmin and other copper-containing proteins, resulting in a 
functional copper deficiency (Vyskocil and Viau 1999).  In monogastric animals exposed to sodium
molybdate, administration of sulfate decreases the toxicity of molybdenum (Miller et al. 1956; Van Reen 
1959).  However, when rats were fed diets containing molybdate and sulfide, there was a substantial
increase in plasma molybdenum and copper levels and liver molybdenum levels and a decrease in
ceruloplasmin activity.  In the plasma, there was a shift in the fraction of copper associated with albumin
and ceruloplasmin (Mills et al. 1981a).  Similar findings were observed in rats administered 
tetrathiomolybdates, but not in rats exposed to molybdates in the absence of sulfide (Mills et al. 1981a).  
In rats, exposure to tetrathiomolybdates resulted in effects similar to those observed in ruminants
including signs of copper deficiency, including loss of pigmentation in hair and a similar distribution of
copper between the plasma proteins (Mills et al. 1981b).  However, these interactions between 
tetrathiomolybdate and copper only occurred when both were present in the gastrointestinal tract (Mills et
al. 1981b).  It is not known if the interactions between copper and molybdenum only occur at higher
molybdenum doses.  As discussed by Brewer et al. (2000), tetrathiomolybdate can form a tripartite
complex with copper and protein, which can prevent copper absorption through the gastrointestinal tract.
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When tetrathiomolybdate is not administered with food, it can complex with copper and serum albumin,
which prevents cellular uptake of copper.  Due to these mechanisms, tetrathiomolybdate is used to treat
individuals with Wilson’s disease, which is a metabolic defect that limits the excretion of copper. Other
molybdenum compounds may also interfere with copper balance in humans.  Significant increases in
serum and urine copper levels were observed in men exposed 0.022 mg molybdenum/kg/day (the source 
of molybdenum was high molybdenum sorghum supplemented with ammonium molybdate) for 10 days,
as compared to exposure to 0.00771 mg molybdenum/kg/day for 10 days (Deosthale and Gopalan 1974).  
However, there was no difference in fecal excretion of copper, suggesting that copper absorption was not
affected. In contrast, another study (Turnlund and Keys 2000) did not find any significant alterations in 
serum copper levels in humans exposed to molybdenum levels of 22–1,490 μg/day (0.0003– 
0.02 mg/kg/day) for 24 days (subjects were fed diets containing naturally high or low levels of
molybdenum).
Other investigators have suggested that the molybdenum-induced effects are due to oxidative damage 
(Zhai et al. 2013; Zhang et al. 2013).  Zhai et al. (2013) showed that the levels of two enzymatic
antioxidants (superoxide dismutase and glutathione peroxidase) paralleled the molybdenum-induced 
sperm effects.  Increases in antioxidant levels and improvements in sperm parameters were observed at
lower molybdenum doses. However, at higher molybdenum doses, there were significant decreases in
antioxidant levels and significant decreases in sperm motility and concentration and an increase in the rate 
of sperm abnormalities.  Zhang et al. (2013) reported a similar finding for superoxide dismutase and 
glutathione peroxidase levels and the rate of MII oocyte abnormalities.
3.5.3 Animal-to-Human Extrapolations 
There are limited data to evaluate potential differences in the toxicity of molybdenum between laboratory
animals and humans.  Most of the available oral exposure studies were conducted in rats, and human data
are mostly limited to a small number of cross-sectional studies.  Within laboratory animal species, some 
differences have been observed between rats and rabbits, with rabbits appearing to be more sensitive than 
rats.  However, the studies are not directly comparable due to differences in the copper content and other
dietary constituents.  In the absence of data to the contrary, it is assumed that the toxicity of molybdenum
will be similar across species (excluding ruminants, see Section 3.5.2).
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3.6  HAZARD IDENTIFICATION AND MINIMAL RISK LEVELS
3.6.1 Hazard Identification
Systematic review of the available human and animal studies that assessed potential health effects 
associated with inhalation and oral exposure to molybdenum identified a number of potential targets of
toxicity.  Hazard identification conclusions for molybdenum, resulting from this systematic review, are
presented in Appendix B and are summarized as follows:
•	 Molybdenum is presumed to cause respiratory effects following inhalation exposure, based on an 
inadequate level of evidence from human studies and a high level of evidence from animal
studies.
•	 Molybdenum is suspected to cause hepatic effects, based on an inadequate level of evidence from
human studies and a moderate level of evidence from animal studies.
•	 Molybdenum is presumed to cause renal effects, based on a high level of evidence from animal
studies; human data are lacking.
•	 Molybdenum is suspected to cause reproductive effects, based on a low level of evidence from
human studies and a moderate level of evidence from animal studies.
•	 The data are not classifiable as to determine whether molybdenum results in developmental
toxicity because some human and animal studies have reported developmental effects and other
studies have not found effects.
•	 The data are not classifiable as to determine whether molybdenum results in alterations in uric
acid levels based on a high level of evidence of no effect in animal studies and an inadequate
level of evidence from human studies.
3.6.2 Minimal Risk Levels (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for molybdenum.  
An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
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Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
3.6.2.1  Inhalation MRLs
Acute-Duration. The database on the acute inhalation toxicity of molybdenum is limited to a study
conducted by NTP (1997) that evaluated the effect of molybdenum trioxide on the nasal cavity and on 
body weight.  No adverse effects were observed in the nasal cavity.  However, weight loss was observed
at the highest concentration tested (200 mg molybdenum/m3); decreases in body weight gain were 
observed in male rats exposed to 67 mg molybdenum/m3 and in female rats and mice exposed to 
200 mg/m3. Given the limited number of end points examined, the decrease in body weight gain was not
considered a suitable basis for an acute-duration inhalation MRL because the database is inadequate for
identifying the critical target of molybdenum toxicity following acute-duration inhalation exposure.
Intermediate-Duration. As with the acute-duration database, data on the intermediate-duration 
toxicity of molybdenum is limited to 90-day studies in rats and mice conducted by NTP (1997) that
examined a wide range of potential targets, including reproductive end points.  No toxicologically
significant alterations were observed at concentrations of molybdenum trioxide as high as 67 mg/m3. 
Consistent with ATSDR’s practice of not using free-standing NOAELs as a point of departure (POD), an 
intermediate-duration inhalation MRL was not derived.
Chronic-Duration. There are limited data on the toxicity of inhaled molybdenum in humans.  A study
of workers at a molybdenite roasting facility exposed to molybdenum trioxide and other oxides found no 
alterations in lung function, but did find increases in serum uric acid levels (Walravens et al. 1979); the
TWA molybdenum concentration was 9.46 mg molybdenum/m3. Another study of workers exposed to 
ultrafine molybdenum trioxide dust reported respiratory symptoms (dyspnea and cough), radiographic
abnormalities, and impaired lung function (Ott et al. 2004); the study did not provide monitoring data.  
Confidence in these cohort studies was considered very low (see Appendix B for additional information).
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NTP (1997) conducted a 2-year study in rats and mice that examined a wide range of potential targets of
toxicity.  Adverse effects were limited to the respiratory tract, specifically the nasal respiratory and
olfactory epithelium, epiglottis, and lungs.  The specific types of lesions and the incidence data are 
presented in Table 3-6.
Benchmark dose (BMD) modeling was used to fit the data for effects with statistically significant
increases in incidences at the lowest concentration (squamous metaplasia of the epiglottis in male and
female rats and mice, hyaline degeneration of the nasal respiratory and olfactory epithelium in female 
rats, histiocyte infiltration in the lungs in male mice, and alveolar epithelial metaplasia in male and female 
mice); the results of the modeling are presented in Appendix A.  Benchmark models provided adequate fit
for most of the datasets, predicting benchmark concentrations (BMCs) ranging from 0.46 to 5.73 mg
molybdenum/m3 and 95% lower confidence limits on the BMC (BMCL) ranging from 0.19 to 4.26 mg
molybdenum/m3.  Human equivalent concentrations (HECs) were calculated by adjusting the BMCLs for
intermittent exposure (6 hours/day, 5 days/week) and multiplying by the regional deposited dose ratio 
(RDDR) for the appropriate region of the respiratory tract.  The lowest HEC was 0.012 mg
molybdenum/m3 for squamous metaplasia of the epiglottis in female mice. This HEC was divided by an 
uncertainty factor of 30 (3 for extrapolation from animals to humans using dosimetric adjustments and 
10 for human variability), resulting in an MRL of 0.0004 mg molybdenum/m3.
3.6.2.2  Oral MRLs
Acute-Duration. A small number of studies have evaluated the acute toxicity of molybdenum.  One
human study (Deosthale and Gopalan 1974) that looked at a limited number of potential end points did 
not find alterations in urinary uric acid levels in subjects exposed to doses as high as 0.022 mg 
molybdenum/kg/day for 10 days.  In rabbits, exposure to 1.2 mg molybdenum/kg/day as ammonium
heptamolybdate in the diet for 14 days resulted in a 60% increase in serum triglyceride levels (Bersenyi et
al. 2008); no histological alterations were observed in the liver or kidneys.  The toxicological significance 
of this finding is not known and has not been reported in a study of male rabbits exposed to 0.58 mg
molybdenum/kg/day as ammonium heptamolybdate (Bersenyi et al. 2008) or rats exposed to 60 mg
molybdenum/kg/day as sodium molybdate for 90 days (Murray et al. 2013).
Reproductive effects have been observed in male and female mice and rabbits.  In females, an increased
rate of abnormal MII oocytes was observed at 11 mg molybdenum/kg/day in mice (Zhang et al. 2013); a
second study did not find histological alterations in the ovaries of rabbits (Bersenyi et al. 2008).  In males, 
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Table 3-6.  Incidence of Non-Neoplastic Respiratory Tract Lesions in Rats and
 
Mice Exposed to Molybdenum Trioxide for 2 Years 

Concentration (mg molybdenum/m3)
0 6.7 20 67
Male rats
Hyaline degeneration of nasal respiratory 2/50 7/49 48/49a 49/50a 
epithelium
Squamous metaplasia of epiglottis 0/49 11/48a 16/49a 39/49a 
Chronic lung inflammation in alveolus 2/50 3/50 25/50a 47/50a 
Female rats
Hyaline degeneration of nasal respiratory 1/48 13/49a 50/50a 50/50a 
epithelium
Hyaline degeneration of nasal olfactory 39/48 47/49b 50/50a 50/50a 
epithelium
Squamous metaplasia of epiglottis 0/49 18/49a 29/49a 49/50a 
Chronic lung inflammation 14/50 13/50 43/50a 49/50a 
Male mice
Nasal suppurative inflammation 2/50 6/50 10/49b 8/50b 
Nasal olfactory epithelium atrophy 3/50 5/50 3/49 10/50b 
Hyaline degeneration of nasal respiratory 11/50 13/50 11/49 41/50a 
epithelium
Squamous metaplasia of epiglottis 0/50 26/49a 37/48a 49/50a 
Laryngeal hyperplasia 1/50 3/49 6/48 41/50
Histiocyte infiltration in the lungs 2/50 16/50a 9/49b 9/50b 
Alveolar epithelial metaplasia 0/50 32/50a 36/49a 49/50a 
Female mice
Hyaline degeneration of nasal respiratory 26/49 23/50 28/49 48/49a 
epithelium
Hyaline degeneration of nasal olfactory 22/49 14/50 14/49 36/49a 
epithelium
Squamous metaplasia of epiglottis 1/49 36/50a 43/49a 49/50a 
Laryngeal hyperplasia 1/49 1/50 7/49 35/50
Alveolar epithelial metaplasia 2/50 26/50a 39/49a 46/49b 
aSignificantly different from controls; p≤0.01.
bSignificantly different from controls; p≤0.05.
Source:  NTP 1997
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a significant decrease in sperm concentration and motility and an increase in sperm abnormalities were
observed at 25 mg molybdenum/kg/day in mice (Zhai et al. 2013); a rabbit study reported a reduction in 
mature spermatocytes in rabbits exposed to 0.58 mg molybdenum/kg/day, but did not report the incidence
or statistical significance (Bersenyi et al. 2008).  Although the Bersenyi et al. (2008) study in male rabbits
identified the lowest LOAEL for reproductive effects, it was not selected as the basis of the acute MRL
because the incidence of the reduction in mature spermatocytes was not reported.  Rather, the Zhang et al. 
(2013) was selected as the key study for the acute-duration oral MRL.
The data were not considered suitable for BMD modeling (see Appendix A); thus, a NOAEL/LOAEL
approach was used to identify the POD for the MRL.  The MRL of 0.05 mg molybdenum/kg/day was
calculated by dividing the NOAEL of 5.3 mg molybdenum/kg/day by an uncertainty factor of 100 (10 for
extrapolation from animals to humans and 10 for human variability). It should be noted that the MRL is 
calculated based on the assumption of healthy dietary levels of molybdenum and copper and represents
the level of exposure above and beyond the normal diet.
Intermediate-Duration. Studies in laboratory animals have evaluated the intermediate-duration 
toxicity of molybdenum.  A number of adverse effects have been reported including kidney damage
(Bompart et al. 1990; Murray et al. 2013), decreases in body weight gain (Bompart et al. 1990; Lyubimov 
et al. 2004; Mills et al. 1958; Murray et al. 2013; Van Reen and Williams 1956), hematological effects
(Arrington and Davis 1953; Lyubimov et al. 2004), neurological effects (Arrington and Davis 1953), 
reproductive effects (Fungwe et al. 1990; Jeter and Davis 1954; Lyubimov et al. 2004; Murray et al. 2013;
Pandey and Singh 2002), and developmental effects (Pandey and Singh 2002).  The lowest LOAEL
values identified are 1.5 mg molybdenum/kg/day for prolonged estrus phase without an effect on fertility
in rats exposed to sodium molybdate in drinking water for 8 weeks (Fungwe et al. 1990) and 4.4 mg
molybdenum/kg/day for anemia, decreases in body weight gain, and decreases in sperm motility and 
count in rats administered via gavage ammonium tetrathiomolybdate for 22–35 days (females) or 59–61 
days (males) (Lyubimov et al. 2004).  The observed renal effects included slight diffuse hyperplasia in 
rats exposed to 60 mg molybdenum/kg/day as sodium molybdate in the diet (Murray et al. 2013) and 
increases in diuresis and creatinuria and decreases in creatinine clearance in rats administered 80 mg
molybdenum/kg/day as ammonium heptamolybdate (Bompart et al. 1990); the NOAELs identified in
these studies are 17 and 40 mg molybdenum/kg/day, respectively.  Two studies have reported 
hematological effects—decreases in erythrocyte count, hemoglobin concentrations, and hematocrit levels
in rats exposed to 4.4 mg molybdenum/kg/day as ammonium tetrathiomolybdate (Lyubimov et al. 2004)
and in rabbits exposed to 54 mg molybdenum/kg/day as sodium molybdate (Arrington and Davis 1953);
***DRAFT FOR PUBLIC COMMENT***
   
 








   
  
   
  
  
   
 
  
     
     
     
 
  
    
    
   
  
 
       
  
    
     
   
 
  
       
   
    
   
  
   
   




however, other studies have not found hematological effects in rats exposed to 60 or 70 mg
molybdenum/kg/day as sodium molybdate (Gray and Daniel 1954; Murray et al. 2013).  Neurological
effects consisting of weakness of the front legs progressing to an “inability to maintain weight and legs
spread outward” was observed in young rabbits exposed to 54 mg molybdenum/kg/day as sodium
molybdate (Arrington and Davis 1953); no neurological effects were observed at 25 mg
molybdenum/kg/day or in mature rabbits exposed to doses as high as 120 mg molybdenum/kg/day
(Arrington and Davis 1953).  Although several studies have reported reproductive effects, particularly
alterations in sperm parameters, there is considerable overlap between the identified NOAELs and
LOAELs that are summarized in Table 3-2.  Some of the overlap may be explained by the copper content
of the diet.  In the Jeter and Davis (1954) and Murray et al. (2013) studies, the copper content of the diet
exceeded the recommended intake for rats (5 ppm) (NAS 1995) by a factor of 4 or 2.8, respectively. Four
studies examined the developmental toxicity of molybdenum following intermediate-duration exposure.  
No alterations in resorptions, post-implantation losses, or fetal body weights were observed in three
studies with doses as high as 37.5 mg molybdenum/kg/day (Jeter and Davis 1954; Lyubimov et al. 2004;
Murray et al. 2014).  A fourth study reported increases in post-implantation losses, increased resorption,
and decreases in fetal growth in a study in which males only were administered 14 mg molybdenum/kg
(5 days/week) for 60 days (Pandey and Singh 2002).
Reproductive toxicity in males and females consistently has the lowest LOAEL values. Reproductive
effects have also been observed following acute-duration exposure, and the systematic review of the 
available human and animal data (Appendix B) showed that reproductive toxicity is “suspected to be a
health effect following oral exposure.” The Fungwe et al. (1990) study identified the lowest LOAEL of
1.5 mg molybdenum/kg/day; the NOAEL was 0.76 mg molybdenum/kg/day.
BMD modeling of the estrous cycle length data from the Fungwe et al. (1990) study was conducted to 
identify the POD for the MRL using a benchmark response (BMR) of 1 SD change from the control.  The 
continuous variable models did not adequately fit the data and a NOAEL/LOAEL approach was used to
identify the POD for the MRL.  An MRL of 0.008 mg/kg/day was derived by dividing the NOAEL of
0.76 mg molybdenum/kg/day by an uncertainty factor of 100 (10 for extrapolation from animals to 
humans and 10 for human variability).  The MRL is calculated based on the assumption of healthy dietary
levels of molybdenum and copper and represents the level of exposure above and beyond the normal diet.
The MRL is approximately 10-fold higher than the recommended dietary allowance of 0.0006 mg/kg/day
(estimated using a reference body weight of 70 kg) (NAS 2001).
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Chronic-Duration. Data on the chronic toxicity of molybdenum come from several population-based
studies; most of these studies looked for associations between background exposure to molybdenum and 
adverse health outcomes.  No laboratory animal studies were identified.  Koval’skiy et al. (1961) found 
increases in blood uric acid and symptoms of gout in residents living in Armenia with high levels of
molybdenum in the soil and food; the investigators estimated that the residents were exposed to 10– 
15 mg/day (0.14–0.21 mg/kg/day).  A series of small studies of residents living in areas of Colorado with
high levels of molybdenum in the drinking water did not find significant increases in uric acid levels; one
study estimated that molybdenum intake was 500 μg/day (0.007 mg/kg/day) (EPA 1979).  Other studies
have found significant associations between serum or urinary molybdenum levels and the severity of
complications from diabetes (Rodriguez Flores et al. 2011), high blood pressure (Yorita Christensen 
2013), semen quality (Meeker et al. 2008), testosterone levels (Meeker et al. 2010), and psychomotor
index in infants (molybdenum levels were measured in the mothers) (Vazques-Salas et al. 2014).  
However, none of these studies established causality, and the molybdenum levels accounted for only a
small percentage of the variance.  No chronic-duration animal toxicity studies were identified.
Although the Koval’sky et al. (1961) study provided an estimated dose, the study was not considered 
suitable for derivation of a chronic-duration oral MRL for molybdenum.  The study has a number of
deficiencies that limit the interpretation of the results: (1) the control group consisted of 5 individuals
compared to 52 subjects in the exposed group; (2) no information was provided on the controls to assess
whether they were matched to the exposed group; (3) it does not appear that the study controlled for
potential confounders, such as diet and alcohol, which can increase uric acid levels; and (4) NAS (2001)
noted that there were potential analytical problems with the measurement of serum and urine copper
levels.
3.7  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
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1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans and/or animals after exposure to 
molybdenum. No in vitro studies were located regarding endocrine disruption of molybdenum.
3.8  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when most biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
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Children sometimes differ from adults in their susceptibility to adverse health effects from exposure to
hazardous chemicals, but whether there is a difference depends on the chemical(s) (Guzelian et al. 1992;
NRC 1993).  Children may be more or less susceptible than adults to exposure-related health effects, and
the relationship may change with developmental age (Guzelian et al. 1992; NRC 1993).  Vulnerability
often depends on developmental stage.  There are critical periods of structural and functional
development during both prenatal and postnatal life that are most sensitive to disruption from exposure to 
hazardous substances.  Damage from exposure in one stage may not be evident until a later stage of
development. There are often differences in pharmacokinetics and metabolism between children and
adults.  For example, absorption may be different in neonates because of the immaturity of their
gastrointestinal tract and their larger skin surface area in proportion to body weight (Morselli et al. 1980;
NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young children (Ziegler et al. 
1978).  Distribution of xenobiotics may be different; for example, infants have a larger proportion of their
bodies as extracellular water, and their brains and livers are proportionately larger (Altman and Dittmer
1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and Dickerson 1964).  Past
literature has often described the fetus/infant as having an immature (developing) blood-brain barrier that 
is leaky and poorly intact (Costa et al. 2004).  However, current evidence suggests that the blood-brain 
barrier is anatomically and physically intact at this stage of development, and the restrictive intracellular
junctions that exist at the blood-CNS interface are fully formed, intact, and functionally effective 
(Saunders et al. 2008, 2012).
However, during development of the brain, there are differences between fetuses/infants and adults that
are toxicologically important. These differences mainly involve variations in physiological transport
systems that form during development (Ek et al. 2012).  These transport mechanisms (influx and efflux)
play an important role in the movement of amino acids and other vital substances across the blood-brain 
barrier in the developing brain; these transport mechanisms are far more active in the developing brain
than in the adult.  Because many drugs or potential toxins may be transported into the brain using these
same transport mechanisms—the developing brain may be rendered more vulnerable than the adult.  
Thus, concern regarding possible involvement of the blood-brain barrier with enhanced susceptibility of
the developing brain to toxins is valid.  It is important to note however, that this potential selective
vulnerability of the developing brain is associated with essential normal physiological mechanisms; and
not because of an absence or deficiency of anatomical/physical barrier mechanisms.
The presence of these unique transport systems in the developing brain of the fetus/infant is intriguing;
whether these mechanisms provide protection for the developing brain or render it more vulnerable to 
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toxic injury is an important toxicological question.  Chemical exposure should be assessed on a case-by-
case basis.  Research continues into the function and structure of the blood-brain barrier in early life
(Kearns et al. 2003; Saunders et al. 2012; Scheuplein et al. 2002).
Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of
growth and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns given their low glomerular filtration rate and not having developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
There are limited data on the toxicity of molybdenum in children.  In studies in rat pups maintained on a
caries-promoting diet, administration of 50 mg molybdenum/kg/day as sodium molybdate resulted in an 
increase in buccal enamel lesions (Hunt and Navia 1975), but exposure to 8 mg molybdenum/kg/day did 
not result in increases in dental caries (Van Reen et al. 1962). Arrington and Davis (1953) exposed young
(6 weeks of age at the start of the study) and mature rabbits to sodium molybdate in the diet for 30– 
84 days.  Marked muscular/skeletal effects were observed in the young rabbits, but were not observed in
the mature rabbits.  Since the investigators did not provide information on dietary intake, it is difficult to
make direct comparisons across the studies.
An observational study did not find an association between maternal urinary molybdenum levels and 
newborn body weight or infant mental development (Shirai et al. 2010).  But another study did find an 
association between third-trimester maternal urinary molybdenum levels and infant psychomotor
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development indices (Vazquez-Salas et al. 2014).  Two rat studies in which the copper content of the diet
was adequate did not find significant alterations in fetal growth, survival, or malformations at maternal 
doses of 4.4 or 38 mg molybdenum/kg/day (Lyubimov et al. 2004; Murray et al. 2014).  However, a third 
study reported decreases in growth and number of live fetuses in the offspring of male rats administered
14 mg molybdenum/kg as sodium molybdate 5 days/week for 60 days prior to mating with unexposed 
females (Pandey and Singh 2002).
3.9  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
The National Report on Human Exposure to Environmental Chemicals provides an ongoing assessment
of a generalizable sample of the exposure of the U.S. population to environmental chemicals using
biomonitoring.  This report is available at http://www.cdc.gov/exposurereport/.  The biomonitoring data
for molybdenum from this report is discussed in Section 6.5.  A biomarker of exposure is a xenobiotic
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The
preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as
copper, zinc, and selenium).  Biomarkers of exposure to molybdenum are discussed in Section 3.9.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
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cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by molybdenum are discussed in Section 3.9.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.11, Populations That Are Unusually Susceptible.
3.9.1  Biomarkers Used to Identify or Quantify Exposure to Molybdenum
Molybdenum levels can readily be measured in tissues, body fluids, and excreta. Dose-related increases 
in serum molybdenum levels were observed in rats and mice exposed via inhalation to molybdenum
trioxide for 2 years (NTP 1997).  In a study examining the relationship between plasma molybdenum
levels and dietary intake, Turnland and Keyes (2004) reported a baseline plasma molybdenum level of
8.2±.5 nmol/L; 25 days after the subjects were maintained on a low molybdenum diet (22 μg/day), the
plasma molybdenum level was 5.1±0.5 nmol/L.  Although a significant correlation between plasma 
molybdenum and dietary molybdenum was observed, comparison between plasma molybdenum levels at
different dietary intakes showed that a significant increase in plasma molybdenum was not observed until
the dietary intake exceeded 460 μg/day (6.6 mg/kg/day) and that tripling the intake resulted in a doubling
of the plasma molybdenum levels.  Urinary molybdenum levels were also significantly correlated to
dietary intakes (Turnland and Keyes 2004) and appeared to be more responsive to changes in dietary
intake. At all dietary concentrations, the urinary molybdenum levels were slightly lower than the dietary
intakes (Turnland and Keyes 2004). The investigators concluded that plasma molybdenum levels were an
indicator of dietary intake, but urinary levels were more directly related to molybdenum intake.
Molybdenum levels were measured in urine samples collected during National Health and Nutrition
Surveys.  The geometric mean urinary molybdenum levels in the United States in 2011–2012 was 
37.1 μg/L and the creatinine-corrected value was 42.0 μg/g creatinine (CDC 2015); see Section 6.5 for
additional information.
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Although several studies have reported molybdenum levels in hair samples (DiPietro et al. 1989; Nagra et
al. 1992; Paschal et al. 1989), no relationship between molybdenum exposure and hair levels has been 
established.  Furthermore, Miekeley et al. (1998) demonstrated large interlaboratory differences in the 
molybdenum levels measured in hair.
3.9.2  Biomarkers Used to Characterize Effects Caused by Molybdenum
No biomarkers to characterize effects caused by molybdenum have been identified.
3.10  INTERACTIONS WITH OTHER CHEMICALS
The interaction between copper and molybdenum has been well-established in animals.  The levels of
copper in the diet have been shown to influence the toxicity of molybdenum.  Marked toxicity has been 
reported in studies in which the copper content of the diet was inadequate.  Observed effects included 
mortality (Valli et al. 1969; Widjajakuma et al. 1973), marked decreases in body weight gain and weight
loss (Brinkman and Miller 1961; Johnson and Miller 1961; Sasmal et al. 1968; Valli et al. 1969; Van 
Reen 1959), and anemia (Brinkman and Miller 1961; Franke and Moxon 1937; Gray and Daniel 1954;
Johnson et al. 1969; Valli et al. 1969).  In general, these effects (or the severity of the effects) have not
been observed when the diet contains an adequate level of copper (Mills et al. 1958; Murray et al. 2013;
Pandey and Singh 2002; Peredo et al. 2013).  Exposure to high levels of copper has been shown to reduce 
the toxicity of molybdenum.  Administration of high doses of copper to moribund rabbits resulted in a
return to normal body weight gain and increases in hemoglobin levels within 2–3 weeks (Arrington and 
Davis 1953).  Lyubimov et al. (2004) showed that administration of a high dose of copper prevented the
molybdenum-induced testicular toxicity observed in rats fed a copper-adequate diet. Similarly, in an
environmental exposure study, Meeker et al. (2008) found a greater decline in sperm concentration in 
men with high molybdenum blood levels and copper blood levels below the median, as compared to when
the men were not stratified by blood copper levels. 
Kinetic studies have demonstrated differences in plasma, liver, and kidney copper and molybdenum
concentrations in rats fed copper-deficient, copper-adequate, and copper-excessive diets (Nederbragt
1980).  Excess copper in the diet resulted in a smaller increase in copper concentrations in plasma, liver, 
and kidneys and molybdenum concentrations in the liver and kidney, as compared to levels in rats fed a 
copper-adequate diet.  Similarly, lower rises in liver copper and molybdenum and kidney molybdenum
levels were observed in rats fed a copper-deficient and high-molybdenum diet, as compared to the copper-
adequate diet.  At the lowest molybdenum dose, kidney molybdenum levels were higher in the copper-
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deficient groups.  In another study (Nederbragt 1982), kidney levels of copper and molybdenum were
5 and 3 times higher, respectively, in the copper-adequate groups as compared to the copper-deficient 
group. Two human studies have also evaluated the effect of molybdenum on copper levels.  In one study, 
increases in serum and urine copper levels were found following a 10-day exposure to 0.022 mg
molybdenum/kg/day (Deosthale and Gopalan 1974). Another study found no significant alterations in 
serum copper levels in humans exposed to 0.0003–0.02 mg molybdenum/kg/day for 24 days (Turnlund 
and Keys 2000).  
3.11  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to molybdenum than will most
persons exposed to the same level of molybdenum in the environment.  Factors involved with increased 
susceptibility may include genetic makeup, age, health and nutritional status, and exposure to other toxic
substances (e.g., cigarette smoke).  These parameters result in reduced detoxification or excretion of
molybdenum, or compromised function of organs affected by molybdenum.  Populations who are at
greater risk due to their unusually high exposure to molybdenum are discussed in Section 6.7, Populations
with Potentially High Exposures.
The available data demonstrate the interaction between copper and molybdenum; more severe effects are 
observed in animals maintained on a copper-deficient diet (Brinkman and Miller 1961; Franke and 
Moxon 1961; Johnson and Miller 1961; Sasmal et al. 1968; Valli et al. 1969; Van Reen 1959;
Widjajakuma et al. 1973). Administration of additional copper results in a reversal of the adverse effect
(Arrington and Davis 1953).  The findings in the animal studies are supported by a report by Koval’skiy
et al. (1961) that gout-like symptoms and increased uric acid levels were observed in a population with
high molybdenum levels in the soil and low copper intakes, but were not observed in an area with high 
molybdenum levels and adequate copper intakes. Thus, individuals with low copper intakes may be 
unusually susceptible to the toxicity of molybdenum.
Studies in rats suggest that the toxicity of molybdenum may be increased in animals maintained on a low
protein diet.  The magnitudes of the decrease in body weight gain (Bandyopadhyay et al. 1981; Cox et al. 
1960) and decreases in femur breaking strength (Fejery et al. 1983) were greater in rats exposed to a low
protein diet, as compared to those maintained on a diet with sufficient protein.
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Since molybdenum is primarily excreted in the urine, individuals with kidney disease may also be more
susceptible to molybdenum toxicity; however, this has not been investigated in humans or animals.
3.12  METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to molybdenum.  Because some of the treatments discussed may be experimental and unproven, 
this section should not be used as a guide for treatment of exposures to molybdenum.  When specific
exposures have occurred, poison control centers, board certified medical toxicologists, board-certified
occupational medicine physicians and/or other medical specialists with expertise and experience treating
patients overexposed to molybdenum can be consulted for medical advice.
No texts were located that provided specific information about treatment following exposures to 
molybdenum.
Additional relevant information can be found in the front section of this profile under QUICK
REFERENCE FOR HEALTH CARE PROVIDERS.
3.12.1  Reducing Peak Absorption Following Exposure 
There are no established methods for managing initial exposure to molybdenum or for reducing peak
absorption.
3.12.2  Reducing Body Burden
Molybdenum is readily eliminated from the body, and there is evidence that ingestion of high 
molybdenum doses results in physiological adaptations that increase urinary excretion (Novotny and 
Turnlund 2007).
3.12.3  Interfering with the Mechanism of Action for Toxic Effects
The mechanism of molybdenum toxicity has not been well established.  Studies in laboratory animals
suggest that co-administration of a high copper diet can reduce the toxicity of molybdenum, but this has
not been tested in humans, and exposure to high levels of copper may be toxic.
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3.13  ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of molybdenum is available. Where adequate information is 
not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure
the initiation of a program of research designed to determine the adverse health effects (and techniques 
for developing methods to determine such health effects) of molybdenum.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health risk assessment. This definition should not be interpreted to 
mean that all data needs discussed in this section must be filled.  In the future, the identified data needs
will be evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.13.1  Existing Information on Health Effects of Molybdenum
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
molybdenum are summarized in Figure 3-5.  The purpose of this figure is to illustrate the existing
information concerning the health effects of molybdenum.  Each dot in the figure indicates that one or
more studies provide information associated with that particular effect. The dot does not necessarily
imply anything about the quality of the study or studies, nor should missing information in this figure be
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. A more detailed summary of the number of studies
examining specific end points is presented in Tables B-3 and B-4 in Appendix B. 
Data on the toxicity of inhaled molybdenum are limited to two occupational exposure studies in which the
exposure is poorly characterized.  A number of cross-sectional studies have examined the associations 
between a biomarker of molybdenum exposure (blood or urine levels) and a specific health effect. These 
studies are not sufficient to establish causality.  Additionally, one study examined a community living in
an area with high levels of molybdenum in the soil and locally grown foodstuffs.  Human data on the
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dermal toxicity of molybdenum are limited to two patch testing studies of individuals undergoing knee or
hip replacement.
Acute-duration studies examining a limited number of end points and comprehensive intermediate- and 
chronic-duration studies in rats and mice have investigated the inhalation toxicity of molybdenum.  The
chronic studies provided evidence that the respiratory tract is a primary target of toxicity and suggestive 
evidence of carcinogenicity; the intermediate-duration study did not identify adverse health effects.  A
number of studies in laboratory animals have examined the oral toxicity of molybdenum following acute-
or intermediate-duration exposures.  Studies in which the basal diet contained adequate levels of copper
identified several targets of toxicity including the kidney, liver, and reproductive system; there was some 
indication that molybdenum exposure may also result in alterations in uric acid levels and developmental
toxicity, but the data were not considered adequate for conclusive hazard identification.  Data on the
dermal toxicity of molybdenum are limited to a guinea pig sensitization assay.
3.13.2  Identification of Data Needs 
Acute-Duration Exposure. No data were located regarding health effects after acute inhalation
exposure to molybdenum in humans.  In laboratory animals, the inhalation exposure data are limited to 
studies conducted in rats and mice (NTP 1997); however, the studies only examined the nasal cavity and
body weight.  Although increased mortality and decreases in body weight gain were observed, the studies 
are not adequate for identifying the primary target of toxicity.  Thus, they were not considered adequate 
for derivation of an acute-duration inhalation MRL.  Additional studies examining a wide-range of end
points would be useful for characterizing the hazard of molybdenum following acute inhalation exposure.
In an acute experiment, no alterations in uric acid levels were observed in volunteers (Deosthale and
Gopalan 1974); the study did not examine other potential end points.  A small number of studies have 
examined the acute oral toxicity in laboratory animals, and none of them examined a wide-range of end
points. One study found an increase in serum triglyceride levels in rabbits, but did not find any
histological alterations in the liver or kidneys (Bersenyi et al. 2008).  Three studies examining
reproductive end points suggest that this is a sensitive target of acute molybdenum toxicity (Bersenyi et
al. 2008; Zhai et al. 2013; Zhang et al. 2013).  These studies identified LOAELs for effects on oocytes
and sperm and were used to derive an acute-duration oral MRL for molybdenum.
***DRAFT FOR PUBLIC COMMENT***
   
 








   
 
      
    
 
       
    
    
   
  
 
   
    
   
    





    
 
     









    
88MOLYBDENUM
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Data on the dermal toxicity of molybdenum are limited to a contact sensitization study in guinea pigs, 
which found positive effects (Boman et al. 1979).  The acute dermal toxicity database is considered
inadequate for identifying sensitive targets of toxicity; additional studies examining a wide range of
potential end points are needed.
Intermediate-Duration Exposure. The available data on the toxicity of molybdenum following
intermediate-duration inhalation exposure are limited to 90-day studies examining a wide range of
potential targets of toxicity in rats and mice (NTP 1997).  No adverse effects were observed in these 
studies, and the studies were not considered suitable for derivation of an intermediate-duration inhalation 
MRL for molybdenum.  Additional studies testing higher concentrations may identify sensitive targets.
A number of studies have examined the intermediate-duration toxicity of ingested molybdenum. Among
studies in which the laboratory animals were provided a diet with adequate levels of copper, a number of
targets of toxicity were identified including the liver, kidney, reproductive system, and possibly the
developing organism (Bompart et al. 1990; Fungwe et al. 1990; Jeter and Davis 1954; Lyubimov et al. 
2004; Murray et al. 2013; Pandey and Singh 2002).  Based on a comparison of LOAEL values, the
reproductive system appeared to be the most sensitive target of toxicity.  An intermediate-duration oral
MRL was derived based on alterations in oocyte morphology (Fungwe et al. 1990).
No studies have examined the dermal toxicity of molybdenum following intermediate-duration exposure;
studies are needed to identify potential targets of toxicity for humans.
Chronic-Duration Exposure and Cancer. Two occupational exposure studies have reported
mixed results on the effect of molybdenum on the respiratory tract (Ott et al. 2004; Walravens et al.
1979).  There is insufficient information on the specific molybdenum compounds involved and limited 
data on exposure levels.  Chronic exposure studies in rats and mice have identified the respiratory tract as 
a sensitive target of molybdenum toxicity (NTP 1997), and an inhalation MRL was derived based on the
findings in the animal studies.
A number of studies have evaluated the chronic toxicity of ingested molybdenum in humans.  A study of
residents living in an area of Armenia with high molybdenum and low copper levels in the soil found 
increases in uric acid levels and gout-like symptoms (Koval’skiy et al. 1961); other studies in which 
residents were exposed to high levels of molybdenum in the water did not find alterations in uric acid 
(EPA 1979).  Other studies that examined the potential of molybdenum to induce adverse health effects 
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presumably involved background environmental exposure (Meeker et al. 2008, 2010; Mendy et al. 2012;
Schroeder and Kraemer 1974; Shiue and Hristova 2014; Vazquez-Salas et al. 2014; Yorita Christensen 
2013).  Although some of these studies reported statistically significant associations between biomarkers 
of molybdenum exposure (plasma or urine levels) and adverse effects, the studies do not establish 
causality and there may have been factors other than molybdenum exposure.  No laboratory animal
studies evaluated the chronic oral toxicity of molybdenum. Additional studies examining a wide range of
potential end points are needed to identify the hazards associated with chronic ingestion of high levels of
molybdenum and establish dose-response relationships.
One study evaluated the carcinogenicity of molybdenum in humans (Droste et al. 1999) and found a
higher risk of lung cancer among workers in jobs related to molybdenum exposure; however, there was
potential exposure to a number of other carcinogens. In the NTP (1997) rat and mouse studies, equivocal
evidence for lung cancer was observed in male rats and some evidence of carcinogenicity was observed in
male and female mice.  No studies have examined the carcinogenicity of molybdenum following oral or
dermal exposure.  Chronic studies by these routes of exposure are needed to evaluate carcinogenicity.
Genotoxicity. There are limited data on the in vivo genotoxicity of molybdenum; a mouse study found 
weakly positive effects for micronuclei formation and dominant lethality (Titenko-Holland et al. 1998).  
Additional in vivo studies, as well as monitoring workers for genotoxicity, would be useful for assessing
the genotoxic potential in humans.  In vitro studies were negative for micronuclei formation (Gibson et al.
1997; Titenko-Holland et al. 1998) and positive for chromosomal aberrations and sister chromatid 
exchange (NTP 1997), but both were only tested in one study.  Mixed results were found in tests of DNA
repair, which may be reflective of the molybdenum compound tested (Kanematsu et al. 1980; Nishioka
1975); additional studies are needed to clarify these conflicting results.
Reproductive Toxicity. A study of men at an infertility clinic found associations between blood 
molybdenum levels and altered sperm parameters and reproductive hormone levels (Meeker et al. 2008, 
2010).  These studies do not establish causality; however, oral exposure studies in laboratory animals
support the reproductive system as a target of molybdenum toxicity (Bersenyi et al. 2008; Fungwe et al. 
1990; Lyubimov et al. 2004; Pandey and Singh 2002; Zhai et al. 2013; Zhang et al. 2013).  Although 
reproductive effects are the basis of the acute- and intermediate-duration oral MRLs for molybdenum, 
there is considerable inconsistency across studies, and some studies testing higher doses have not found
effects (Jeter and Davis 1954; Murray et al. 2013).  Additional studies designed to assess potential
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differences in routes of oral exposure and with different molybdenum compounds could help explain the
conflicting results.
Developmental Toxicity. Two studies examined whether there was a relationship between
molybdenum exposure and developmental effects in humans (Shirai et al. 2010; Vazquez-Salas et al.
2014) and found mixed results.  Two studies in rats failed to find a relationship between oral exposure to 
molybdenum and birth outcomes (Lyubimov et al. 2004; Murray et al. 2014).  A third study found 
decreases in fetal growth in a male-only exposure study (Pandey and Singh 2002).
Immunotoxicity. The immunotoxicity of molybdenum has not been adequately addressed.  No 
inhalation or oral exposure studies addressed immune function; intermediate- and chronic-duration 
inhalation studies did not find histological alterations in the thymus or spleen (NTP 1997).  Very low
levels of positive results of patch tests were observed in patients undergoing hip or knee replacements 
(Koster et al. 2000; Menezes et al. 2004; Zeng et al. 2014).  In animals, contact sensitization was
observed in guinea pigs in a sensitization assay with molybdenum pentachloride (Boman et al. 1979). 
Studies examining immune function would be useful in evaluating whether this is a target of molybdenum
toxicity.
Neurotoxicity. There are limited data on the neurotoxicity of molybdenum.  No histological
alterations in the brain or overt signs of toxicity were observed in laboratory animals after intermediate-
duration inhalation (NTP 1997) or oral (Murray et al. 2013) exposure or chronic-duration inhalation 
exposure (NTP 1997).  Additional studies, particularly in young animals, should be conducted to assess
whether molybdenum affects the neuromuscular system, in the absence of copper deficiency.
Epidemiological and Human Dosimetry Studies. A small number of epidemiology studies were 
identified for molybdenum; however, most of these studies presumably involve background 
environmental exposure to molybdenum.  Two occupational exposure studies found conflicting results
regarding the respiratory toxicity of molybdenum (Walravens et al. 197; Ott et al. 2004).  Additional
studies of worker populations examining a wide range of potential end points, including the respiratory
tract, would provide valuable information on the toxicity of inhaled molybdenum.  General population
studies have identified a number of potential targets of toxicity of ingested molybdenum including blood 
pressure (Shiue and Hrisova 2014), liver (Mendy et al. 2012), the reproductive system (Meeker et al.
2008, 2010), and the developing organism (Shirai et al. 2010); however, none of the studies established
causality.  Studies of populations exposed to high levels of molybdenum in drinking water or from foods
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grown in molybdenum-rich soil would provide support for establishing sensitive targets of molybdenum
toxicity.  One study of a community living in an area with high molybdenum in the soil reported gout-like
symptoms and increased uric acid levels (Koval’skiy et al. 1961); however, low intakes of copper may
have contributed to these effects.  Additional studies to confirm the results of this study would be
valuable.
Biomarkers of Exposure and Effect.
Exposure. Molybdenum levels can be measured in blood, tissues, and excreta, and background urinary
levels of molybdenum have been established in healthy individuals (CDC 2015).  Blood and urinary
levels have been shown to increase in response to increased molybdenum ingestion (Turnland and Keyes
2004), although plasma molybdenum levels are likely to be reflective of recent dietary intake. Studies
that quantified the relationship between blood and/or urinary levels and intake would provide valuable
information on screening and comparison with adverse effect levels.
Effect. No biomarkers of effect were identified. The available data have identified the following
sensitive targets:  respiratory tract (inhalation only), kidney, and reproductive system.  Studies examining
the possible relationship between blood or urinary levels of molybdenum with these adverse health effects
could facilitate medical surveillance leading to early detection and possible treatment.
Absorption, Distribution, Metabolism, and Excretion. For humans, detailed quantitative
information is available regarding the absorption, distribution, and excretion of ingested molybdate
(Mo[VI]O42-) and molybdenum incorporated into food.  Although molybdate is most likely the dominant
chemical species of molybdenum in the body, there are no data for humans on toxicokinetics following
exposures to other forms of molybdenum that could occur in the environment, such as tetrathiomolybdate
(MoVIS42-) or MoIV compounds. Studies conducted in rats have shown that molybdenum is absorbed 
following exposure to tetrathiomolybdate (Mills et al. 1981a).  No quantitative information is available on
the toxicokinetics of molybdenum in humans following chronic oral exposure, and there is no information
on inhalation or dermal exposures. A study conducted in mice showed that molybdenum is absorbed 
following inhalation exposure to molybdenum trioxide (NTP 1997).
Studies conducted in humans have provided data for development of PBPK models of molybdenum
kinetics in humans (Giussani 2008; Novotny and Turnlund 2007).  Models have not been developed for
rodents or other animal species that could be used in dosimetry extrapolation of animal bioassay results.
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Comparative Toxicokinetics. The available data on the toxicity of molybdenum in humans and 
laboratory animals suggest that they have similar targets of toxicity; however, there are limited 
epidemiology data. The available data suggest similarities in the absorption, distribution, and elimination 
of ingested molybdenum in humans and rats.  Additional studies are needed to compare the toxicokinetics
of inhaled molybdenum and to assess whether there are species differences.
Methods for Reducing Toxic Effects. No information was identified on methods for reducing
toxic effects of molybdenum.  Although animal studies provide evidence that a high copper diet may
decrease molybdenum toxicity, it is unclear whether this would be effective in humans.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
There are limited data on the toxicity of molybdenum in children; studies are needed to evaluate whether
the susceptibility of children differs from adults.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.13.3  Ongoing Studies 
No ongoing studies on the toxicity of molybdenum or its toxicokinetic properties were identified in the
National Institute of Health (NIH) RePORTER (2015) database. The International Molybdenum
Association is currently sponsoring a 2-generation reproductive toxicity study in rats orally exposed to 
sodium molybdate.
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
Molybdenum is a naturally occurring trace element that can be found extensively in natural minerals, but
not as the free metal.  Biologically, it plays an important role as a micronutrient in plants and animals,
including humans.  It is also used widely in industry for metallurgical applications (EPA 1979).
Molybdenum (Mo) metal exists as a dark-gray or black powder with a metallic luster or as a silvery-white
mass (HSDB 2010).  It is a member of the group VIb series of the periodic table and can exist in five
different oxidation states (2–6), with the most common and stable species being Mo(IV) and Mo(VI)
(Barceloux 1999).  It does not occur naturally in the pure metallic form, but principally as oxide or sulfide
compounds (Barceloux 1999; EPA 1979).  Important naturally occurring molybdenum compounds are the 
minerals molybdenite, powellite, wulfenite, ferrimolybdite, and ilsemannite.  Molybdenum anions include
molybdate, a tetrahedral poly atomic anion, or other isopolyanions, which can form salts used in industrial
applications (EPA 1979).  While molybdenum may occur as naturally as molybdenum sulfide, this
compound can also be produced synthetically.
Under physiological conditions (pH>6.5), molybdate anion, [MoO4]2- is the sole molybdenum species in
aqueous media (Cruywagen 2000; Cruywagen et al. 2002). Molybdenum compounds (e.g., molybdenum
trioxide and polymolybdates) transform rapidly to the [MoO4]2- ion under environmental relevant test
conditions (Deltombe et al. 1974; Greenwood and Earnshaw 1997).
Molybdenum in nature consists of seven stable isotopes (masses 92, 94–98, and 100).  Radioisotopes of
masses 83–91, 93, 99, and 101–115 have been reported.  The only one of major worldwide importance is
Mo-99 (99Mo), a 100% beta-emitting isotope with a 65.976-hour radioactive half-life that is used to 
produce technetium-99m (Tc-99m or 99mTc) for medical scans (Doll et al. 2014; Parma 2009; Richards
1989).
Information regarding the chemical identity of molybdenum and molybdenum compounds is provided in 
Table 4-1.
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1. Chemical Identity of Molybdenum and Compoundsa 
Characteristic Information












Registered trade name(s) Amperit 105.054;
Amperit 106.2; Metco 
63
DAG 325; Molykote No data















NIOSH RTECS QA4680000b QA4697000b No data
EPA Hazardous Waste No data No data No data
OHM/TADS No data No data No data
DOT/UN/NA/IMDG UN 3089; UN 4.1c No data UN 3288c 
HSDB 5032 1660 1661
NCI No data No data No data
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4.  CHEMICAL AND PHYSICAL INFORMATION








Registered trade name(s) No data
Chemical formula Mo(CO)6
Chemical structure O O 




NIOSH RTECS No data
EPA hazardous waste No data
OHM/TADS No data
























No data No data
No data No data
No data No data
7540 7540
No data No data









CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System;
RTECS = Registry of Toxic Effects of Chemical Substances
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4.  CHEMICAL AND PHYSICAL INFORMATION
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
Metallic molybdenum, in the form of dust or powder, is a combustible/flammable solid and is potentially
explosive (HSDB 2010).
Information regarding the physical and chemical properties of molybdenum and molybdenum compounds
is provided in Table 4-2.
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Molybdenum and Compoundsa 
Property Information
Chemical name Molybdenum Molybdenite (natural Molybdenum trioxide
mineral)/molybdenum
disulfide
Molecular weight 95.94 160.07 143.95
Color Dark-gray or black Black White or slightly yellow
or slightly blue
Physical state Cubic powder Crystalline solid Crystalline solid
Melting point 2,622°C Not applicable 795°C
Boiling point 4,639°C 450°C (sublimes) 1,155°C (sublimes)
Density 10.2 g/cm3 5.06 (15°C/15°C) 4.69 (26°C/4°C)
Odor No data Odorless Odorless
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water at 25°C Insoluble Insoluble 490 mg/L (28°C)b 
Organic solvents Soluble in nitric acid, No data Insolubleb 
concentrated sulfuric
acid; slightly soluble in 
hydrochloric acid;
insoluble in hydrofluoric
acid, dilute sulfuric acid
Inorganic solvents No data Soluble in hot sulfuric Soluble in aqueous
acid, aqua regia, nitric alkali and ammonia;
acid 140 mg/L in nitric acid 
(4 mol/L, 20°C)b 
Partition coefficients:
Log Kow No data No data No data
Log Koc No data No data No data
Vapor pressure:
at 20°C No data No data No data
at 2,469°C 7.5x10-3 mm Hg No data No data
at 2,721°C 7.5x10-2 mm Hg No data No data
at 3,039°C 0.75 mm Hg No data No data
at 3,434°C 7.5 mm Hg No data No data
at 3,939°C 75 mm Hg No data No data
at 4,606°C 750 mm Hg No data No data
Henry's law constant at 25°C No data No data No data
Autoignition temperature No data No data No data 
Flashpoint No data No data No data
Flammability limits Flammable (dust or No data Not flammablec 
powder)
Explosive limits No data No data No data
Conversion factors No data No data No data
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Molybdenum and Compoundsa 
Property Information





Molecular weight 205.92 273.21 1,235.8
Color Whiteb Dark green-black Colorless or slightly
greenish or yellowishd 
Physical state Crystalline solide Crystalline solid Crystalline solidd 
Melting point 687°Ce 194°C 90°C (loses H2O)
Boiling point Not applicable No data 190°C (decomposes)
Density 3.78 g/cm3f 2.928 g/cm3g 2.86 (20°C)d 
Odor Odorlesse Odorlessc Odorlesse 
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water 40 wt% (anhydrous salt
in 100 g saturated 
solution, 25°C)b 
Hydrolyzes 206.5 g/L (20°C,
tetrahydrate)d 
Organic solvents Soluble in ethanol; very
soluble in carbon 
disulfideb 




Inorganic solvents No data No data Soluble in aqueous
alkali and ammonia;
140 mg/L in HNO3
(4 mol/L, 20°C)b 
Partition coefficients:
Log Kow No data No data No data
Log Koc No data No data 0–2.614
Vapor pressure at 20°C No data 1.75 mm Hgg No data
Henry's law constant at 25°C No data No data No data
Autoignition temperature No data No data No data 
Flashpoint No data No data No data
Flammability limits No data No data No data
Explosive limits No data No data No data
Conversion factors No data No data No data
***DRAFT FOR PUBLIC COMMENT***



















    
    
 
 
    
    
     
      
    
    
     
     
    
     
 
 
   
 
  
     
    
     
     
    
      
    
    
    
    
    
 














4.  CHEMICAL AND PHYSICAL INFORMATION








Molecular weight 264.002 196.01b 260.28b 




Physical state Crystalline solid Crystalline solidb Crystalline solidb 
Melting point 150°C No data >300°Ci 
Boiling point 156.4°C (sublimes)b No data No data
Density 4.692 g/cm3 (21°C)b 1.4h No data
Odor No data Odorlessh No data
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:





Organic solvents Soluble in most organic
solventsj 
No data No data
Inorganic solvents No data No data No data
Partition coefficients:
Log Kow No data No data No data
Log Koc No data No data No data
Vapor pressure at 25°C 9.8 mm Hg (20°C) No data No data
Henry's law constant at 25°C No data No data No data
Autoignition temperature No data No data No data 
Flashpoint No data Not flammableh No data
Flammability limits No data Not flammableh No data
Explosive limits No data No data No data
Conversion factors No data No data No data
aAll information obtained from HSDB (2009a, 2009b, 2009c, 2010) unless otherwise noted.
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
Molybdenum is a naturally occurring trace element that can be found extensively in nature.  Biologically,
it plays an important role as a micronutrient in plants and animals, including humans.  It is also used 
widely in industry for metallurgical applications (USGS 2015a).
Molybdenum does not occur naturally in the pure metallic form, but is in minerals principally as oxide or
sulfide compounds (Barceloux 1999; EPA 1979).  Important naturally occurring molybdenum compounds
are the minerals molybdenite (MoS2, the predominant source), powellite, wulfenite, ferrimolybdate, and 
ilsemannite.  Molybdenum may also form molybdate, a tetrahedral poly atomic anion, or other
isopolyanions, which can form salts used in industrial applications. The earth’s crust contains an average 
of 0.0001% (1 ppm) of molybdenum.  Deposits that are economically feasible for mining contain
≥200 ppm of molybdenum, with lower concentrations obtained as a byproduct of copper mining (EPA
1979).
Molybdenite (MoS2) is the principal mineral from which molybdenum is obtained.  Mining and milling of
crude ore produces molybdenite concentrate containing ≥90% of MoS2, almost all of which is converted 
to technical-grade molybdenum trioxide.  Molybdenum trioxide is the base material for the production of
a variety of chemical compounds, ferromolybdenum, and purified molybdenum (EPA 1979).
Roasting molybdenite concentrate in a multiple hearth furnace at temperatures up to 600°C produces
technical-grade molybdenum trioxide.  This can be further purified by sublimation or selective
recrystallization at about 1,000–1,100°C (EPA 1979).
Worldwide mine production of molybdenum was estimated to be 258,000 mt in 2013, with approximately
92% produced, in descending order, by China, the United States, Chile, Peru, Mexico, and Canada.  The
United States accounted for 24% of world production with 60,700 mt in 2013, down slightly from
61,500 mt in 2012.  Primary molybdenum operations accounted for 53% of total U.S. molybdenum
production, while byproduct production made up 47% of the total in 2013.  All U.S. molybdenum
concentrates and products are from the mining of ore (USGS 2015a).  U.S. production of molybdenum
increased roughly 8% in 2014 to 65,500 mt (USGS 2015b).
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Molybdenum is a chemical that manufacturing and processing facilities would be required to report under
Section 313 of the Emergency Planning and Community Right-to-Know Act (Title III of the Superfund
Amendments and Reauthorization Act of 1986 [SARA]) (EPA 1998a).  Table 5-1 contains a list the
number of facilities per state that produced, processed, or used molybdenum trioxide in 2013, as well as
information on the amount of molybdenum on site and related activities and uses (TRI13 2015).  
Manufacturers are required to report Toxics Release Inventory (TRI) data to satisfy EPA requirements.
The TRI data should be used with caution since only certain types of facilities are required to report (EPA
2005b). This is not an exhaustive list.
Molybdenum-99 (99Mo) is a radioactive form of molybdenum and the only molybdenum radioisotope of
commercial importance.  It is produced in nuclear reactors; then processed, packaged, and shipped to
medical facilities throughout the world, where the 99Tc progeny into which it transforms is eluted and 
injected into patients for imaging purposes (e.g., cardiac stress tests).
99Mo has been being produced in one of eight nuclear reactors (mainly at the Chalk River complex in 
Canada) using highly enriched uranium, then commercialized at five processing facilities and six 
generator manufacturing facilities. The availability of those reactors was reduced by the closure of the 
Chalk River facility, and this has impacted the supply stream.  The United States has established a high
national priority on assuring an adequate supply of 99Mo and urged manufacturers to switch from using
highly enriched uranium (HEU) to low enriched uranium (LEU) to reduce the use of HEU for civilian 
applications (Ballinger 2010; The White House 2012; USNRC 2015; Van Noorden 2013).
Currently, 99Mo can be produced by placing HEU or LEU targets in an operating nuclear reactor and
allowing the neutron flux to produce 99Mo and its radioactive precursors.  The quantity of 99Mo peaks 
after approximately 6 days, at which time, the target is removed, processed, and prepared for shipment.  
New facilities for producing 99Mo from LEU in the United States are being planned (Welsh et al. 2015).
5.2  IMPORT/EXPORT
Molybdenum-containing exports rose from 49,900 mt in 2010 to 55,300 mt in 2014, while imports for
consumption rose from 19,700 mt in 2010 to 23,600 mt in 2014 (USGS 2015b).  These data along with
U.S. production volumes from 2010 to 2014 are summarized in Table 5-2.
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103MOLYBDENUM
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1.  Facilities that Produced, Processed, or Used Molybdenum Trioxide in 
2013 
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AL 3 100 99,999 1, 4, 7, 10
AR 1 100,000 999,999 7
AZ 4 100,000 9,999,999 1, 4, 7, 9
CA 14 100 999,999 1, 2, 3, 4, 7, 10, 11, 12
CO 1 10,000 99,999 1, 6, 12, 13
CT 1 100,000 999,999 6
DE 1 100,000 999,999 12
FL 1 1,000 9,999 1, 5, 13
HI 1 100,000 999,999 2, 3, 6, 10
IA 2 1,000,000 9,999,999 1, 3, 4, 7
IL 9 10,000 999,999 1, 5, 6, 7, 10, 11, 12
IN 3 10,000 999,999 1, 5, 7, 10
KS 4 0 999,999 2, 3, 8, 10
KY 4 1,000 999,999 1, 2, 3, 4, 6, 7, 10
LA 19 10,000 9,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12
MD 1 10,000 99,999 1, 4, 6, 7
ME 1 10,000 99,999 1, 2, 5, 6
MI 3 0 999,999 1, 5, 6, 7, 8, 10, 13
MN 3 10,000 9,999,999 1, 3, 6, 7, 9, 10, 11, 13
MS 3 10,000 999,999 1, 5, 7, 10
MT 2 1,000 99,999 1, 2, 3, 5, 6, 10, 12, 13
ND 3 1,000 99,999 1, 9, 10, 12, 13, 14
NJ 2 100,000 999,999 10
NM 2 10,000 99,999 10
NV 1 10,000 99,999 2, 3, 12
OH 11 1,000 999,999 1, 5, 6, 7, 8, 9, 11, 13
OK 5 10,000 999,999 1, 4, 5, 10, 11, 14
OR 3 1,000 99,999 7, 8
PA 16 100 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13
TN 2 10,000 999,999 6, 7, 9, 10
TX 42 0 99,999,999 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 14
UT 4 100 999,999 10, 11, 12
WA 3 1,000 999,999 7, 11, 12
WI 2 1,000 99,999 1, 5, 7, 11, 14
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1.  Facilities that Produced, Processed, or Used Molybdenum Trioxide in 
2013 
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
WV 1 1,000,000 9,999,999 2, 3, 7
WY 2 100 999,999 1, 10, 13
aPost office state abbreviations used.
 




1.  Produce 6.  Reactant 11.  Manufacturing Aid
2.  Import 7. Formulation Component 12.  Ancillary/Other Uses
3.  Onsite use/processing 8.  Article Component 13.  Manufacturing Impurity
4.  Sale/Distribution 9.  Repackaging 14.  Process Impurity
5.  Byproduct 10.  Chemical Processing Aid
Source:  TRI13 2015 (Data are from 2013)
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-2.  Molybdenum U.S. Production, Import, and Export Data from 2010 to 
2014 in Metric Tons
2010 2011 2012 2013 2014
Total U.S. production 59,400 63,700 61,500 60,700 65,500
U.S. imports for consumption 19,700 21,100 19,800 20,200 23,600
U.S. exports for consumption 49,900 56,700 48,900 53,100 55,300
Source:  USGS 2015b
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.3  USE 
Molybdenum is used primarily in metallurgical applications, including as an alloying agent in cast iron, 
steel, and superalloys to enhance properties such as hardenability, strength, toughness, and wear- and 
corrosion-resistance.  Principally in the form of molybdenum trioxide or ferromolybdenum, molybdenum
is commonly used in combination with other alloy metals like chromium, manganese, nickel, niobium, 
and tungsten.  The leading form of molybdenum used by industry, particularly in stainless steel
production, is molybdenum trioxide (USGS 2015a).
Molybdenum is used significantly as a refractory metal and in a variety of non-metallurgical chemical
applications, such as catalysts, lubricants, and pigments.  Most molybdenum catalysts are nitrogen
deficient due to thermodynamically unfavorable conditions at atmospheric pressure; however, 
molybdenum nitride was recently produced in a high temperature and pressure environment by solid state
ion exchange. Testing found its catalytic activity to be 3 times that of MoS2 and its selectivity to
hydrogenation to be 3 times that of MoS2 for hydrosulfurizing dibenzothiophene (Wang et al. 2015).  As
green technology is becoming more popular, molybdenum has become increasingly important in areas 
like biofuels, catalysts, ethanol, solar panels, and wind power (USGS 2015a).  
A radioactive isotope of molybdenum, 99Mo, is used as a source to produce the metastable radioisotope 
technetium-99m (99mTc), which is used in the vast majority of medical imaging tests performed today
(Doll et al. 2014; Parma 2009; Richards 1989).  It was estimated that 85% of all medical radioisotope
procedures use 99mTc and that about 50,000 99mTc-based diagnostic procedures are performed in the
United States each day, resulting in about 13 million procedures annually (Parma 2009).
Molybdenum concentrate produced by domestic mines is roasted, exported for conversion, or purified to 
lubricant-grade molybdenum disulfide.  Purified MoS2 is used directly as a solid or in coatings that are 
bonded onto the metal surface by burnishing, vapor deposition, or bonding processes that use binders,
solvents, and mechanochemical procedures (Stiefel 2011).  
Metallurgical applications accounted for about 87% of total molybdenum use in 2013.  The principle non-
metallurgical use was in catalysts, primarily catalysts used in petroleum refining.  Molybdenum
compounds are also used to produce pigments (USGS 2015a).
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.4  DISPOSAL
Recycling is the most environmentally acceptable means of disposal for stable molybdenum (USGS
2015b).  Recovery processes have been developed for the recycling of molybdenum scrap, flue dusts, 
spent catalysts, and other industrial wastes (HSDB 2010).
Conventional waste water and water treatment methods are unsuccessful in the removal of molybdenum
(EPA 1979).  Removal of molybdenum in conventional waste water treatment plants averages only 15%.  
Carbon adsorption raised removal efficiency to about 50%.
Another method for removal of molybdenum from industrial waste streams involves the addition of ferric
iron followed by dissolved-air flotation. This technique was shown to have a removal efficiency of 99%
(EPA 1979).  Milling and mining operations may also use ion exchange technology to treat effluent,
which has reported removal efficiencies of about 98% (EPA 1979).
A 99mTc generator containing a depleted uranium shield or sufficient residual 99Mo radioactivity to be
considered radioactive can be disposed of by shipping to an authorized licensee following Nuclear
Regulatory Commission agreement state requirements along with those of the Department of
Transportation (USNRC 2015).  If the 99Mo is allowed to decay sufficiently (typically ≥10 half-lives) and 
the internal shield is lead or tungsten, then disposal should follow state and local requirements.
***DRAFT FOR PUBLIC COMMENT***
   
 











5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
This page is intentionally blank.
***DRAFT FOR PUBLIC COMMENT***












   
 
     
  
    
  
 
   
   
   
   
   







   
 
  
     
  
    
  
 






6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
Molybdenum has been identified in at least 86 of the 1,832 hazardous waste sites that have been proposed
for inclusion on the EPA National Priorities List (NPL) (ATSDR 2015).  However, the number of sites in 
which molybdenum has been evaluated is not known. The frequency of these sites can be seen in
Figure 6-1.
Molybdenum is a naturally occurring trace element that can be found extensively in nature.  Biologically, 
molybdenum plays an important role as a micronutrient in plants and animals, including humans.  It is
also used widely in industry for metallurgical applications (EPA 1979).  A radioactive isotope of
molybdenum (99Mo) is used as a source for producing metastable technetium-99 (99mTc), which is an 
important radiopharmaceutical that is used in the vast majority of high resolution medical imaging tests 
conducted today (Parma 2009).  Important, naturally occurring molybdenum compounds are the minerals
molybdenite, powellite, wulfenite, ferrimolybdite, and ilsemannite.  Molybdenum may also form
molybdate, a tetrahedral polyatomic anion, or other isopolyanions, which can form salts used in industrial
applications.  The molybdate ion is the most common form of molybdenum found in the aqueous
environment (EPA 1979).
If released to the atmosphere, molybdenum will be returned to earth by wet and dry deposition.  In water, 
pH levels and oxidation/reduction conditions of the sediment govern the speciation of molybdenum and 
adsorption potential in natural aquifers.  In the pH range of 3–5, molybdenum tends to exist as hydrogen 
molybdate and is adsorbed to sediment composed of clay and other oxic minerals (Fitzgerald et al. 2008).  
The adsorption and mobility of molybdenum in soils is also inversely correlated with pH.  Adsorption of
molybdenum to 36 surface and subsurface soils was maximized under acidic conditions (pH 2–5) and
decreased rapidly at pH 5–8 (Goldberg et al. 2002).  The availability of molybdenum to plants and
vegetation is also affected by pH and soil properties.  Since adsorption to soil decreases with increasing
pH, it becomes more bioavailable for uptake to vegetation under nonacidic conditions.
Molybdenum is infrequently detected in ambient air, but is a natural constituent of water and soils.  The
earth’s crust contains an average of 0.0001% (1 ppm) of molybdenum, and surface waters usually have
molybdenum concentrations of <5 µg/L (EPA 1979).  A decade-long study conducted by the U.S. 
Geological Survey (USGS) of over 5,000 monitoring and drinking water wells from over 40 major
aquifers in the United States reported a median molybdenum concentration of 1 µg/L (USGS 2011).
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6.  POTENTIAL FOR HUMAN EXPOSURE
Figure 6-1.  Frequency of NPL Sites with Molybdenum
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6.  POTENTIAL FOR HUMAN EXPOSURE
Anthropogenic activities such as mining operations may result in localized areas where molybdenum
levels greatly exceed background levels.
The primary route of exposure for the general population to molybdenum is through the ingestion of food.  
The National Academy of Sciences (NAS) has estimated that the average dietary intakes (AVDIs) of
molybdenum by adult men and women are 109 and 76 μg/day, respectively (NAS 2001).  Other routes of
exposure, such as inhalation of ambient air, ingestion of drinking water, and dermal exposure, are
negligible for the general population; however, they may be important routes of exposure in certain 
occupational settings such as mining activities and metallurgical applications where molybdenum is used. 
For example, molybdenum levels in air samples of two plants that produce molybdenum salts were 0.5– 
200 and 0.2–30 mg/m3, depending upon the location of the sample and operation being performed (EPA
1979). Respirable dust samples contained molybdenum at levels of 0.471, 1.318, 0.142, and 0.318 mg/m3 
during mining, crushing, milling, and open pit operations, respectively, at a Colorado mine (EPA 1979).
The extensive nationwide use of radioactive 99Mo in generators that produce 99mTc for nuclear medicine 
imaging scans can expose medical staff and the public in medical facilities to low levels of ionizing
radiation. The extent of those exposures are limited by Nuclear Regulatory Commission and agreement
state regulations (USNRC 2016a, 2016b).
6.2  RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing
facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces,
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
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6.  POTENTIAL FOR HUMAN EXPOSURE
Molybdenum mining, milling, and smelting, along with its association with uranium mining and milling, 
copper mining and milling, shale oil production, oil refining, and coal-fired power plants, have resulted in 
major releases to the environment (EPA 1979).
6.2.1 Air
Estimated releases of 109,063 pounds (~49.5 metric tons) of molybdenum to the atmosphere from
178 domestic manufacturing and processing facilities in 2013 accounted for about 12% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI13 2015). These releases are
summarized in Table 6-1.
The primary source of molybdenum emissions to the atmosphere is coal combustion.  In 1970, it was
estimated that 550 mt of molybdenum were released via coal combustion in the United States, in 
comparison to 900 mt estimated from all air pollution sources.  A total of 909 mt of molybdenum can be
emitted from a single 1,000 megawatt power plant per year (EPA 1979).  The concentration of
molybdenum in fly ash from coal combustion ranges from 7 to 160 mg/kg (Barceloux 1999).
6.2.2 Water
Estimated releases of 23,474 pounds (~10.6 metric tons) of molybdenum to surface water from
178 domestic manufacturing and processing facilities in 2013 accounted for about 2.6% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI13 2015).  These releases are
summarized in Table 6-1.
As a result of secondary treatment processes in publicly owned treatment works (POTWs), up to 85% of
molybdenum that enters POTWs can be subsequently released to surface water. This information is 
available for some chemicals in the open literature.
Per year, it has been estimated that natural processes result in the release of 3.6x1010 g of molybdenum
into surface waters (EPA 1979).
Aqueous effluents from industries with a high presence of molybdenum, including molybdenum mining, 
milling, and smelting, uranium mining and milling, copper mining and milling, shale oil production, oil
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Reported amounts released in pounds per yearb 
Total release
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek On- and off-site
AL 3 2 0 0 43 0 2 43 45
AR 1 7 0 0 188 2,288 7 2,476 2,483
AZ 4 18,002 0 0 149 0 18,002 149 18,151
CA 14 443 42 0 92,870 278 91,967 1,666 93,632
CO 1 3 0 0 0 0 3 0 3
CT 1 688 0 0 0 9,677 688 9,677 10,364
DE 1 14 0 0 0 0 14 0 14
FL 1 255 2,451 0 8,002 0 10,708 0 10,708
HI 1 0 0 0 0 0 0 0 0
IA 2 22,800 3,700 0 250 0 26,750 0 26,750
IL 9 11,400 2,437 0 38,444 3,522 13,837 41,966 55,803
IN 3 280 4,000 0 50,090 2,278 54,282 2,366 56,648
KS 4 250 0 0 10,638 0 255 10,633 10,888
KY 4 1,303 1 0 1,014 174 1,314 1,178 2,492
LA 19 4,797 103 67,073 73,687 374 71,876 74,158 146,033
MD 1 500 1,192 0 250 8,800 1,942 8,800 10,742
ME 1 163 21 0 0 0 184 0 184
MI 3 592 75 0 0 0 667 0 667
MN 3 343 1 0 375 0 344 375 719
MS 3 51 970 0 6,800 0 1,022 6,799 7,821
MT 2 60 240 0 0 93 300 93 393
ND 2 1 0 0 38,053 0 1 38,053 38,054
NJ 2 9 0 0 6,641 0 9 6,641 6,650
NM 2 0 0 0 0 0 0 0 0
NV 1 4 0 0 68,622 0 68,626 0 68,626
OH 11 2,630 280 31,751 5,019 3,975 34,386 9,269 43,655
OK 5 2,386 255 0 52 12,474 2,641 12,526 15,167
OR 3 47 0 0 1,885 0 1,500 432 1,932
PA 16 30,360 648 0 43,710 10,711 32,914 52,515 85,429
TN 2 10 250 0 0 0 260 0 260
TX 41 11,386 6,658 76,400 89,559 76 118,274 65,805 184,079
UT 4 11 0 0 0 0 11 0 11
WA 3 260 0 0 0 0 260 0 260
WI 2 2 150 0 836 0 152 836 988
WV 1 0 0 0 0 0 0 0 0
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6.  POTENTIAL FOR HUMAN EXPOSURE




Reported amounts released in pounds per yearb 
Total release
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek On- and off-site
WY 2 5 0 0 16,000 0 16,005 0 16,005
Total 178 109,063 23,474 175,224 553,177 54,719 569,202 346,454 915,657
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.
 
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 




gClass I wells, Class II-V wells, and underground injection.
 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 

impoundments, other land disposal, other landfills.
 




jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
 
kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI13 2015 (Data are from 2013)
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6.  POTENTIAL FOR HUMAN EXPOSURE
refining, and coal-fired power plants, contain molybdenum at concentrations ranging from 100 to 
800,000 µg/L (EPA 1979).  Molybdenum levels in leachate samples obtained from a landfill located in 
Caledonia, Wisconsin ranged from 1.28 to 16 µg/L (WDNR 2013).
Effluent concentrations of molybdenum from three molybdenum mining and milling operations (two in 
Colorado, one in New Mexico) ranged on the order of 1,000–10,000 µg/L.  In 1972, a mine in Colorado 
released approximately 100,000 kg of molybdenum into a receiving stream.  Releases of molybdenum
from coal power plants to surface waters in the United States average about 1,800 mt/year.  A uranium
mill in Colorado reported leaking of the tailings ponds containing 860,000 µg/L molybdenum in 1965.  
Some uranium operations in New Mexico reported as much as 1,000 µg/L molybdenum in aqueous
effluents.  Copper milling operations have reported molybdenum effluent concentrations as high as
30,000 µg/L (EPA 1979).
6.2.3 Soil 
Estimated releases of 553,177 pounds (~251 metric tons) of molybdenum to soils from 178 domestic
manufacturing and processing facilities in 2013 accounted for about 58% of the estimated total
environmental releases from facilities required to report to the TRI (TRI13 2015).  An additional
175,224 pounds (~79 metric tons), constituting about 19% of the total environmental emissions, were 
released via underground injection (TRI13 2015). These releases are summarized in Table 6-1.
Metals, such as molybdenum, may leach into soil via municipal solid waste incineration bottom ash 
(IMOA 2015).
6.3  ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
Molybdenum released to the air by industrial processes will be subject to atmospheric deposition (IMOA
2015).  Deposition from the atmosphere is only a minor source to terrestrial and aquatic environments
(Fitzgerald et al. 2008).
Molybdenum can be leached into the aquatic environment near industrial use areas via direct release or
atmospheric wet deposition by rain (IMOA 2015).  The pH of water, along with the composition and 
redox conditions of the sediment, greatly affect the speciation and adsorption behavior of molybdenum in 
***DRAFT FOR PUBLIC COMMENT***










   
  
 
   
 
 
    
  
     
    
  
 
   
      
   






    
 
     
  
    
    
   





6.  POTENTIAL FOR HUMAN EXPOSURE
natural waterbodies.  Molybdenum accumulation in the sediment phase is favored under conditions of low
pH and in sediments with low redox potential and high iron and organic matter content (Fitzgerald et al.
2008).  In more favorable reducing geochemical conditions, solid-phase iron and manganese 
oxyhydroxides tend to undergo dissolution, and sorbed molybdenum may be released back into the water
phase.
In a seasonally anoxic basin, the distribution of molybdenum in the pore water of sediments was
relatively uniform.  In a perennially oxic basin, however, there was a redistribution of molybdenum in the
sediment-water interface subsequent to deposition.  This was determined to be a consequence of
adsorption of molybdenum to iron oxyhydroxides at a rate of 36 cm3/molecule-second in the first 1–2 cm 
depth (IMOA 2015).
Geological uplift and atmospheric deposition result in the molybdenum enrichment of surface soils
(IMOA 2015).  Molybdenum concentrations are found to be the highest in the top soil layer, due to strong
binding to natural organic matter.  Goldberg et al. (2002) studied the adsorption potential of molybdenum
as a function of pH on 36 surface and subsurface soil samples from 27 soil series belonging to six 
different soil orders, which provided a wide range of soil physical-chemical characteristics such as 
organic carbon content, cation exchange capacity, and iron content.  In general, maximum adsorption 
occurred under acidic pH conditions (pH 2–5) and sorption decreased rapidly from pH 5 to 8 and was
minimal in all soils at pH >9.
As reviewed by Regolia et al. (2012), the bioaccumulation factor (BAF) ranged from 30.1 to 
71.6 (average of 49) in fish exposed to molybdenum levels <65 ug/L.  At higher molybdenum levels (up 
to 766 μg/L), the BAF ranged from 0.4 to 9.9 (average 1.4). A laboratory study in rainbow trout found a
similar inverse relationship between molybdenum concentration in the water and bioconcentration factor
(BCF) (Regolia et al. 2012).  A 60-day exposure to 880 μg/L resulted in tissue levels below the limit of
detection.  Exposure to 11,100 μg/L for 28 days resulted in whole-body molybdenum levels of
0.53 mg/kg fish; the calculated average BCF was 0.05.  In another study, fish in a creek near a 
molybdenum tailings pile had measured BCFs of <100 after a 2-week exposure (CCME 1999).  The
molybdenum levels in the liver and kidney were higher than in controls; the molybdenum concentration 
of the water was not reported.  Molybdenum is not expected to bioaccumulate in fish or vegetation.  
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6.  POTENTIAL FOR HUMAN EXPOSURE
6.3.2 Transformation and Degradation
As a naturally occurring trace element, molybdenum can be found extensively in nature.  The
predominant form of molybdenum in natural waters is as the molybdate anion, MoO4-2 (Barceloux 1999), 
while naturally occurring molybdenum salts are the dominant form in dry environments (EPA 1979).
6.3.2.1  Air
No information regarding the chemical forms of molybdenum in the atmosphere and their transformations
could be located.  It is generally assumed that metals, especially those from combustion sources, exist in
the atmosphere as oxides since metallic species are readily attacked by atmospheric oxidants.
6.3.2.2  Water
Molybdenum in aquatic systems readily forms organometallic complexes.  The predominant form of
molybdenum in natural waters is as the molybdate anion, MoO4-2 (Barceloux 1999).  It can also exist as
molybdenum sulfide and bimolybdate (CCME 1999).  The molybdate species is most abundant in aquatic
environments with pH >7, whereas at pH <7, polymeric species, such as a tetrahedral polyatomic anion or
other isopolyanions, may form.  At pH <5, molybdenum may also form complexes with excess iron and 
aluminum (CCME 1999; Cruywagen 2000; Cruywagen et al. 2002).
In low redox environments, the molybdate anion can be reduced to molybdenum disulfide or molybdenite
(Fitzgerald et al. 2008).
6.3.2.3  Sediment and Soil
Molybdenum is found naturally in soil as the minerals molybdenite, powellite, wulfenite, ferrimolybdite, 
and ilsemannite (EPA 1979; Fitzgerald et al. 2008).
The predominant form of molybdenum in wet soil is as the molybdate anion, MoO4-2 (Barceloux 1999).
6.3.2.4  Other Media
No data for the degradation of molybdenum in other media were located.
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6.  POTENTIAL FOR HUMAN EXPOSURE
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to molybdenum depends in part on the reliability
of supporting analytical data from environmental samples and biological specimens.  Concentrations of
molybdenum in unpolluted atmospheres and in pristine surface waters are often so low as to be near the
limits of current analytical methods.  In reviewing data on molybdenum levels monitored or estimated in 
the environment, it should also be noted that the amount of chemical identified analytically is not 
necessarily equivalent to the amount that is bioavailable. The analytical methods available for monitoring
molybdenum in a variety of environmental media are detailed in Chapter 7.
6.4.1 Air 
Molybdenum concentrations in ambient air have been reported to range from below detection limits to 
0.03 mg/m3 (EPA 1979).  Concentrations of molybdenum in ambient air of urban areas, 0.01–0.03 µg/m3, 
are higher than those found in rural areas, 0.001–0.0032 µg/m3 (Barceloux 1999).
6.4.2 Water
It has been reported that concentrations of molybdenum are generally <1.0 µg/L in surface waters (USGS
2006) and 1.0 µg/L in drinking water (USGS 2011).  Groundwaters contain about 1.0 µg/L (USGS 2011).  
It was noted that concentrations >20 µg/L can be attributed to anthropogenic sources, such as mining, 
upgrading, or other industrial processes (EPA 1979).  Near industrial sources, surface water molybdenum
concentrations can reach 0.2–0.4 mg/L and groundwater concentrations can reach 25 mg/L (Barceloux
1999).  Concentrations as high as 1,400 µg/L have been detected in drinking waters in areas impacted by
mining and milling operations, far exceeding the USGS health-based screening level of 40 µg/L (USGS
2011).  
A USGS study of surface water from 51 of the nation’s major river basins was conducted from 1991 to 
2002 (USGS 2006).  The median concentration of molybdenum in 2,773 surface water samples was
<1.0 µg/L, with a maximum concentration of 157 µg/L.  There were eight samples (approximately 0.29%
of the total) that exceeded the USGS health-based screening level of 40 µg/L for molybdenum.
In a study of surface waters collected from 197 sampling stations in Colorado, molybdenum was found at
concentrations <10 µg/L in 87% of the 299 samples.  Samples that contained concentrations >5 µg/L
were concluded to be the result of proximity to mineralization or mining and milling operations (EPA
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6.  POTENTIAL FOR HUMAN EXPOSURE
1979).  However, another study comparing surface waters draining highly mineralized areas to those with
baseline molybdenum areas found that molybdenum mineralization did not contribute significantly to 
concentrations in surface waters. The waters from streams draining the highly mineralized areas rarely
had molybdenum concentrations above 1–2 µg/L (EPA 1979).
DOI (1967) collected river and lake water samples from 100 sampling stations around the United States 
from 1962 to 1967.  The samples were taken from areas susceptible to contamination, including highly
populated areas, industrial areas, recreational use areas, and state and national boundaries.  Molybdenum
was detected in the water samples at maximum concentrations >100 µg/L at 38 of the sample sites, while 
26 sites had mean molybdenum concentrations >50 µg/L.
In sea water, the mean molybdenum concentration has been reported as 4–12 µg/L (EPA 1979).  
Kulathilake and Chatt (1980) reported the molybdenum concentration in the Atlantic Ocean as 7.2–7.9 µg 
Mo/L.  Another study reported that the molybdenum concentration in the North Atlantic ranged from
0.5 to 1.0 µg Mo/L (Chan and Riley 1966).  In the Pacific Ocean, measured molybdenum concentrations
included 8.8 µg Mo/L in the Eastern Pacific (Kiriyama and Kuroda 1984) and 1.5 µg Mo/L in the
Western Pacific (Nakata et al. 1983). Kawabuchi and Kuroda (1969) reported a mean molybdenum
concentration of 7.7 µg Mo/L in Tokyo Bay.  Molybdenum concentrations measured in the English 
Channel ranged from 12 to 16 µg Mo/L (Chan and Riley 1966), while the Irish Sea was reported to have a
mean molybdenum concentration of 8.4 µg Mo/L (Riley and Taylor 1968).
A comprehensive groundwater monitoring study conducted from 1992 to 2003 by the USGS of
5,183 monitoring and drinking-water wells representative of over 40 principal aquifers in humid and dry 
regions and in various land-use settings reported that the median concentration of molybdenum in 
3,063 samples was 1.0 µg/L, with a maximum value of 4,700 µg/L (USGS 2011).  Approximately 1.5%
of the groundwater samples had molybdenum levels exceeding the USGS health-based screening level of
40 µg/L (USGS 2011).  Levels of molybdenum tended to be greatest in glacial unconsolidated sand and
gravel aquifers as compared to other major aquifer groups in the study.
A report issued by the Wisconsin Department of Natural Resources found elevated levels of molybdenum
in private supply wells and groundwater monitoring wells near the We Energies Oak Creek power plant
located in Caledonia, Wisconsin (WDNR 2013).  Molybdenum levels in 21 private well samples
exceeded the state of Wisconsin groundwater enforcement standard of 40 µg/L.  It was not determined 
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6.  POTENTIAL FOR HUMAN EXPOSURE
whether the elevated levels of molybdenum were naturally occurring or were a consequence of the
activities of the power plant and the coal ash fill areas located nearby the plant.
In a study of finished drinking water supplies from the 100 largest cities in the United States in 1964, 
median and maximum molybdenum concentrations of 1.4 and 68 µg/L, respectively, were reported
(USGS 1964).  Another study reported a mean molybdenum concentration of 8 µg/L in samples collected 
from 161 drinking water sources from 44 states in the United States (Hadjimarkos 1967).  Molybdenum
levels measured onsite at 12 public water facilities across England and Wales ranged from below the
detection limit (0.03 µg/L) to 1.51 µg/L over an 18-month collection period (Smedley et al. 2014).  
Corresponding molybdenum levels in tap water from 24 residences in three towns (North Wales, the
English Midlands, and South East England) served by these public water facilities ranged from <0.03 to 
1.00 µg/L.  The study indicated that there was little variability in molybdenum concentrations when 
comparing levels in tap water versus respective water supply facilities, construction ages of the residences 
(i.e., new homes versus older homes), and pre-flush versus post-flush tap samples, suggesting that water
distribution pipework has a negligible effect on supplied tap water levels of molybdenum.
Drinking water may also be affected by industrial contamination, as water treatment facilities are 
ineffective at removing molybdenum from source waters.  In tap waters samples collected in 1971 from
Golden, Colorado, a community that derives its water supply from a stream draining a molybdenum mine
and mill, the mean molybdenum concentration was reported to be 440 µg/L.  However, after the mine 
closed in 1974, the mean concentration in drinking water samples decreased to 150 µg/L by January 
1975, 60 µg/L by June 1975, and 30 µg/L by 1977 (EPA 1979).
6.4.3 Sediment and Soil
Globally, most soils contain molybdenum at concentrations between 0.6 and 3.5 ppm, although total
concentrations in soils can vary widely depending on geological composition or industrial contamination.  
The average concentration of soils is generally 1–2 ppm.  In the United States, it has been reported that
the median concentration of molybdenum in soils is 1.2–1.3 ppm, with a range of 0.1–40 ppm (EPA
1979).  The Forum of European Geological Surveys (FOREGS), under the International Union of
Geological Sciences/International Association of Geochemistry (IUGS/IAGC) Global Geochemical
Baselines Programme, collected 840 top soil samples from 26 European countries and reported 
molybdenum concentrations ranging from <0.1 to 21.3 mg/kg (mean 0.943 mg/kg) (FOREGS 2005).
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6.  POTENTIAL FOR HUMAN EXPOSURE
Above average molybdenum soil concentrations may occur in areas containing molybdenum-rich rock
formations or in areas of industrial contamination.  Natural sources sampled, including soils covering a
mineralized area, soil derived from a marine black shale, alluvial soils on the eastern footslopes of Sierra 
Nevada, and soils formed from volcanic ash in Kauai, Hawaii, contained mean molybdenum
concentrations of 76, 12, 17.4, and 14.9 ppm, respectively.  Soils sampled near industrial contamination, 
such as soils downstream from a molybdenum mine and mill in Colorado, soil irrigated with water
contaminated by a uranium mill, and soils 2 miles from a molybdenum smelter in Pennsylvania, had 
mean molybdenum concentrations of 59, 61, and 29 ppm, respectively (EPA 1979).
Typical molybdenum concentrations found in stream sediments were reported to range from 1 to 5 ppm
(EPA 1979).  Sediments in streams that drain water from natural deposits of molybdenum in the United 
States have been reported to have molybdenum concentrations ranging from 10 to 200 ppm.  Another
study reported molybdenum levels of up to 300 ppm in sediments derived from black marine shales in 
England.  Stream sediment collected from water below a molybdenum mine and mill in Colorado had 
molybdenum concentrations ranging from 50 to 1,800 ppm (mean of 530 ppm).  Molybdenum content in 
stream sediments have been shown to reflect mineralization, as the concentration increases with
decreasing sediment grain size (EPA 1979).  FOREGS collected 848 freshwater sediment samples from
26 European countries and reported molybdenum concentrations ranging from 0.12 to 117 mg/kg (mean 
1.34 mg/kg) (FOREGS 2005).
6.4.4 Other Environmental Media 
In a study detecting and comparing trace elements in the milk of guinea pigs (n=87), dairy cattle (n=48), 
horses (n=35), and humans (n=84), the average molybdenum concentrations measured were 0.026, 0.022, 
0.016, and 0.017 ppm, respectively (Anderson 1992).  Average concentrations of molybdenum detected in
six kinds of milk, including cow’s milk-based formula, breast milk, soya milk, bottled milk, dried milk, 
and evaporated milk, were 18, 4, 160, 34, 35, and 29 µg/L, respectively (Biego et al. 1998).  Most of the
molybdenum is in the cream fraction (Archibald 1951).
Food derived from aboveground plants, such as legumes, leafy vegetables, and cauliflower generally has
a relatively higher concentration of molybdenum in comparison to food from tubers or animals.  Beans,
cereal grains, leafy vegetables, legumes, liver, and milk are reported as the richest sources of
molybdenum in the average diet (Barceloux 1999).
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6.  POTENTIAL FOR HUMAN EXPOSURE
Typical concentrations of molybdenum in plants are 1–2 ppm; however, a range of tenths to hundreds of
ppm have been reported (EPA 1979).
Tobacco contains molybdenum concentrations of 0.3–1.76 µg/g (Barceloux 1999).
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Molybdenum exposure to the general population via ambient air and drinking water is expected to be
negligible compared with exposure through food (Barceloux 1999).  Molybdenum does not occur
naturally in the pure metallic form.  It is principally found as oxide or sulfide compounds (Barceloux 
1999; EPA 1979).  Therefore, almost all exposure is to a molybdenum compound rather than the metal
alone. The average dietary intakes of molybdenum in the United States by adult men and women are
109 and 76 μg/day, respectively (NAS 2001).  A study of the dietary intake of adult residents in Denver, 
Colorado reported a mean molybdenum ingestion rate of 180 µg/day (range 120–240 µg/day) (Barceloux 
1999).  Daily intake ranged from 74 to 126 µg molybdenum in a study of older children and adults in the
Northeastern United States (Barceloux 1999).
The European Food Safety Authority (EFSA) used dietary intake studies to derive estimates of which 
foods were most responsible for molybdenum intake in European populations (EFSA 2013).  Cereals and
cereal-based products (including bread) are the largest contributors to molybdenum intake in a Western 
diet; these products contribute one-third to one-half of the total molybdenum intake.  Other contributors to
total molybdenum intake include dairy products and vegetables.
A summary of molybdenum concentrations positively identified in foods analyzed during the FDA Total
Diet Study (TDS) of 2006–2011 is summarized in Table 6-2 (FDA 2014).  The data for molybdenum
arose from Market Basket Surveys conducted in 2010 and 2011, in which 382 store-bought foods
purchased in four geographic regions of the United States (northeast, southeast, central, and west) were 
analyzed.  Only those food items in which the molybdenum content of at least one sample was above the 
detection limit of the analytical method are reported.  Another survey of levels of molybdenum in food 
found the highest molybdenum concentrations in legumes; grains and grain products; nuts; meat, fish, and 
poultry (including liver); eggs; and milk, yogurt, and cheese (76.7, 30.0, 29.5, 8.9, 6.3, and 4.6 µg/100 g, 
respectively) (Pennington and Jones 1987). 










   
 
   
 
       
        
       
 
 
      
         
        
       
        
       
         
 
  
       
        
       
          
 
  
       





6. POTENTIAL FOR HUMAN EXPOSURE 




Number of Positive Mean Median Maximum LOD LOQ 
Food samples detections (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg)
Liver (beef/calf), pan-cooked 8 8 1.450 1.425 1.660 0.700 3.000
with oil
Pinto beans, dry, boiled 8 8 1.320 1.270 1.640 0.700 3.000
Pork and beans, canned 8 1 0.088 0 0.700 0.700 3.000
Peanut butter, 8 3 0.508 0 1.880 0.900 3.000
smooth/creamy
Shredded wheat cereal 8 5 0.554 0.883 0.984 0.700 3.000
Raisin bran cereal 8 1 0.088 0 0.701 0.700 3.000
Crisped rice cereal 8 8 0.898 0.837 1.280 0.700 3.000
Granola w/ raisins 8 6 0.589 0.772 0.815 0.700 3.000
Oat ring cereal 8 8 1.260 1.290 1.440 0.700 3.000
Collards, fresh/frozen, boiled 8 2 0.262 0 1.580 0.500 2.000
Chili con carne w/ beans, 8 2 0.179 0 0.730 0.700 3.000
canned
Refried beans, canned 8 2 0.254 0 1.100 0.800 3.000
White beans, dry, boiled 8 8 1.137 1.116 1.780 0.700 3.000
Granola bar, w/ raisins 8 1 0.164 0 1.310 0.800 3.000
Candy bar, chocolate, 8 1 0.115 0 0.922 0.800 3.000
nougat, and nuts
aTrace values were defined as results ≥LOD and <LOQ. Results ≥LOD and <LOQ (trace values) were used as
reported when calculating the means.
LOD = limit of detection; LOQ = limit of quantification
Source:  FDA 2014
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6.  POTENTIAL FOR HUMAN EXPOSURE
Since molybdenum is biologically essential for good health, it is sometimes necessary for individuals to
take vitamins containing molybdenum or dietary molybdenum supplements.  Based on data from
NHANES, the median molybdenum intake from dietary supplements was about 23 and 24 µg/day for
men and women who reported supplement use, respectively.  Dietary supplements generally contain 
molybdenum in the form of sodium molybdate or ammonium molybdate (Momcilovic 1999; NAS 2001).
It was reported in 1979 that in the United States, the average human intake of molybdenum via drinking
water was <5 µg/day (EPA 1979).  Drinking water coming from sources close to areas with high 
molybdenum contamination from industrial effluents may contain a higher concentration of molybdenum
(>50 µg/L) (EPA 1979).
Urinary levels of molybdenum were measured for the U.S. population from NHANES studies from 1999 
to 2012 (CDC 2015).  For survey years 1999–2000, 2001–2002, 2003–2004, 2005–2006, 2007–2008, 
2009–2010, and 2011–2012, the geometric mean urinary concentrations of molybdenum were 43.2, 42.5, 
39.4, 44.3, 47.1, 45.5, and 42.0 µg/g of creatinine, respectively.  The 95th percentile mean concentrations
of molybdenum in urine were 144, 130, 120, 132, 137, 143, and 130 µg/g of creatinine in survey years 
1999–2000 (sample size 2,257), 2001–2002 (sample size 2,689), 2003–2004 (sample size 2,558), 2005– 
2006 (sample size 2,576), 2007–2008 (sample size 2,627), 2009–2010 (sample size 2,848), and 2011– 
2012 (sample size 2,502), respectively (CDC 2015).  When the population was divided by age, the
geometric mean urinary concentrations (2011–2012 data) were 83.5, 44.4, and 38.6 μg/g creatinine for
ages 6–11, 12–19, and ≥20 years, respectively (CDC 2015).
Paschal et al. (1998) analyzed the levels of molybdenum and 12 other metals in the urine of 496 residents
of the United States obtained from the NHANES III survey conducted from 1988 to 1994.  The
specimens randomly selected were from a broad spectrum of the population (e.g., both urban and rural
communities, both male and females and persons aged 6–88 years from all major ethnicities).  The
geometric mean molybdenum concentration of the samples was 46.8 µg/L and the 25th, 50th, 75th, and 
95th percentiles were 27.9, 56.5, 93.9, and 168.0, µg/L, respectively.  The creatinine-adjusted 25th, 50th, 
75th, and 95th percentiles were 30.9, 45.7, 64.3, and 133.8 µg/g, respectively, with a geometric mean of
39.6 µg/g.  Urinary molybdenum levels were about 1–2 orders of magnitude greater than any of the other
12 metals analyzed.  
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6.  POTENTIAL FOR HUMAN EXPOSURE
Molybdenum levels in whole blood are typically <5 ng/mL in the general population; however, blood 
samples from persons from areas with natural molybdenum deposits or from molybdenum mining areas
may have concentrations of up to 150 µg/mL (Barceloux 1999).
Blood samples collected from 18 miners at a molybdenum mine in New Mexico had plasma molybdenum
levels <5 µg/L in 12 of the 18 samples and 6–18 µg/L in the remaining 6 samples.  The concentration of
molybdenum in urine collected from 11 of the miners ranged from 20 to 74 µg/L.  It was noted that
molybdenum levels in urine and blood of miners mainly exposed to molybdenite may not be above
average, since molybdenite is a relatively insoluble compound (EPA 1979).
In a survey of a molybdenite mining, crushing, and milling operation in Colorado, mean molybdenum
levels in respirable dust samples were 0.471, 1.318, 0.142, and 0.318 mg/m3 during mining, crushing, 
milling, and open pit operations, respectively (EPA 1979).  In settled dust and air samples collected from
a molybdenum smelting operation, concentrations of molybdenum, in the form of molybdenum trioxide, 
were 57–61% and 3–33 mg/m3, respectively (EPA 1979).  Forty air samples collected above a crucible in
a molybdenum trioxide smelting plant contained a mean molybdenum concentration of 0.22 mg/m3, while
air samples collected in the breathing zone of workers had molybdenum concentrations ranging from
1.4 to 5.4 mg/m3 (EPA 1979).  The air concentrations of molybdenum in two plants that produce
molybdenum salts were 0.5–200 and 0.2–30 mg/m3 (EPA 1979). More recent monitoring data for mining
and milling operations were not located; current levels may be lower due to possible changes in 
occupational standards, engineering and administrative controls, and personal protective equipment
requirements.
Workers involved in metal refining and metal working may be exposed to airborne particulates containing
molybdenum.  In a study assessing the exposure of a group of 20 workers performing welding, polishing, 
and assembly of stainless steel constructions, molybdenum was detected in personal air samplers at
concentrations of 0.27–9.7, 0.03–4.2, and 0.14–0.60 µg/m3, respectively.  Stationary air samplers in the 
facility detected course (equivalent aerodynamic diameter [EAD] 2–10 µm) and fine (EAD <2 µm)
molybdenum particles at concentrations of 0.015–0.087 and 0.093–0.54 µg/m3, respectively (Kucera et al.
2000).
The National Occupational Exposure Survey (NOES) conducted by NIOSH in 1983 estimated that
245,024 workers employed at 15,996 facilities were potentially exposed to molybdenum (pure, powder, 
and unknown forms) in the United States (RTECS 2009).  The NOES database does not contain 
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6.  POTENTIAL FOR HUMAN EXPOSURE
information on the frequency, concentration, or duration of exposure; the survey provides only estimates 
of workers potentially exposed to chemicals in the workplace.
The extensive nationwide use of radioactive 99Mo in generators that produce 99mTc for nuclear medicine 
imaging scans can expose medical staff and the public in medical facilities to low levels of ionizing
radiation. The extent of those exposures are limited by the Nuclear Regulatory Commission and 
agreement state regulations (USNRC 2016a, 2016b).
6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.8, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume than adults.  A child’s diet often differs from that of
adults.  The developing human’s source of nutrition changes with age: from placental nourishment to 
breast milk or formula to the diet of older children who eat more of certain types of foods than adults.  A
child’s behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their
mouths, sometimes eat inappropriate things (such as dirt or paint chips), and may spend more time
outdoors.  Children also are generally closer to the ground and have not yet developed the adult capacity
to judge and take actions to avoid hazards (NRC 1993).
Breast milk and infant formula are the primary sources of molybdenum in infants aged 0–6 months (NAS
2001).  The primary source of dietary molybdenum intake among children in the United States is milk
(EPA 1979). Several studies have measured molybdenum levels in human breast milk; average 
molybdenum levels ranged from 1.5 to 17 μg/L (Anderson 1992; Aquilio et al. 1996; Biego et al. 1998;
Bougle et al. 1988).  As shown in Table 6-3, highest molybdenum concentrations occur within the first
week after birth and tend to be higher in the mothers of term infants, as compared to preterm infants
(Aquilio et al. 1988; Bougle et al. 1988).  
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Table 6-3.  Molybdenum Levels in Breast Milk in Mothers of Term and Preterm
Infants
Lactation day
Molybdenum levels in breast milk (μg/L)
Term infants Preterm infants Reference
2-6 6.8 3.9a Aquilio et al. 1996
12-16b 5.7 2.4a
21c 3.6 1.9a




60e No data 1.2
aSignificantly different from term infant levels (p<0.05).
 
bSignificantly different from molybdenum concentration at 2-6 days (p<0.01).
 
cSignificantly different from molybdenum concentration at 2-6 days (p<0.05).

dSignificantly different from molybdenum concentration for whole group at 3-5 days (p<0.01).
 
eSignificantly different from molybdenum concentration at for whole group at 3-5 days (p<0.05).
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Urinary levels of molybdenum in children 6–11 years old were measured during the NHANES study
assessing exposure from 1999 to 2012 (CDC 2015).  For survey years 1999–2000, 2001–2002, 2003– 
2004, 2005–2006, 2007–2008, 2009–2010, and 2011–2012, the mean urinary concentrations of
molybdenum were 85.9, 77.2, 72.5, 81.0, 90.4, 88.6, and 83.5 µg/g of creatinine, respectively.  The 95th 
percentile mean concentrations of molybdenum in urine were 214, 185, 160, 201, 274, 195, and 259 µg/g 
of creatinine in survey years 1999–2000 (sample size 310), 2001–2002 (sample size 368), 2003–2004 
(sample size 290), 2005–2006 (sample size 355), 2007–2008 (sample size 394), 2009–2010 (sample size 
378), and 2011–2012 (sample size 398), respectively (CDC 2015).
6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Workers in an industrial setting such as mining, metal refining, and metal working can be exposed to 
significant levels of molybdenum (Kucera et al. 2000).  Populations living close to areas with high 
molybdenum contamination from industrial effluents and high mineral deposits are at risk for higher
exposures (EPA 1979).
99Mo generators are the major source of ionizing radiation exposure to nuclear medicine staff in medical
facilities that perform 99mTc diagnostic imaging scans (Ahasan 2004).
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of molybdenum is available. Where adequate information is 
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of molybdenum. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed.
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6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical-chemical properties of molybdenum are 
provided in Chapter 4.  No data needs are identified.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this
information for 2013, became available in October of 2014.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions.
Environmental Fate. Molybdenum is a naturally occurring trace element that can be found 
extensively in nature (EPA 1979).  Its transport and partitioning are well understood.  No data needs are
identified.
Bioavailability from Environmental Media. Biologically, molybdenum plays an important role as
a micronutrient in plants and animals, including humans (EPA 1979).  Its bioavailability is well
documented.  No data needs are identified.
Food Chain Bioaccumulation. Measured BCFs of molybdenum in fish suggest that
bioaccumulation in aquatic organisms is not high.  No data needs are identified.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of
molybdenum in contaminated media at hazardous waste sites are needed so that the information obtained
on levels of molybdenum in the environment can be used in combination with the known body burden of
molybdenum to assess the potential risk of adverse health effects in populations living in the vicinity of
hazardous waste sites.
Exposure Levels in Humans. Exposure to molybdenum to the general population is almost entirely
through food.  Food derived from aboveground plants, such as legumes, leafy vegetables, and cauliflower
generally has a relatively higher concentration of molybdenum in comparison to food from tubers or
animals.  Beans, cereal grains, leafy vegetables, legumes, liver, and milk are reported as the richest
sources of molybdenum in the average diet.  Vitamins and nutritional supplements are also a source of
dietary exposure.  Drinking water coming from sources close to areas with high molybdenum
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contamination from industrial effluents may contain a higher concentration of molybdenum.  Exposure to 
molybdenum in an industrial setting such as mining can be significant (Barceloux 1999; EPA 1979;
Momcilovic 1999; NAS 2001).
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. There are limited data on estimates of molybdenum exposure in children.  
Milk is reported to be the primary source of dietary molybdenum intake among children in the United 
States (Biego et al. 1998; EPA 1979); however, this is based on older data. More recent monitoring data
would be valuable in assessing whether molybdenum exposure sources vary between children and adults.
Child health data needs relating to susceptibility are discussed in Section 3.13.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. The information amassed in the National Exposure Registry facilitates the 
epidemiological research needed to assess adverse health outcomes that may be related to exposure to this 
substance; however, no exposure registries for molybdenum were located. Molybdenum is not currently
one of the compounds for which a sub-registry has been established in the National Exposure Registry.
Molybdenum will be considered in the future when chemical selection is made for sub-registries to be 
established.
6.8.2 Ongoing Studies 
As part of the National Health and Nutrition Evaluation Survey (NHANES), the Environmental Health 
Laboratory Sciences Division of the National Center for Environmental Health, Centers for Disease
Control and Prevention, will be analyzing human urine samples for molybdenum. These data will give an
indication of the frequency of occurrence and background levels of these compounds in a representative 
sample of the U.S. general population.
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring molybdenum, its metabolites, and other biomarkers of exposure and effect
to molybdenum.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the 
intention is to identify well-established methods that are used as the standard methods of analysis.  Many
of the analytical methods used for environmental samples are the methods approved by federal agencies 
and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).
Other methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
7.1  BIOLOGICAL MATERIALS
Table 7-1 lists methods used for determining molybdenum in biological materials.  Inductively coupled 
plasma-mass spectrometry (ICP-MS) is a precise, sensitive, multi-element technique capable of
measuring biological fluids (typically urine, blood, or serum) with minimal sample preparation and still
achieving sub-µg/L method detection limits.  Currently, the most widely used ICP-MS instruments are 
quadrupole analyzers (Q-ICP-MS), with or without collision or reaction gas technology to remove
polyatomic interferences (especially problematic for lower mass isotopes [i.e., below m/z 100, but not
typically deemed necessary for molybdenum analysis]).  Sector field instruments (SF-ICP-MS) have 
higher sensitivity compared to Q-ICP-MS and resolve isobaric and polyatomic interferences using
physical resolution capabilities, but are typically higher cost than Q-ICP-MS.  Inductively coupled plasma
optical (atomic) emission spectrometry (ICP-OES/ICP-AES) is, like ICP-MS, a multi-element technique 
but with higher limits of detection (µg/L).  Electrothermal atomic absorption spectrometry (ETAAS) is a 
widely accepted technique that is less expensive than ICP instruments and capable of detecting µg/L
levels of elements in a wide variety of sample types with small (µL) sample sizes. However, ETAAS
instruments are more limited in multi-element capabilities than ICP instruments.
ICP analysis coupled with AES is used in NIOSH method 8005 for the determination of molybdenum in 
blood or tissue (NIOSH 1994a).  The detection limits for this method are 1 µg/100 g blood and 0.2 µg/g 
tissue, which is the average LOD for 20 elements, including molybdenum.
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Table 7-1. Analytical Methods for Determining Molybdenum in Biological Samples
Sample 
Sample Analytical detection Percent
matrixa Preparation method method limit recovery Reference
Human plasma 	Addition of 10 µg vanadium-51.
(95Mo, 96Mo 	 Dried at 35°C, powdered, and 
isotopes)	 compressed.  Irradiation of sample 
with 10 µA proton beam for
6 hours.
Blood or tissue	 Acid digestion with 3:1:1 (v/v/v)
nitric, perchloric, and sulfuric acids.
Heat.
Blood	 Direct injection of 20 µL sample in 
a ratio 1:2 with 0.1% (v/v) Triton
X-100™ to the platform pretreated
with Erbium (25 µg).
Blood	 500 µL of blood diluted 1:10 with 
100 µL of 0.1% (v/v) Triton-X-
100™, 500 µL of 25 µg/L Tb in 2%
(v/v) HNO3, and 3,900 µL of 0.5%
(v/v) NH4OH.
Blood	 1 mL blood microwave digested 
(23 minutes) with 2 mL 
concentrated HNO3 and 1 mL 30%
H2O2.  Digestate diluted 1+9 with 
10 µg/L Ga and Y in water.
Urine	 Urine diluted 1+9 with 2% v/v
HNO3, 10 µg/L Ir.
Urine	 Add nitric acid.  Adjust pH to 
2.0 with 5M NaOH.  Extraction with 
60 mg polydithiocarbamate resin.
Agitate and filter.
Urine	 Repeated acid digestion with nitric
acid followed by drying.
Fecal samples	 Homogenize and dry samples
followed by acid digestion using 
nitric acid. Separate from other
metals by eluting with hydrochloric
acid using an ion exchange
column.
PAA/HPGe 2 ng/mL
ICP/AES 1 µg/100 g 
(NIOSH blood;
method 0.2 µg/g 
8005) tissue
ETAAS	 0.6 µg/L




















No data	 Cantone et al.
1997





No data	 Burguera et
al. 2002





No data Caldwell et al.
2005
100% NIOSH 1994b
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Table 7-1. Analytical Methods for Determining Molybdenum in Biological Samples
Sample 
Sample 	 Analytical detection Percent
matrixa	 Preparation method method limit recovery Reference
Milk	 3 g liquid (0.5 mg dried) milk mixed 
with 3 mL water. Add 4 mL 25%
TMAH, 4 mL 5 % w/v Triton
X-100™, and 4 mL H2O2 (20 
volume). Water bath (70°C) for
2 hours with periodic vortexing.
Digest diluted to 20 mL with water
and 1mL of 400 µg/L Sb.
Centrifuged at 5,000 rpm for
5 minutes.
Milk (mammal)	 5 mL homogenized milk wet
washed with nitric and perchloric
acids (10:1 v/v).
Milk (formula, Digestion in microwave oven with 
human, soy, 6 mL 65% nitric acid and 1 mL 30%
bottled, dried, perhydrol.  Dilution to a nitric acid 
evaporated) concentration of 2%.
Q-ICP-MS	 0.01 µg/g No data Reid et al.
powder 2008
ICP 0.08 ppm No data	 Anderson 
1992
ICP/MS 0.9 µg/L 97.8%	 Biego et al.
1998
aMolybdenum is the target analyte unless otherwise specified.
AES = atomic emission spectrometry; HPGe = high-purity geranium detector; ICP = inductively coupled argon plasma 
spectroscopy; LOQ = limit of quantification; MS = mass spectrometry; NaOH = sodium hydroxide; NIOSH = National
Institute for Occupational Safety and Health; PAA = proton activation analysis; Q-ICP-MS = quadrapole inductively
coupled plasma-mass spectrometry; rpm = rotations per minute; RSD = relative standard deviation;
SF-ICP-MS = sector field inductively coupled plasma-mass spectrometry; TIMS = thermal ionization mass
spectrometry
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A method for detecting stable molybdenum isotopes in human blood uses proton activation analysis
followed by the measurement of gamma-rays emitted from the activation using a high-purity geranium
(HPGe) radiation detector (Cantone et al. 1997).  The detection limit for this method was reported to be
2 ng/mL.
NIOSH method 8310 describes a technique for the determination of molybdenum in urine by extraction
with a polydithiocarbamate resin.  This method uses ICP-AES analysis and has a detection limit of
0.1 µg/sample (NIOSH 1994b).
A method using ICP analysis for the detection of trace elements in homogenized milk has been described 
(Anderson 1992).  The limit of detection was reported as 0.08 ppm.  Another method for the detection of
molybdenum in various types of milk, including cow’s milk-based formula, breast milk, soy milk, bottled 
milk, dried milk, and evaporated milk was described that uses digestion vessels for sample preparation
followed by ICP-MS and has a detection limit of 0.9 µg/L (Biego et al. 1998).
7.2  ENVIRONMENTAL SAMPLES 
Table 7-2 lists the methods used for determining molybdenum in environmental samples.  Analytical
methods determine the total molybdenum content of the samples.
A variety of techniques have been effective in the analytical detection of molybdenum.  Emission
spectroscopy, x-ray fluorescence, and neutron activation have all been used successfully for aqueous 
samples; however, these methods are not cost effective. The most widely used analytical methods for the 
determination of molybdenum in water samples are colorimetric, atomic absorption spectrophotometry
(AAS), either flame or graphite furnace (GF), and ICP with AES (EPA 1979; NIOSH 2003a, 2003b, 
2003c).  Spectral interferences are the primary problems encountered in ICP-AES analysis (NIOSH 
2014b).
Molybdenum in air samples can be analyzed using NIOSH methods 7300 and 7301, both of which use
acid ashing for sample preparation followed by ICP-AES detection.  The limit of detection for these two 
methods is 0.8 ng/mL of digest or 0.020 µg per filter using either a 5- or 0.45-µm mixed cellulose ester
filter with an air volume collection range of 5–67 L of air (NIOSH 2003a, 2003b).  NIOSH method 7303 
is also used for the analysis of molybdenum in air, but uses hot block digestion instead of acid ashing.  
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Sample Analytical detection Percent
















0.8 µm membrane filter.  Acid 
ashing with nitric/perchloric
(4:1) acid.
Filter collection on 0.8 µm
membrane filter. Acid ashing 
with 5% aqua regia (nitric/HCl 
(1:3)) acid.
Filter collection on 0.8 µm
membrane filter. Hot block
digestion at 95°C with 5% HCl
and 5% nitric acid.
Filter collection on 0.8 µm
MCE filter. Add 10 mL of
1:1 nitric acid and water.
Microwave digestion.
Wipe surface, place wipe in
beaker, and add 20 mL 
concentrated nitric acid and
1 mL concentrated perchloric
acid and heat.
Filter collection on 5.0 µm PVC
filter.  Add 12 mL of 5:1 nitric
acid and water. Microwave
digestion.
Filter sample through 0.45 µm




nanoparticles on silica gel.
Elution with 0.5 mol/L NaOH.
Evaporation to dryness.
Pyrolysis and atomization at
high temperatures.
Addition of thiocyanate and
MTOAC.  Extraction with 
PBITU in 1-pentanol.
Extraction by refluxing with 

































(800 µg/mL) (2.47% RSD
at 2.4 ng/mL)
0.8 ng/mLb	 108.9%







at 2.25 µg/ 
sample)
0.010 µg/ No data
sample




0.6 ng/L	 100% (3.4%
(600 µg/L)	 RSD at
10 ng/mL)
1 µg/L	 No data
5 ng/mL No data
(5x103 µg/mL)
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Sample Analytical detection Percent
matrixa Preparation method method limit recovery Reference
Hand wipes Wipe added to 20 mL 4:1 nitric ICP-AES 0.010 µg/ No data NIOSH 2003d
acid/perchloric acid.  Heating (NIOSH sample
and drying. Dissolution in Method 9102)
0.5 mL acid mixture.
aMolybdenum is the target analyte unless otherwise specified.

bDectection limit is based on a per mL of acid digest used in the sample preparation procedure.
 
AAS = atomic absorption spectrophotometry; AES = atomic emission spectroscopy; GF = graphite furnace;
 
EPA = Environmental Protection Agency; HCl = hydrochloric acid; ICP = inductively coupled argon plasma 

spectroscopy; IMOA = International Molybdenum Association; MCE = mixed cellulose ester membrane; MS = mass 

spectrometry; MTOAC = methyltrioctyl ammonium chloride; NaOH = sodium hydroxide; NEMI = National
 
Environmental Methods Index; NERL = National Exposure Research Laboratory; NIOSH = National Institute for
 
Occupational Safety and Health; NWQL = National Water Quality Laboratory; PBITU = N-phenylbenzimidoyl
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The detection method is also ICP-AES, with a detection limit of 0.0072 µg/mL of digest and a limit of
quantification (LOQ) of 0.60 µg/sample with a collection volume range of 0.5–10,000 L of air (NIOSH 
2003c).
Methods have also been reported for the detection of molybdenum in metal and nonmetal dust.  NIOSH 
methods 7302 and 7304 use microwave digestion for sample preparation followed by ICP-AES detection 
(NIOSH 2014).  The limits of detection were reported to be 0.2 µg/sample for method 7302 and 
0.4 µg/sample for method 7304.
A method for determining trace amounts of molybdenum in water samples separated and preconcentrated 
with titanium dioxide nanoparticles on silica gel followed by GF-AAS detection has been reported
(IMOA 2015).  The detection limit is 0.6 ng/L.  Two other methods using GF-AAS for the determination 
of molybdenum in water and waste samples that have detection limits of 1 and 3 µg/L have been
described (NEMI 2015).
Molybdenum in environmental samples has been determined using surfactant-mediated liquid-liquid 
extraction followed by spectrophotometry.  The detection limit is 5 ng/mL (IMOA 2015).
NIOSH method 9102 uses ICP-AES for determination of molybdenum on hand wipes and has a detection 
limit of 0.01 µg/wipe (NIOSH 2003d).
7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of molybdenum is available. Where adequate information is
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of molybdenum. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
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that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.
Exposure.  Methods for determining background and elevated levels of molybdenum in biological
materials are well developed, sensitive, specific, and reliable.  Standardized methods are available from
NIOSH and other sources.  
Effect. No biomarkers of effect were identified.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. Methods for determining background and elevated levels of molybdenum in environmental
media are well-developed, sensitive, and selective.  Standardized methods of analysis for molybdenum in 
air, water, soil, and milk are available from EPA, NIOSH, and other sources.  Analytical methods
measure total molybdenum.
7.3.2 Ongoing Studies 
No ongoing studies were identified in the NIH RePORTER database.
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8. REGULATIONS, ADVISORIES, AND GUIDELINES
 
MRLs are substance specific estimates that are intended to serve as screening levels. They are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
The international and national regulations, advisories, and guidelines regarding molybdenum in air, water,
and other media are summarized in Table 8-1.  
A chronic-duration inhalation MRL of 0.0004 mg molybdenum/m3 was derived for molybdenum.  The
MRL is based on a BMCLHEC of 0.013 mg molybdenum/m3 calculated from the incidence data for
squamous metaplasia in female mice (NTP 1997) and an uncertainty factor of 30 (3 for extrapolation from
animals to humans using dosimetric adjustments and 10 for human variability).
An acute-duration oral MRL of 0.05 mg molybdenum/kg/day was derived based on a NOAEL of 5.3 mg
molybdenum/kg/day for increased rate of abnormal MII oocytes in female mice (Zhang et al. 2013) and 
an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability).
An intermediate-duration oral MRL of 0.008 mg molybdenum/kg/day was derived based on a NOAEL of
0.76 mg molybdenum/kg/day for increased estrous cycle length in female rats (Fungwe et al. 1990) and 
an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability).
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Molybdenum
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification No data IARC 2015
WHO Air quality guidelines No data WHO 2010





ACGIH TLV (8-hour TWA) ACGIH 2015
Molybdenum (soluble compounds) 0.5 mg/m3 b 
Molybdenum (Metal and insoluble 10 mg/m3 c 
compounds)
3 mg/m3 b 
AIHA ERPGs No data AIHA 2014
DOE PACs DOE 2012a
PAC-1d 
Molybdenum 10 mg/m3 
Molybdenum(IV) sulfide 50 mg/m3 
Molybdenum dioxide 1.1 mg/m3 
Molybdenum trioxide 0.75 mg/m3 
Ammonium molibdate 3.5 mg/m3 
Diammonium dimolybdate 2.6 mg/m3 
Ammonium molybdate(VI) 2.8 mg/m3 
tetrahydrate
Disodium molybdate 1.1 mg/m3 
Sodium molybdate dihydrate 2.9 mg/m3 
Molybdenum carbide 11 mg/m3 
Molybdenum pentachloride 4.3 mg/m3 
Molybdenum hexacarbonyl 83 mg/m3 
***DRAFT FOR PUBLIC COMMENT***










    
 
    
   
    
   
   
   
   
   
   




   
   
   
   
   
   
    
    
    
    
    




    
    
    
    
    
     
     
     
    
 
 




    
141MOLYBDENUM
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Molybdenum












































































Molybdenum (soluble compounds) 1,000 mg/m3 
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Molybdenum
Agency Description Information Reference
NATIONAL (cont.)
OSHA PEL (8-hour TWA) for general OSHA 2013a,
industry, shipyards and construction 2013b, 2014
Molybdenum (soluble compounds) 5 mg/m3 
Molybdenum (insoluble 15 mg/m3 
compounds as Mo; total dust)
USNRC Annual limit on intake NAS 2014
99Molybdenum compounds except 3x103 μCi
oxides, hydroxides, and 
molybdenum disulfide
Derived air concentration
99Molybdenum compounds except 1x10-6 μCi/mL
oxides, hydroxides, and 
molybdenum disulfide 
b. Water
EPA Designated as hazardous substances No data EPA 2013b
in accordance with Section 40 CFR 116.4
311(b)(2)(A) of the Clean Water Act
Drinking water standards and health EPA 2012
advisories for molybdenum
1-day health advisory for a 10-kg 0.08 mg/L
child
10-day health advisory for a 10-kg 0.08 mg/L
child
DWEL 0.2 mg/L
Life-time health advisory 0.04 mg/L
National primary drinking water No data EPA 2009
standards
National recommended water quality No data EPA 2015b
criteria:  Human health for the 
consumption of
Reportable quantities of hazardous No data EPA 2013c
substances designated pursuant to 40 CFR 117.3
Section 311 of the Clean Water Act
c. Food
FDA EAFUS No dataf FDA 2013
d. Other
ACGIH Carcinogenicity classification ACGIH 2015
Molybdenum (soluble compounds) A3g 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Molybdenum
Agency Description Information Reference
NATIONAL (cont.)
EPA Carcinogenicity classification No data IRIS 2003
RfC No data
RfD (Molybdenum) 5x10-3 mg/kg-day
Superfund, emergency planning, and No data EPA 2014a
community right-to-know 40 CFR 302.4
Effective date of toxic chemical EPA 2014b
release reporting 40 CFR 372.65
Molybdenum trioxide 01/01/1987
TSCA chemical lists and reporting No data EPA 2014c
periods 40 CFR 712.30
DHHS Carcinogenicity classification No data NTP 2014




bRespirable fraction; deposited in the gas-exchange region.
 
cInhalable fraction; deposited anywhere in the respiratory tract.

dDefinitions of PAC terminology are available from U.S. Department of Energy (DOE 2012b).
 
eA proposed PEL TWA of 5 mg/m3 for soluble compounds as molybdenum was reviewed by NIOSH in 1988.  As a 

result, NIOSH questioned whether the proposed PEL was adequate to protect workers from recognized health 

hazards. Additionally, NIOSH also concluded that the documentation cited by OSHA was inadequate to support the 

proposed PEL (as an 8-hour TWA) of 10 mg/m3 for insoluble compounds as molybdenum (NIOSH 2015b).
 
fThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 

additives or listed or affirmed as GRAS.
 
gA3: confirmed animal carcinogen with unknown relevance to humans.
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
 
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response,
 
Compensation, and Liability Act; CFR = Code of Federal Regulations; DHHS = Department of Health and Human 

Services; DOE = Department of Energy; DWEL = drinking water equivalent level; EAFUS = Everything Added to 

Food in the United States; EPA = Environmental Protection Agency; ERPG = emergency response planning 

guidelines; FDA = Food and Drug Administration; GRAS = Generally Recognized As Safe; IARC = International
 
Agency for Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information 

System; MCL = maximum contaminant level; NAS = National Academy of Sciences; NIOSH = National Institute for
 
Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health 

Administration; PAC = Protective Action Criteria; PEL = permissible exposure limit; RCRA = Resource Conservation
 
and Recovery Act; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral
 
reference dose; TLV = threshold limit values; TSCA = Toxic Substances Control Act; TWA = time-weighted average;
 
USNRC = U.S. Nuclear Regulatory Commission; WHO = World Health Organization
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study— A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-control study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without the outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
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Ceiling Value—A concentration that must not be exceeded. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that, if met, would reduce the uncertainties of
human health risk assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—A condition that poses a threat of life or health, or
conditions that pose an immediate threat of severe exposure to contaminants that are likely to have 
adverse cumulative or delayed effects on health.  
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.
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Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of new cases of individuals in a population who develop a specified condition to 
the total number of individuals in that population who could have developed that condition in a specified 
time period.
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study,
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
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Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
hazardous substance.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
regulatory limit on the amount or concentration of a substance not to be exceeded in workplace air
averaged over any 8-hour work shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests (insects or other organisms harmful to cultivated plants or animals).
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
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Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows. These models require a
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as blood:air partition coefficients, and metabolic parameters.  PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a hazardous substance.  The toxicity may be directed to the reproductive organs and/or
the related endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual
behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the
integrity of this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
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Risk—The possibility or chance that some adverse effect will result from a given exposure to a hazardous 
substance.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, existing health 
condition, or an inborn or inherited characteristic that is associated with an increased occurrence of
disease or other health-related event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—A STEL is a 15-minute TWA exposure that should not be
exceeded at any time during a workday.  
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists
(ACGIH) concentration of a substance  to which it is believed that nearly all workers may be repeatedly
exposed, day after day, for a working lifetime without adverse effect. The TLV may be expressed as a 
Time Weighted Average (TLV-TWA), as a Short-Term Exposure Limit (TLV-STEL), or as a ceiling
limit (TLV-C).
Time-Weighted Average (TWA)—An average exposure within a given time period.  
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any substance that is foreign to the biological system.
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A-1MOLYBDENUM
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified route and
duration of exposure.  MRLs are based on noncancer health effects only and are not based on a
consideration of cancer effects. These substance-specific estimates, which are intended to serve as 
screening levels, are used by ATSDR health assessors to identify contaminants and potential health
effects that may be of concern at hazardous waste sites.  It is important to note that MRLs are not
intended to define clean-up or action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach. They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure.  MRLs are generally based on the most sensitive substance-induced
endpoint considered to be of relevance to humans.  Serious health effects (such as irreparable damage to
the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that
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are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public.  They
are subject to change as new information becomes available concomitant with updating the toxicological
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop 
F-57, Atlanta, Georgia 30329-4027.
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Profile Status: Final for Public Comment
Route: [X] Inhalation   [ ] Oral
Duration: [ ] Acute [ ] Intermediate  [X] Chronic
Graph Key: 8
Species: Mouse
Minimal Risk Level: 0.0004   [ ] mg/kg/day  [X] mg molybdenum/m3 
Reference: NTP.  1997.  Toxicology and carcinogenicity studies of molybdenum trioxide (CAS No. 
1313-27-5) in F344/N rats and B6C3F1 mice (inhalation studies).  National Toxicology Program, 
Research Triangle Park, NC.  NT PTR 462.
Experimental design: Groups of male and female F344/N rats and B6C3F1 mice (50/sex/species/group)
were exposed to target concentrations of 0, 10, 30, or 100 mg/m3 molybdenum trioxide (0, 6.7, 20, and 
67 mg Mo/m3) 6 hours/day, 5 days/week for 106 (rats) or 105 (mice) weeks; actual concentrations were
within 15% of the target level.  The average particle sizes (mass median aerodynamic diameter) (and
geometric standard deviation) were 1.5 (1.8), 1.6 (1.8), and 1.7 (1.8) μm for the 6.7, 20, and 67 mg/m3 
concentrations, respectively.  The following parameters were used to assess toxicity:  twice daily cage-
side observations, body weights (weekly for 12 weeks, at 15 weeks, monthly thereafter, and at
termination), and histopathological examination of major tissues and organs.  In addition, bone density
and femoral curvature studies were conducted in 10 animals/sex/species/group.
Effect noted in study and corresponding doses: No significant alterations in survival rates or body weight
gain and no toxicologically significant alterations in bone density or curvature were found.  Non-
neoplastic lesions were only observed in the nose, larynx, and lungs; a summary of the type of lesions and
incidences is presented in Table A-1.  The severity of the respiratory lesions was concentration-related.
Significant increases in the incidence of alveolar/bronchiolar carcinoma and/or adenoma were observed in
mice:  carcinoma in male mice at ≥6.7 mg/m3, adenoma or carcinoma (combined) in male mice at 6.7 and 
20 mg/m3, adenoma in female mice at ≥20 and 67 mg/m3, and adenoma or carcinoma (combined) in
female mice at 67 mg/m3. In rats, the incidence of alveolar/bronchiolar adenoma or carcinoma
(combined) was increased in males; however, the incidences (0/50, 1/49, 1/49, 4/60) were within the
range of historical controls and NTP considered this to be equivocal evidence of carcinogenic activity.
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A-4MOLYBDENUM
APPENDIX A
Table A-1.  Incidence of Non-Neoplastic Respiratory Tract Lesions in Rats and
 
Mice Exposed to Molybdenum Trioxide for 2 Years

Concentration (mg molybdenum/m3)
0 6.7 20 67
Male rats
Hyaline degeneration of nasal respiratory
epithelium
2/50 7/49 48/49a 49/50a 
Squamous metaplasia of epiglottis 0/49 11/48a 16/49a 39/49a 
Chronic lung inflammation in alveolus 2/50 3/50 25/50a 47/50a 
Female rats
Hyaline degeneration of nasal respiratory
epithelium
1/48 13/49a 50/50a 50/50a 
Hyaline degeneration of nasal olfactory
epithelium
39/48 47/49b 50/50a 50/50a 
Squamous metaplasia of epiglottis 0/49 18/49a 29/49a 49/50a 
Chronic lung inflammation 14/50 13/50 43/50a 49/50a 
Male mice
Nasal suppurative inflammation 2/50 6/50 10/49b 8/50b 
Nasal olfactory epithelium atrophy 3/50 5/50 3/49 10/50b 
Hyaline degeneration of nasal respiratory
epithelium
11/50 13/50 11/49 41/50a 
Squamous metaplasia of epiglottis 0/50 26/49a 37/48a 49/50a 
Laryngeal hyperplasia 1/50 3/49 6/48 41/50
Histiocyte infiltration in the lungs 2/50 16/50a 9/49b 9/50b 
Alveolar epithelial metaplasia 0/50 32/50a 36/49a 49/50a 
Female mice
Hyaline degeneration of nasal respiratory
epithelium
26/49 23/50 28/49 48/49a 
Hyaline degeneration of nasal olfactory
epithelium
22/49 14/50 14/49 36/49a 
Squamous metaplasia of epiglottis 1/49 36/50a 43/49a 49/50a 
Laryngeal hyperplasia 1/49 1/50 7/49 35/50
Alveolar epithelial metaplasia 2/50 26/50a 39/49a 46/49b 
aSignificantly different from controls; p≤0.01.
bSignificantly different from controls; p≤0.05.
Source:  NTP 1997
Dose and end point used for MRL derivation: The MRL was based on a BMCL of 0.19 mg
molybdenum/m3 for squamous metaplasia of the epiglottis in female mice
[ ] NOAEL   [ ] LOAEL [X] BMCL
The incidence data (Table A-1) for respiratory tract lesions, which had significant increases in incidence 
at ≥6.7 mg/m3 (squamous metaplasia of the epiglottis in male and female rats and mice, hyaline 
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degeneration of the nasal respiratory and olfactory epithelium in female rats, histiocyte infiltration in the 
lungs in male mice, and alveolar epithelial metaplasia in male and female mice), were fit to all available 
dichotomous models in EPA’s Benchmark Dose Software (BMDS, version 2.4.0) using the extra risk
option.  Adequate model fit was judged by three criteria: goodness-of-fit statistics (p-value >0.1), visual
inspection of the dose-response curve, and scaled residual at the data point (except the control) closest to
the predefined BMR.  Among all of the models providing adequate fit to the data, the lowest BMCL (95% 
lower confidence limit on the BMC) was selected as the POD when the difference between the BMCLs 
estimated from these models was >3-fold; otherwise, the BMCL from the model with the lowest Akaike’s 
Information Criterion (AIC) was chosen.  For all lesion types, a BMR of 10% was used.  Since the 
incidence of hyaline degeneration in the olfactory epithelium of female rats was essentially the same 
response level across groups, the data were not modeled since they provide limited information on the
dose-response relationship.  The incidence data for histiocyte infiltration in the lungs did not fit any of the
available dichotomous models.  The model prediction for the other end points are presented in Tables A-2 
through A-8 and the fits of the selected models are presented in Figures A-1 through A-7. Although the
data for squamous metaplasia of the epiglottis in female mice fit several BMD models, the high incidence
in the lowest molybdenum group (72%) decreases the certainty in the modeling results.  
Table A-2.  Model Predictions for Squamous Metaplasia of the Epiglottis in Male
Rats Exposed to Molybdenum Trioxide (NTP 1997)
χ2 Scaled residualsb 
Goodne Dose Dose 
ss of fit below above Overall BMC10 BMCL10 
Model DF χ2 p-valuea BMC BMC largest AIC (mg/m3) (mg/m3)
Gammac,d 3 3.07 0.38 0.00 1.55 1.55 167.98 4.36 3.53
Logistic 2 9.63 0.01 1.53 0.95 -2.48 181.94 ND ND
LogLogistice 2 3.56 0.17 0.00 0.98 -1.42 170.75 3.809 2.23
LogProbite 2 11.85 0.01 3.00 -1.39 3.00 174.85 ND ND
Multistage (1-degree)f 3 3.07 0.38 0.00 1.55 1.55 167.98 4.36 3.53
Multistage (2-degree)f 3 3.07 0.38 0.00 1.55 1.55 167.98 4.36 3.53
Multistage (3-degree)f 3 3.07 0.38 0.00 1.55 1.55 167.98 4.36 3.53
Probit 2 9.35 0.01 1.62 0.92 -1.38 181.23 ND ND
Weibullc 3 3.07 0.38 0.00 1.55 1.55 167.98 4.36 3.53
aValues <0.1 fail to meet conventional goodness-of-fit criteria.

bScaled residuals at doses immediately below and above the BMC; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSelected model. BMCLs for models providing adequate fit were sufficiently close (differed by <3-fold).  Therefore,
the model with the lowest AIC was selected.
eSlope restricted to ≥1.
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
ND = not determined, goodness-of-fit criteria, p<0.10
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Figure A-1.  Fit of Gamma Model to Data on Incidence of Squamous Metaplasia of
the Epiglottis in Male Rats Exposed to Molybdenum Trioxide (mg/m3)

















0  10  20  30  40  50  60  70 
dose 
09:34 11/05 2015 
***DRAFT FOR PUBLIC COMMENT***










   
 
 












   
          
          
          
          
          
          
          
          

















Table A-3.  Model Predictions for Hyaline Degeneration of the Nasal Respiratory
 
Epithelium in Female Rats Exposed to Molybdenum Trioxide (NTP 1997)
 
χ2 Scaled residualsb 
Goodness Dose Dose 
of fit below above Overall BMC10 BMCL10 
Model DF χ2 p-valuea BMC BMC largest AIC (mg/m3) (mg/m3)
Gammac,d 2 0.00 1.00 0.00 0.00 0.01 70.42 5.73 4.26
Logistic 2 0.40 0.82 0.44 -0.17 0.44 70.97 4.47 3.46
LogLogistice 2 0.00 1.00 0.00 0.00 0.00 70.42 6.30 4.83
LogProbite 1 0.00 1.00 0.00 0.00 0.00 72.42 6.03 4.73
Multistage (1-degree)f 2 18.41 0.00 0.28 -3.28 -3.28 95.80 ND ND
Multistage (2-degree)f 2 2.81 0.24 0.20 -1.21 -1.21 74.57 3.40 2.54
Multistage (3-degree)f 2 0.02 0.99 0.01 -0.05 0.15 70.46 4.77 2.39
Probit 2 0.48 0.79 0.49 -0.28 0.49 71.03 4.09 3.12
Weibullc 1 0.00 1.00 0.00 0.00 0.00 72.42 5.10 3.58
aValues <0.1 fail to meet conventional goodness-of-fit criteria.

bScaled residuals at doses immediately below and above the BMC; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSelected model. BMCLs for models providing adequate fit were sufficiently close (differed by <3-fold).  Therefore,
the model with the lowest AIC was selected.
eSlope restricted to ≥1.
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
ND = not determined, goodness-of-fit criteria, p<0.10
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Figure A-2.  Fit of Gamma Model to Data on Incidence of Hyaline Degeneration of
the Nasal Respiratory Epithelium in Female Rats Exposed to Molybdenum
Trioxide (mg/m3)
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Table A-4.  Model Predictions for Squamous Metaplasia of the Epiglottis in
 
Female Rats Exposed to Molybdenum Trioxide (NTP 1997)
 
χ2 Scaled residualsb 
Goodness Dose Dose 
of fit below above Overall BMC10 BMCL10 
Model DF χ2 p-valuea BMC BMC largest AIC (mg/m3) (mg/m3)
Gammac,d 3 2.05 0.56 0.00 1.00 1.00 144.51 1.97 1.60
Logistic 2 15.55 0.00 -2.67 2.17 -2.67 163.85 ND ND
LogLogistice 2 5.02 0.08 0.00 0.82 -1.58 150.04 ND ND
LogProbite 3 4.97 0.17 0.00 1.25 -1.69 147.37 3.27 2.67
Multistage (1-degree)f 3 2.05 0.56 0.00 1.00 1.00 144.51 1.97 1.60
Multistage (2-degree)f 2 2.05 0.36 0.00 1.04 1.04 146.50 1.99 1.60
Multistage (3-degree)f 2 1.98 0.37 0.00 1.11 1.11 146.42 2.02 1.61
Probit 2 17.51 0.00 -2.85 2.00 -2.85 166.05 ND ND
Weibullc 3 2.05 0.56 0.00 1.00 1.00 144.51 1.97 1.60
aValues <0.1 fail to meet conventional goodness-of-fit criteria.

bScaled residuals at doses immediately below and above the BMC; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSelected model.  BMCLs for models providing adequate fit were sufficiently close (differed by <3-fold).  Therefore,
the model with the lowest AIC was selected.
eSlope restricted to ≥1.
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
ND = not determined, goodness-of-fit criteria, p<0.10
***DRAFT FOR PUBLIC COMMENT***


















Figure A-3. Fit of Gamma Model to Data on Incidence of Squamous Metaplasia of
the Epiglottis in Female Rats Exposed to Molybdenum Trioxide (mg/m3)
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Table A-5.  Model Predictions for Squamous Metaplasia of the Epiglottis in Male
 
Mice Exposed to Molybdenum Trioxide (NTP 1997)
 
χ2 Scaled residualsb 
Goodness Dose Dose 
of fit below above Overall BMC10 BMCL10 
Model DF χ2 p-valuea BMC BMC largest AIC (mg/m3) (mg/m3)
Gammac 3 5.55 0.14 0.00 1.60 -1.65 135.46 1.30 1.06
Logistic 2 61.77 0.00 -3.19 2.80 -6.62 164.85 ND ND
LogLogisticd,e 2 1.42 0.49 0.00 0.34 -0.85 134.73 1.29 0.47
LogProbitd 3 2.74 0.43 0.00 1.11 1.19 133.83 2.10 1.69
Multistage (1-degree)f 3 5.55 0.14 0.00 1.60 -1.65 135.46 1.30 1.06
Multistage (2-degree)f 3 5.55 0.14 0.00 1.60 -1.65 135.46 1.30 1.06
Multistage (3-degree)f 3 5.55 0.14 0.00 1.60 -1.65 135.46 1.30 1.06
Probit 2 90.03 0.00 -3.63 2.65 -8.24 171.89 ND ND
Weibullc 3 5.55 0.14 0.00 1.60 -1.65 135.46 1.30 1.06
aValues <0.1 fail to meet conventional goodness-of-fit criteria.

bScaled residuals at doses immediately below and above the BMC; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSlope restricted to ≥1.
eSelected model.  BMCLs for models providing adequate fit were sufficiently close (differed by <3-fold).  Therefore,
the model with the lowest AIC was selected.
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
ND = not determined, goodness-of-fit criteria, p<0.10
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Figure A-4.  Fit of LogLogistic Model to Data on Incidence of Squamous
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Table A-6.  Model Predictions for Alveolar Epithelial Metaplasia in Male Mice 

Exposed to Molybdenum Trioxide (NTP 1997)
 
χ2 Scaled residualsb 
Goodness Dose Dose 
of fit below above Overall BMC10 BMCL10 
Model DF χ2 p-valuea BMC BMC largest AIC (mg/m3) (mg/m3)
Gammac 3 15.12 0.00 0.00 2.91 2.91 146.34 ND ND
Logistic 2 44.97 0.00 -3.71 3.74 -4.41 177.74 ND ND
LogLogisticd,e 2 4.20 0.12 0.00 0.63 -1.55 140.27 0.54 0.35
LogProbitd 3 10.82 0.01 0.00 2.15 -2.43 143.68 ND ND
Multistage (1-degree)f 3 15.12 0.00 0.00 2.91 2.91 146.34 ND ND
Multistage (2-degree)f 3 15.12 0.00 0.00 2.91 2.91 146.34 ND ND
Multistage (3-degree)f 3 15.12 0.00 0.00 2.91 2.91 146.34 ND ND
Probit 2 54.33 0.00 -4.10 3.67 -4.84 183.04 ND ND
Weibullc 3 15.12 0.00 0.00 2.91 2.91 146.34 ND ND
aValues <0.1 fail to meet conventional goodness-of-fit criteria.

bScaled residuals at doses immediately below and above the BMC; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSlope restricted to ≥1.
eSelected model.  The only model that provided adequate fit to the data was the Log-Logistic model.
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
ND = not determined, goodness-of-fit criteria, p<0.10
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Figure A-5.  Fit of LogLogistic Model to Data on Incidence of Alveolar Epithelial 

Metaplasia in Male Mice Exposed to Molybdenum Trioxide (mg/m3)
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Table A-7. Model Predictions for Squamous Metaplasia of the Epiglottis in 

Female Mice Exposed to Molybdenum Trioxide (NTP 1997)
 
χ2 Scaled residualsb 
Goodness Dose Dose 
of fit below above Overall BMC10 BMCL10 
Model DF χ2 p-valuea BMC BMC largest AIC (mg/m3) (mg/m3)
Gammac 2 57.98 0.00 -0.29 2.32 -7.21 131.51 ND ND
Logistic 2 413.85 0.00 -3.51 3.42 -19.74 159.94 ND ND
LogLogisticd,e 1 0.32 0.57 0.00 0.15 -0.41 121.62 0.46 0.19
LogProbitd 2 5.96 0.05 -0.08 1.26 -1.71 123.72 ND ND
Multistage (1-degree)f 2 57.98 0.00 -0.29 2.32 -7.21 131.51 ND ND
Multistage (2-degree)f 2 57.98 0.00 -0.29 2.32 -7.21 131.51 ND ND
Multistage (3-degree)f 2 57.98 0.00 -0.29 2.32 -7.21 131.51 ND ND
Probit 2 511.74 0.00 -4.31 3.51 -21.88 172.08 ND ND
Weibullc 2 57.98 0.00 -0.29 2.32 -7.21 131.51 ND ND
aValues <0.1 fail to meet conventional goodness-of-fit criteria.

bScaled residuals at doses immediately below and above the BMC; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSlope restricted to ≥1.
eSelected model.  The only model that provided adequate fit to the data was the Log-Logistic model.
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
ND = not determined, goodness-of-fit criteria, p<0.10
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Figure A-6.  Fit of LogLogistic Model to Data on Incidence of Squamous
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Table A-8.  Model Predictions for Alveolar Epithelial Metaplasia in Female Mice 

Exposed to Molybdenum Trioxide (NTP 1997)
 
χ2 Scaled residualsb 
Goodness Dose Dose 
of fit below above Overall BMC10 BMCL10 
Model DF χ2 p-valuea BMC BMC largest AIC (mg/m3) (mg/m3)
Gammac 2 15.17 0.0005 -0.58 1.79 -3.32 171.71 ND ND
Logistic 2 37.47 0.00 -3.49 2.02 -4.18 194.28 ND ND
LogLogisticd,e 1 0.00 0.94 0.00 -0.02 0.05 164.20 1.03 0.47
LogProbitd 2 6.53 0.04 0.22 1.25 -2.20 166.91 ND ND
Multistage (1-degree)f 2 15.17 0.0005 -0.58 1.79 -3.32 171.71 ND ND
Multistage (2-degree)f 2 15.17 0.0005 -0.58 1.79 -3.32 171.71 ND ND
Multistage (3-degree)f 2 15.17 0.0005 -0.58 1.79 -3.32 171.71 ND ND
Probit 2 33.34 0.00 -3.87 1.94 -3.87 199.12 ND ND
Weibullc 2 15.17 0.0005 -0.58 1.79 -3.32 171.71 ND ND
aValues <0.1 fail to meet conventional goodness-of-fit criteria.

bScaled residuals at doses immediately below and above the BMC; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSlope restricted to ≥1.
eSelected model.  The only model that provided adequate fit to the data was the Log-Logistic model.
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
ND = not determined, goodness-of-fit criteria, p<0.10
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Figure A-7.  Fit of LogLogistic Model to Data on Incidence of Alveolar Epithelial 

Metaplasia in Female Mice Exposed to Molybdenum Trioxide (mg/m3)
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Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  3 for extrapolation from animals to humans with dosimetric adjustments
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
HECs were calculated for each potential POD by adjusting for intermittent exposure (6 hours/24 hours, 
5 days/7 days) and multiplying the PODADJ by the RDDR for the appropriate region of the respiratory
tract.  The RDDRs were calculated using EPA’s RDDR calculator with reference body weights of 0.40, 
0.25, 0.040, and 0.035 kg for the male rats, female rats, male mice, and female mice, respectively.  The 
PODHEC values are presented in Table A-9.
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PODs RDDR HECsa 
End point (mg Mo/m3) values (mg Mo/m3)
Squamous metaplasia of the epiglottis in male rats 3.53 (BMCL) 0.459 0.28
Hyaline degeneration of the respiratory epithelium in female rats 4.26 (BMCL) 0.248 0.19
Hyaline degeneration of the olfactory epithelium in female rats 6.7 (LOAEL) 0.248 0.30
Squamous metaplasia of the epiglottis in female rats 1.60 (BMCL) 0.248 0.071
Squamous metaplasia of the epiglottis in male mice 0.47 (BMCL) 0.441 0.037
Histiocyte infiltration in the lungs of male mice 6.7 (LOAEL) 1.046 1.3
Alveolar epithelial metaplasia in male mice 0.35 (BMCL) 1.046 0.065
Squamous metaplasia of the epiglottis in female mice 0.19 (BMCL) 0.367 0.012
Alveolar epithelial metaplasia in female mice 0.47 (BMCL) 3.067 0.26
aHEC calculated by multiplying the duration-adjusted POD (POD x 6 hours/24 hours x 5 days/7days) by the RDDR
value.
BMCL = 95% lower confidence limit on the benchmark concentration; HEC = human equivalent concentration;
LOAEL = lowest observed adverse effect level; POD = point of departure; RDDR = regional deposited dose ratio for 
the specific region of the respiratory tract
Was a conversion used from intermittent to continuous exposure? As described above, the PODs were 
adjusted for intermittent exposure (6 hours/day, 5 days/week).
Other additional studies or pertinent information that lend support to this MRL: There are limited data on 
the toxicity of inhaled molybdenum in humans.  A study of workers at a molybdenite roasting facility
exposed to molybdenum trioxide and other oxides, found no alterations in lung function, but did find 
increases in serum uric acid levels (Walravens et al. 1979); the TWA molybdenum concentration was
9.46 mg molybdenum/m3. Another study of workers exposed to ultrafine molybdenum trioxide dust
reported respiratory symptoms (dyspnea and cough), radiographic abnormalities, and impaired lung
function (Ott et al. 2004); the study did not provide monitoring data.  Confidence in these cohort studies
was considered very low (see Appendix B for additional information). Data on the chronic toxicity of
molybdenum in laboratory animals is limited to 2-year studies in rats and mice exposed to molybdenum
trioxide (NTP 1997).
Agency Contacts (Chemical Managers): Dan Todd
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Profile Status: Final for Public Comment
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 5
Species: Mouse
Minimal Risk Level: 0.05 [X] mg molybdenum/kg/day   [ ] ppm
The MRL is calculated based on the assumption of healthy dietary levels of molybdenum and copper and 
represents the level of exposure above and beyond the normal diet.  
Reference: Zhang Y-L, Liu F-J, Chen X-L, et al.  2013.  Dual effects of molybdenum on mouse oocyte 
quality and ovarian oxidative stress.  Sys Bio Repro Med 59:312-318.
Experimental design: Groups of 25 female ICR mice (4–8 weeks of age) were exposed to 0, 5, 10, 20, or
40 mg/L molybdenum as sodium molybdate dihydrate in distilled drinking water for 14 days.  Doses of 0, 
1.3, 2.6, 5.3, and 11 mg molybdenum/kg/day were estimated using a reference body weight of 0.0246 kg
and water intake of 0.0065 L/day.  The copper content of the commercial pellet diet was not reported, but
it was assumed to be adequate. The following parameters were used to assess reproductive toxicity:
ovarian weight, number of ovulations, oocyte ultrastructure, and oocyte quality.  
Effect noted in study and corresponding doses: A significant decrease in relative ovarian weight was 
observed at 11 mg molybdenum/kg/day; no information on body weight gain was reported.  Hyperemia
was noted in the ovaries of mice exposed to 5.3 or 11 mg molybdenum/kg/day; however, the incidence
and statistical significance was not reported.  A significant increase in the rate of abnormal MII oocytes 
(defined as the [number of total ovulations – number of normal MII oocytes]/number of total ovulations)
was observed at 11 mg molybdenum/kg/day.  At 1.3 mg molybdenum/kg/day, there was a significant
decrease in the number of abnormal oocytes and increase in the number of ovulations, which were 
considered beneficial effects. The oocyte abnormality rates are presented in Table A-10. The study also
found some significant alterations in superoxide dismutase (increased at 2.6 mg molybdenum/kg/day and 
decreased at 5.3 and 11 mg molybdenum/kg/day), glutathione peroxidase (increased at 1.3 and 2.6 mg
molybdenum/kg/day and decreased at 11 mg molybdenum/kg/day), and malondialdehyde (increased at
5.3 and 11 mg molybdenum/kg/day) levels.
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MOLYBDENUM A-21
APPENDIX A
Table A-10.  MII Oocyte Morphology Alterations in Female Mice Exposed to 

Sodium Molybdate for 14 Days
 






aMean ± standard deviation; n = 25/group.

bStatistically different from controls, p<0.01.
 
Source:  Zhang et al. 2013
Dose and end point used for MRL derivation: NOAEL of 5.3 and LOAEL of 11 mg molybdenum/kg/day
for an increase in the rate of MII oocyte abnormalities.
[X] NOAEL   [ ] LOAEL
BMD modeling was not used to identify a potential POD for the MRL. The plot of the rate of abnormal
oocyte morphology versus dose has a U-shaped curve anchored by the beneficial effect observed at
1.3 mg molybdenum/kg/day and the adverse effect observed 11 mg molybdenum/kg/day.  To accurately
define the shape of the curve and allow for estimating a BMD for the adverse effect, additional data
points would be needed. Thus, a NOAEL/LOAEL approach was used to identify the POD for the MRL. 
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Doses were 
estimated using the reported molybdenum concentration in the drinking water and reference drinking
water intakes and body weight of 0.0065 L/day and 0.0246 kg, respectively.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: Two other studies 
evaluated the reproductive toxicity of molybdenum following acute-duration oral exposure.  Significant
decreases in sperm concentration and motility and increases in sperm abnormalities were observed in
male mice exposed to 25 mg molybdenum/kg/day as sodium molybdate in drinking water for 14 days
(Zhai et al. 2013).  Bersenyi et al. (2008) reported reductions in mature spermatocytes in rabbits exposed 
to 0.58 mg molybdenum/kg/day as ammonium heptamolybdate in carrots; however, the incidence and 
statistical significance of the finding were not reported.  Bersenyi et al. (2008) also examined female 
rabbits exposed to 1.2 mg molybdenum/kg/day as ammonium heptamolybdate in the diet and found no 
histological alterations in the ovaries.  Male and female reproductive effects have also been observed in
***DRAFT FOR PUBLIC COMMENT***










   
 
 
   
    
   
      





rats following intermediate-duration oral exposure (Fungwe et al. 1990; Lyubimov et al. 2004; Pandey
and Singh 2002).  
Limited data are available on the systemic toxicity of molybdenum following acute oral exposure.  No 
alterations in uric acid levels were observed in volunteers administered 0.022 mg molybdenum/kg/day for
10 days (Deosthale and Gopalan 1974).  No histological alterations were observed in the liver and 
kidneys of rabbits exposed to 1.2 mg molybdenum/kg/day in the diet for 14 days (Bersenyi et al. 2008);
however, an increase in serum triglyceride levels was observed at this dose.
Agency Contacts (Chemical Managers): Dan Todd
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Profile Status: Final for Public Comment
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute   [X] Intermediate   [ ] Chronic
Graph Key: 24
Species: Rat
Minimal Risk Level: 0.008 [X] mg molybdenum/kg/day   [ ] ppm
The MRL is calculated based on the assumption of healthy dietary levels of molybdenum and copper and 
represents the level of exposure above and beyond the normal diet.  
Reference: Fungwe TV, Buddingh F, Demick DS, et al.  1990.  The role of dietary molybdenum on 
estrous activity, fertility, reproduction and molybdenum and copper enzyme activities of female rats.
Nutr Res 10:515-524.
Experimental design: Groups of 21 female Sprague-Dawley rats (21 days of age) were exposed to
drinking water containing 0, 5, 10, 50, or 100 mg/L molybdenum as sodium molybdate dihydrate; doses
of 0.76, 1.5, 7.6, and 15 mg molybdenum/kg/day were estimated using a reference water intake of
0.031 L/day and body weight of 0.204 kg (EPA 1988).  The diet contained 0.025 mg/kg molybdenum and 
6.3 mg/kg copper.  The investigators noted that the average molybdenum intake from the diet was
0.002 mg/kg/day (0.00028 mg/kg/day).  After 6 weeks of exposure, the estrous cycle was determined 
through three cycles by vaginal cytology and microscopic examination.  At the end of the third cycle, 
groups of 15 rats were mated with unexposed males.  
Effect noted in study and corresponding doses: No alterations in body weight gain were observed.  
Exposure to 1.5 mg/kg/day resulted a significant prolonging of the length of the estrus cycle. The 
investigators noted that the estrus phase appeared to be the most affected stage of estrous; it was extended
by 6–12 hours in the affected animals.  In the published paper, the estrous cycle length was presented in a
histogram; using GrabIt! software, Figure 1 of the Fungwe et al. (1990) paper was digitized; the estrous
cycle lengths are summarized in Table A-11.  No significant alterations in the conception rate were
observed. This study also reported several developmental effects in the rats exposed to ≥10 mg/L
molybdenum; effects included decreased total litter weight and increased number of resorption sites.
Because the copper content of the diet was lower than the recommended level of 8 ppm for gestational
exposure, this portion of the study was not considered suitable for MRL derivation. 
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Table A-11.  Estrous Cycle Length in Rats Exposed to Sodium Molybdate in the
 
Drinking Water for 6 Weeksa
 






aData extracted using GrabIt! Software from Figure 1 in the Fungwe et al. (1990) study.

bMean ± standard error.
 
cStatistically different from controls, p<0.05.
 
Source:  Fungwe et al. 1990
Dose and end point used for MRL derivation: The NOAEL and LOAEL values of 0.76 and 1.5 mg
molybdenum/kg/day were used as the POD for the MRL.
[X] NOAEL   [ ] LOAEL
BMD modeling of the estrous cycle length data in Table A-11 was conducted with EPA’s BMDS (version
2.5.0).  The following procedure for fitting continuous data was used.  The simplest model (linear) was
first applied to the data while assuming constant variance.  If the data were consistent with the assumption 
of constant variance (p≥0.1), then the fit of the linear model to the means was evaluated and the
polynomial, power, exponential, and Hill models were fit to the data while assuming constant variance.  
Adequate model fit was judged by three criteria: goodness-of-fit p-value (p>0.1), visual inspection of the
dose-response curve, and scaled residual at the data point (except the control) closest to the predefined
BMR.  If the test for constant variance was negative, the linear model was run again while applying the 
power model integrated into the BMDS to account for nonhomogenous variance.  If the nonhomogenous
variance model provided an adequate fit (p≥0.1) to the variance data, then the fit of the linear model to the
means was evaluated and the polynomial, power, exponential, and Hill models were fit to the data and 
evaluated while the variance model was applied.  If the test for constant variance was negative and the 
nonhomogenous variance model did not provide an adequate fit to the variance data, then the data set was
considered unsuitable for modeling.  A BMR of 1 SD change from the control was selected. The data set
for estrous cycle length was not adequate fit to the linear model under the assumption of constant variance
or nonhomogenous variance.  Thus, the NOAEL/LOAEL approach was used to identify the POD for the
MRL.
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Doses were 
calculated using the reported drinking water concentrations and references water intake and body weights
of 0.031 L/day and 0.204 kg.
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MOLYBDENUM A-25
APPENDIX A
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL:  Several studies have 
reported reproductive effects following intermediate-duration; a summary of these studies is presented in
Table A-12.




Duration NOAEL LOAEL Reference
(route) (mg Mo/kg/day) (mg Mo/kg/day) Effect (compound)
8 weeks 0.76 1.5 Prolonged estrus phase; no Fungwe et al. 1990
(drinking water) effect on female fertility (sodium molybdate)
≥8 weeks (diet) 7 No effect on fertility; male and Jeter and Davis 1954 
female rats were exposed (sodium molybdate)
59–61 days 1.5 4.4 Decreases in sperm motility Lyubimov et al. 2004 
(males), and sperm count, and (ammonium
22–35 days increased sperm morphology. tetrathiomolybdate)
(females) No effects in females
(gavage)
90 days (diet) 17 60 Decrease in percentage of Murray et al. 2013
progressive motile sperm. No (sodium molybdate)
significant alterations in other
sperm parameters. No 
alterations in vaginal cytology,
estrus cycle, or histology of
male or female reproductive 
tissues 
60 days 3.4a 10a Decreases in sperm count and Pandey and Singh 
(gavage) motility; increases in sperm 2002 (sodium
abnormalities molybdate)
60 days 10 Decreases in male fertility Pandey and Singh 
(gavage) 2002 (sodium
molybdate)
aAdjusted for intermittent exposure (5 days/week).
Other effects that have been observed at higher doses include kidney damage at ≥60 mg
molybdenum/kg/day (Bompart et al. 1990; Murray et al. 2013), neuromuscular effects at 54 mg
molybdenum/kg/day (Arrington and Davis 1953), and body weight (most studies did not report alterations
below 60 mg molybdenum/kg/day [Bompart et al. 1990; Mills et al. 1958; Murray et al. 2013; Van Reen 
and Williams 1956], although one study reported effects at 4.4 mg molybdenum/kg/day [Lyubimov et al. 
2004]).
Agency Contacts (Chemical Managers): Dan Todd
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B-1MOLYBDENUM
APPENDIX B.  FRAMEWORK FOR ATSDR’S SYSTEMATIC REVIEW OF 

HEALTH EFFECTS DATA FOR MOLYBDENUM
 
To increase the transparency of ATSDR’s process of identifying, evaluating, synthesizing, and 
interpreting the scientific evidence on the health effects associated with exposure to molybdenum, 
ATSDR utilized a slight modification of NTP’s Office of Health Assessment and Translation (OHAT)
systematic review methodology (NTP 2013, 2015; Rooney et al. 2014).  ATSDR’s framework is an eight-
step process for systematic review with the goal of identifying the potential health hazards of exposure to
molybdenum:
• Step 1.  Problem Formulation
• Step 2.  Literature Search and Screen for Health Effects Studies
• Step 3.  Extract Data from Health Effects Studies
• Step 4.  Identify Potential Health Effect Outcomes of Concern
• Step 5.  Assess the Risk of Bias for Individual Studies
• Step 6.  Rate the Confidence in the Body of Evidence for Each Relevant Outcome
• Step 7.  Translate Confidence Rating into Level of Evidence of Health Effects
• Step 8.  Integrate Evidence to Develop Hazard Identification Conclusions
B.1  PROBLEM FORMULATION
The objective of the toxicological profile and this systematic review was to identify the potential health 
hazards associated with inhalation, oral, or dermal/ocular exposure to molybdenum.  The inclusion 
criteria used to identify relevant studies examining the health effects of molybdenum are presented in 
Table B-1. 
Data from human and laboratory animal studies were considered relevant for addressing this objective.
Human studies were divided into two broad categories:  observational epidemiology studies and 
controlled exposure studies.  The observational epidemiology studies were further divided:  cohort studies
(retrospective and prospective studies), population studies (with individual data or aggregate data), and 
case-control studies.
B.2  LITERATURE SEARCH AND SCREEN FOR HEALTH EFFECTS STUDIES
A literature search and screen was conducted to identify studies examining the health effects of
molybdenum.  Studies for other sections of the toxicological profile were also identified in the literature 
search and screen step.  Although these studies were not included in the systematic review process, the
results of some studies (e.g., mechanistic studies, toxicokinetic studies) were considered in the final steps 
of the systematic review. ATSDR primarily focused on peer-reviewed articles without publication date or
language restrictions.  Non-peer-reviewed studies that were considered relevant to the assessment of the 
health effects of molybdenum have undergone peer review by at least three ATSDR-selected experts who
have been screened for conflict of interest.
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B.2.1  Literature Search
The following databases were searched, without date restrictions, in December 2014:
• PubMed 
• National Library of Medicine’s TOXLINE
• Scientist and Technical Information Network’s TOXCENTER
• National Pesticide Information Retrieval System (NPIRS)
• Toxic Substances Control Act Test Submissions (TSCATS) and TSCATS2 
Review articles were identified and used for the purpose of providing background information and 
identifying additional references.  ATSDR also identified reports from the grey literature, which included 
unpublished research reports, technical reports from government agencies, conference proceedings and 
abstracts, and theses and dissertations.
The search strategy used the chemical name, CAS numbers (i.e., 7439-98-7; 1317-33-5; 12033-29-3;
12033-33-9; 11098-99-0; 18868-43-4; 1313-27-5; 1313-29-7; 11098-84-3; 27546-07-2; 12054-85-2;
15060-55-6; 7631-95-0; 10102-40-6; 7789-82-4; 12011-97-1; 11119-46-3; 11062-51-4; 10241-05-1;
1309-56-4; 7783-77-9; 13939-06-5; 14221-06-8; 13814-74-9), synonyms, and Medical Subject
Headings (MeSH) terms for molybdenum.  A total of 9,217 records were identified and imported into 
EndNote (version 5).  After the identification and removal of 489 duplicates by EndNote, the
remaining 8,728 records were moved to the literature screening step.  
B.2.2  Literature Screening 
A two-step process was used to screen the literature search to identify relevant studies examining the 
health effects of molybdenum:
• Title and Abstract Screen
• Full Text Screen
Title and Abstract Screen. Within the Endnote library, titles and abstracts were screened manually for
relevance.  Studies that were considered relevant were moved to the second step of the literature 
screening process.  Studies were excluded when the title and abstract clearly indicated that the study did
not meet the inclusion criteria (Table B-1).  In the Title and Abstract Screen step, 8,728 records were 
reviewed; 219 studies were considered relevant to Section 3.2 of the toxicological profile and were moved 
to the next step in the process.
Full Text Screen. The second step in the literature screening process was a full text review of individual
studies considered relevant in the Title and Abstract Screen step.  Each study was reviewed to determine 
whether it met the inclusion criteria; however, the quality of the studies was not evaluated at this step of
the process.  Of the 219 studies undergoing Full Text Screen, 145 studies did not meet the inclusion 
criteria; some of the excluded studies were used as background information on toxicokinetics or
mechanisms of action or were relevant to other sections of the toxicological profile.
A summary of the results of the literature search and screening is presented in Figure B-1.
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B-4MOLYBDENUM
APPENDIX B
Figure B-1.  Literature Search and Screen for Molybdenum Health Effect Studies
aRed numbers will go up based on new records found during reference check (excluded not relevant will be new items cited but not in Section 3.2, articles
screened will go up based on new references cited in Section 3.2).
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B.3  EXTRACT DATA FROM HEALTH EFFECTS STUDIES
Relevant data extracted from the individual studies selected for inclusion in the systematic review were 
collected in customized data forms in Distiller.  A summary of the type of data extracted from each study
is presented in Table B-2.  For references that included more than one experiment or species, data
extraction records were created for each experiment or species.
A summary of the extracted data for each study is presented in the Supplemental Document for
Molybdenum and overviews of the results of the inhalation, and oral exposure studies are presented in
Section 3.2 of the profile and in the Levels Significant Exposures tables in Section 3.2 of the profile
(Tables 3-1 and 3-2, respectively).
B.4  IDENTIFY POTENTIAL HEALTH EFFECT OUTCOMES OF CONCERN 
Overviews of the potential health effect outcomes for molybdenum identified in human and animal
studies are presented in Tables B-3 and B-4, respectively.  The available human studies examined a
limited number of end points and reported respiratory, hepatic, endocrine, other systemic (alterations in 
uric acid levels), reproductive, and developmental effects.  Animal studies examined a number of end 
points following inhalation and oral exposure; no dermal exposure studies were identified.  These studies
examined most systemic end points and reported respiratory, gastrointestinal, hematological, 
musculoskeletal, hepatic, renal, endocrine, dermal, and body weight effects.  Additionally, animal studies
have reported neurological, reproductive, and developmental effects.  Although animal studies have 
identified a number of affected tissues and systems, interpretation of much of the data is limited by an 
inadequate amount of copper in the diet.  Studies in which the diet did not contain adequate levels of
copper were carried through Step 3 of the systematic review, but were not considered in the identification
of potential health effect outcomes of concern.  Additionally, body weight effects were not considered a
primary effect especially since most studies did not provide data on food intake; thus, this end point was
not considered in the assessment of potential human hazards.
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Table B-2.  Data Extracted From Individual Studies
Citation
Chemical form
Route of exposure (e.g., inhalation, oral, dermal)
Specific route (e.g., gavage in oil, drinking water)
Species
Strain
Exposure duration category (e.g., acute, intermediate, chronic)
Exposure duration
Frequency of exposure (e.g., 6 hours/day, 5 days/week)
Exposure length
Number of animals or subjects per sex per group 
Dose/exposure levels
Parameters monitored
Description of the study design and method
Summary of calculations used to estimate doses (if applicable)
Summary of the study results
Reviewer’s comments on the study
Outcome summary (one entry for each examined outcome)
No-observed-adverse-effect level (NOAEL) value
 
Lowest-observed-adverse-effect level (LOAEL) value
 
Effect observed at the LOAEL value
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Number of studies examining end point 0 1 2 3 4 5-9 ≥10
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Number of studies reporting outcome 0 1 2 3 4 5-9
 ≥10




























































































































Chronic-duration 2 22 2
Oral studies
Acute-duration 4 2 2 5 44 1 1 0 3






Number of studies examining end point 0 1 2 3 4 5-9 ≥10
Number of studies reporting outcome 0 1 2 3 4 5-9 ≥10
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B.5 ASSESS THE RISK OF BIAS FOR INDIVIDUAL STUDIES
B.5.1  Risk of Bias Assessment
The risk of bias of individual studies was assessed using OHAT’s Risk of Bias Tool (NTP 2015). The
risk of bias questions for observational epidemiology studies, human-controlled exposure studies, and 
animal experimental studies are presented in Tables B-5, B-6, and B-7, respectively.  Each risk of bias 
question was answered on a four-point scale:
• Definitely low risk of bias (++)
• Probably low risk of bias (+)
• Probably high risk of bias (-)
• Definitely high risk of bias (– –)
In general, “definitely low risk of bias” or “definitely high risk of bias” were used if the question could be
answered with information explicitly stated in the study report.  If the response to the question could be
inferred, then “probably low risk of bias” or “probably high risk of bias” responses were typically used.  
Table B-5.  Risk of Bias Questionnaire for Observational Epidemiology Studies
Selection bias
Were the comparison groups appropriate?
Confounding bias
Did the study design or analysis account for important confounding and modifying variables?
Attrition/exclusion bias
Were outcome data complete without attrition or exclusion from analysis?
Detection bias
Is there confidence in the exposure characterization?
Is there confidence in outcome assessment?
Selective reporting bias
Were all measured outcomes reported?
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Table B-6.  Risk of Bias Questionnaire for Human-Controlled Exposure Studies
Selection bias
Was administered dose or exposure level adequately randomized?
Was the allocation to study groups adequately concealed?
Performance bias
Were the research personnel and human subjects blinded to the study group during the study?
Attrition/exclusion bias
Were outcome data complete without attrition or exclusion from analysis?
Detection bias
Is there confidence in the exposure characterization?
Is there confidence in outcome assessment?
Selective reporting bias
Were all measured outcomes reported?
Table B-7.  Risk of Bias Questionnaire for Experimental Animal Studies
Selection bias
Was administered dose or exposure level adequately randomized?
 
Was the allocation to study groups adequately concealed?
 
Performance bias
Were experimental conditions identical across study groups?
 
Were the research personnel blinded to the study group during the study?
 
Attrition/exclusion bias
Were outcome data complete without attrition or exclusion from analysis?
Detection bias
Is there confidence in the exposure characterization?
 
Is there confidence in outcome assessment?
 
Selective reporting bias
Were all measured outcomes reported? 
Other bias
Did the study design or analysis account for important confounding and modifying variables?
This question addresses whether the copper levels of the diet met nutritional requirements.
After the risk of bias questionnaires were completed for the health effects studies, the studies were 
assigned to one of three risk of bias tiers based on the responses to the key questions listed below and the 
responses to the remaining questions.
•	 Is there confidence in the exposure characterization? (only relevant for observational studies)
•	 Is there confidence in the outcome assessment? 
•	 Does the study design or analysis account for important confounding and modifying variables?
(only relevant for observational studies)
First Tier. Studies placed in the first tier received ratings of “definitely low” or “probably low” risk of
bias on the key questions AND received a rating of “definitely low” or “probably low” risk of bias on the
responses to at least 50% of the other applicable questions.
***DRAFT FOR PUBLIC COMMENT***











         
 









Second Tier. A study was placed in the second tier if it did not meet the criteria for the first or third tiers.
Third Tier. Studies placed in the third tier received ratings of “definitely high” or “probably high” risk of
bias for the key questions AND received a rating of “definitely high” or “probably high” risk of bias on 
the response to at least 50% of the other applicable questions.
The results of the risk of bias assessment for the different types of molybdenum health effects studies 
(observational epidemiology, human experimental, and animal experimental studies) are presented in
Tables B-8, B-9, and B-10, respectively.
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Table B-8.  Summary of Risk of Bias Assessment for Molybdenum—Observational Epidemiology Studies
Risk of bias criteria and ratings
Confounding Attrition / Selective 
















































































































































































Outcome:  Respiratory effects
Cohort studies
Ott et al. 2004 – – + na + ++ Second
Walravens et al. 1979 – – + + – + Second
Outcome:  Hepatic effects
Cross-sectional studies
Mendy et al. 2012 + + + + – + Second
Outcome:  Alterations in Uric Acid Levels 
Cross-sectional studies
Koval’sky et al. 1961 – – + – + + Second
Cohort studies
Walravens et al. 1979 – – + + – + Second
Outcome:  Reproductive Effects
Cross-sectional studies
Lewis and Meeker 2015 na - + + + + First
Meeker et al. 2008 + + + ++ ++ ++ First
Meeker et al. 2010 + + ++ + ++ ++ First
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Table B-8.  Summary of Risk of Bias Assessment for Molybdenum—Observational Epidemiology Studies
Risk of bias criteria and ratings
Confounding Attrition / Selective 
















































































































































































Outcome:  Developmental Effects
Cross-sectional studies
Vazquez-Salas et al. 2014 + + + + ++ + First
Shirai et al. 2010 na – + + + + Second
++ = definitely low risk of bias; + = probably low risk of bias; – = probably high risk of bias; – – = definitely high risk of bias; na = not applicable
*Key question used to assign risk of bias tier.
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Table B-9.  Summary of Risk of Bias Assessment for Molybdenum—Human-Controlled Exposure Studies
Risk of bias criteria and ratings
Performance Attrition/ Selective 
Selection bias bias exclusion bias Detection bias reporting bias
Reference














































































































































































































Deosthale and Gopalan 1974 na + + + + + ++ First
++ = definitely low risk of bias; + = probably low risk of bias; – = probably high risk of bias; – – = definitely high risk of bias; na = not applicable
*Key question used to assign risk of bias tier.
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Table B-10.  Summary of Risk of Bias Assessment for Molybdenum—Experimental Animal Studies
Risk of bias criteria and ratings



























































































































































































































































































Outcome:  Respiratory effects
Inhalation acute exposure
NTP 1997 (rat) ++ + ++ + ++ ++ ++ ++ + First
NTP 1997 (mouse) ++ + ++ + ++ ++ ++ ++ + First
++ + ++ + ++ ++ ++ ++ + First
++ + ++ + ++ ++ ++ ++ + First
++ + ++ + ++ ++ ++ ++ + First
++ + ++ + ++ ++ ++ ++ + First
Inhalation intermediate exposure
NTP 1997 (rat) ++ + ++ + ++ ++ ++ ++ + First







Outcome:  Hepatic effects
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Table B-10.  Summary of Risk of Bias Assessment for Molybdenum—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 






















































































































































































































































































NTP 1997 (rat) ++ + ++ + ++ ++ ++ ++ + First
NTP 1997 (mouse) ++ + ++ + ++ ++ ++ ++ + First
Bersenyi et al. 2008 (rabbit) – + + – ++ – + + + First
Bersenyi et al. 2008 (rabbit) – + + – ++ – + + + First
Oral intermediate exposure
++ + ++ – ++ ++ ++ ++ ++
– + + – ++ + – ++ –
– + + – ++ – – + –
+ + – – ++ – + ++ –
+ + – – ++ + + ++ –
– + + – ++ – + + +
Oral acute exposure
Murray et al. 2013 (rat)
 




Rana and Kumar 1980b (rat)
 
Rana and Kumar 1980c (rat)
 
Rana and Kumar 1983 (rat)
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Table B-10.  Summary of Risk of Bias Assessment for Molybdenum—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 





















































































































































































































































































Rana et al. 1980 (rat) – + + – + – + + + First
Rana et al. 1985 (rat) + + + – ++ + + + + First
++ + ++ + ++ ++ ++ ++ + First
++ + ++ + ++ ++ ++ ++ + First
++ + ++ + ++ ++ ++ ++ + First
++ + ++ + ++ ++ ++ ++ + First
– + + – ++ – + + + First
– + + – ++ – + + + First
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Table B-10.  Summary of Risk of Bias Assessment for Molybdenum—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 


























































































































































































































































































Bompart et al. 1990 (rat)
 
Murray et al. 2013 (rat)
 
Rana et al. 1980 (rat)
 
Rana and Kumar 1980c
 
Rana and Kumar 1983 (rat)
 
– + + – ++ – + ++ ++
+ + + – ++ + + ++ +
++ + ++ – ++ ++ ++ ++ ++
– + + – + – + + +
+ + – – ++ – + ++ –
+ + – – ++ + + ++ –
Murray et al. 2013 (rat) ++ + ++ - ++ ++ ++ ++ ++ First
NTP 1997 (rat) ++ + ++ + ++ ++ ++ ++ + First







Outcome:  Alterations in Uric Acid Levels
Oral intermediate exposure
Outcome:  Reproductive effects
Inhalation intermediate exposure
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Table B-10.  Summary of Risk of Bias Assessment for Molybdenum—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 






















































































































































































































































































Zhang et al. 2013 (mouse)
Zhai et al. 2013 (mouse)
Bersenyi et al. 2008 (rabbit, 
males)
 




– + ++ – ++ – – + ++ –
– + ++ – ++ – – + ++ +
– + + – ++ – + + +
– + + – ++ – + + +
+ + + – ++ – + + – –
– + + – ++ – + + –
– + + – ++ – + + – –
+ + ++ – ++ + + ++ ++
++ + ++ – ++ ++ ++ ++ ++






Fungwe et al. 1990 (rat)
 








Lyubimov et al. 2004 (rat)
 
Murray et al. 2013 (rat)
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Table B-10.  Summary of Risk of Bias Assessment for Molybdenum—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 




















































































































































































































































































Pandey and Singh 2002 (rat
Reference
++ ++ ++
Jeter and Davis 1954 (rat, 
weanling) – + + – ++ – + + – –
First
Lyubimov et al. 2004 (rat) + + ++ – ++ + + ++ ++ First
Murray et al. 2014 (rat) ++ + + – ++ ++ + ++ + First
Pandey and Singh 2002 (rat) – + ++ – ++ + + ++ – First
First– + – –+ +fertility study)
Outcome:  Developmental effects
Oral intermediate exposure
++ = definitely low risk of bias; + = probably low risk of bias; – = probably high risk of bias; – – = definitely high risk of bias; na = not applicable
*Key question used to assign risk of bias tier.
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B.6  RATE THE CONFIDENCE IN THE BODY OF EVIDENCE FOR EACH RELEVANT
OUTCOME
Confidences in the bodies of human and animal evidence were evaluated independently for each potential
outcome.  ATSDR did not evaluate the confidence in the body of evidence for carcinogenicity; rather, the 
Agency defaulted to the cancer weight-of-evidence assessment of other agencies including DHHS, EPA,
and IARC.  The confidence in the body of evidence for an association or no association between exposure
to molybdenum and a particular outcome was based on the strengths and weaknesses of individual
studies.  Four descriptors were used to describe the confidence in the body of evidence for effects or when
no effect was found:
•	 High confidence: the true effect is highly likely to be reflected in the apparent relationship
•	 Moderate confidence: the true effect may be reflected in the apparent relationship
•	 Low confidence: the true effect may be different from the apparent relationship




Confidence in the body of evidence for a particular outcome was rated for each type of study: case-
control, case series, cohort, population, human-controlled exposure, and experimental animal.  In the
absence of data to the contrary, data for a particular outcome were collapsed across animal species, routes 
of exposure, and exposure durations.  If species (or strain), route, or exposure duration differences were
noted, then the data were treated as separate outcomes.
B.6.1 Initial Confidence Rating
In ATSDR’s modification to the OHAT approach, the body of evidence for an association (or no 
association) between exposure to molybendum and a particular outcome was given an initial confidence 
rating based on the key features of the individual studies examining that outcome. The presence of these 
key features of study design was determined for individual studies using four “yes or no” questions in 
Distiller, which were customized for epidemiology or experimental animal study designs. Separate 
questionnaires were completed for each outcome assessed in a study.  The key features for observational
epidemiology (cohort, population, and case-control) studies, human-controlled exposure studies, and 
experimental animal studies are presented in Tables B-11, B-12, and B-13, respectively.  The initial
confidence in the study was determined based on the number of key features present in the study design:
•	 High Initial Confidence: Studies in which the responses to the four questions were “yes”.
•	 Moderate Initial Confidence: Studies in which the responses to only three of the questions
were “yes”.
•	 Low Initial Confidence: Studies in which the responses to only two of the questions were “yes”.
•	 Very Low Initial Confidence: Studies in which the response to one or none of the questions
was “yes”.
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Exposure was experimentally controlled 
Exposure occurred prior to the outcome
Outcome was assessed on individual level rather than at the population level
A comparison group was used




A comparison group was used or the subjects served as their own control
A sufficient number of subjects were tested
Appropriate methods were used to measure outcomes (i.e., clinically-confirmed outcome versus self-
reported)
Appropriate statistical analyses were performed and reported or the data were reported in such a way to 
allow independent statistical analysis
Table B-13.  Key Features of Study Design for Experimental Animal Studies
A concurrent control group was used
A sufficient number of animals per group were tested
Appropriate parameters were used to assess a potential adverse effect
Appropriate statistical analyses were performed and reported or the data were reported in such a way to 
allow independent statistical analysis
The presence or absence of the key features and the initial confidence levels for studies examining
respiratory, gastrointestinal, renal, dermal, and ocular effects observed in the observational epidemiology, 
human experimental, and animal experimental studies are presented in Tables B-14, B-15, and B-16, 
respectively.
A summary of the initial confidence ratings for each outcome is presented in Table B-17.  If individual
studies for a particular outcome and study type had different study quality ratings, then the highest
confidence rating for the group of studies was used to determine the initial confidence rating for the body 
of evidence; any exceptions were noted in Table B-17.
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Outcome:  Respiratory effects
Cohort studies
Ott et al. 2004
Walravens et al. 1979
No Yes Yes No Low
No No No No Very Low
No No Yes Yes Low
No No Yes Yes Low
No No Yes Yes Low
No No Yes Yes
Outcome:  Hepatic effects
Cross-sectional studies
Mendy et al. 2012 No No Yes Yes Low
Outcome:  Alterations in Uric Acid Levels
Cross-sectional studies
Koval’sky et al. 1961 No Yes Yes No Low
Cohort studies
Walravens et al. 1979 No No No No Very Low
Outcome:  Reproductive Effects
Cross-sectional studies
Lewis and Meeker 2015
Meeker et al. 2008
Meeker et al. 2010
Outcome:  Developmental Effects
Cross-sectional studies
Vazquez-Salas et al. 2014 No No Yes Yes Low
Shirai et al. 2010 Low
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Outcome:  Alterations in Uric Acid Levels
Oral acute exposure
Deosthale and Gopalan 1974 Yes No Yes No Low
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Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes No Yes Yes Moderate
Yes No Yes Yes Moderate
Yes Yes Yes Yes High
Yes Yes No Yes
Yes Yes No Yes
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Bersenyi et al. 2008 (rabbit, males)
Bersenyi et al. 2008 (rabbit, females)
Oral intermediate exposure
Murray et al. 2013 (rat)
Rana and Chauhan 2000 (rat)
Rana and Kumar 1980b (rat)
Rana and Kumar 1980c (rat)
Rana and Kumar 1983 (rat)
Rana and Prakash 1986 (rat)
Rana et al. 1980 (rat)
Rana et al. 1985 (rat)
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Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes No Yes Yes Moderate
Yes No Yes Yes Moderate
Yes No Yes No Low
Yes No Yes Yes Moderate
Yes Yes Yes Yes High
Yes Yes No No Low
Yes Yes No Yes Moderate
Yes Yes No Yes Moderate
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes No Yes Moderate
Yes Yes No Yes Moderate
Yes No No Yes Low
Yes No No No Very Low
Yes No Yes Yes Moderate
Yes No No No Very Low
Yes No No No Very Low
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes No Yes Moderate
Yes Yes Yes Yes High
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Bersenyi et al. 2008 (rabbit, males)
Bersenyi et al. 2008 (rabbit, females)
Oral intermediate exposure
Bandyopadhyay et al. 1981 (rat)
Bompart et al. 1990 (rat)
Murray et al. 2013 (rat)
Rana et al. 1980 (rat)
Rana and Kumar 1980c
Rana and Kumar 1983 (rat)
Outcome:  Alterations in Uric Acid Levels
Oral intermediate exposure
Murray et al. 2013 (rat)





Zhang et al. 2013 (mouse)
Zhai et al. 2013 (mouse)
Bersenyi et al. 2008 (rabbit, males)
Bersenyi et al. 2008 (rabbit, females)
Oral intermediate exposure
Fungwe et al. 1990 (rat)
Jeter and Davis 1954 (rat, adult)
Jeter and Davis 1954 (rat, weanlings)
Lyubimov et al. 2004 (rat)
Murray et al. 2013 (rat)
Pandey and Singh 2002 (rat)
Pandey and Singh 2002 (rat, fertility study)
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Outcome:  Developmental effects
Oral intermediate exposure
Jeter and Davis 1954 (rat, weanling) Yes No No No Very Low
Lyubimov et al. 2004 (rat) Yes Yes Yes Yes High
Murray et al. 2014 (rat) Yes Yes Yes Yes High
Pandey and Singh 2002 (rat) Yes Yes Yes Yes High
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Table B-17.  Initial Confidence Rating for Molybdenum Health Effects Studies
Initial study Initial confidence
confidence rating




Ott et al. 2004
























Outcome:  Hepatic effects
Human studies
Cross-sectional studies

















Bersenyi et al. 2008 (rabbit, males)






Murray et al. 2013 (rat) High
Rana and Chauhan 2000 (rat) Moderate
Rana and Kumar 1980b (rat) Moderate
Rana and Kumar 1980c (rat) Moderate High
Rana and Kumar 1983 (rat) Moderate
Rana and Prakash 1986 (rat) Moderate
Rana et al. 1980 (rat) Low
Rana et al. 1985 (rat) Moderate
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Table B-17.  Initial Confidence Rating for Molybdenum Health Effects Studies
Initial study Initial confidence
confidence rating

















Bersenyi et al. 2008 (rabbit, males)






Bandyopadhyay et al. 1981 (rat) Low
Bompart et al. 1990 (rat) Moderate
Murray et al. 2013 (rat)




Rana and Kumar 1980c Moderate
Rana and Kumar 1983 (rat) Moderate
Outcome:  Alterations in Uric Acid Levels
Human studies
Cross-sectional studies
Koval’sky et al. 1961 Low Low
Cohort studies




Deosthale and Gopalan 1974 Low Low
Oral intermediate exposure
Animal studies
Murray et al. 2013 (rat) High High
Outcome:  Reproductive Effects
Human studies
Cross-sectional studies
Lewis and Meeker 2015 Low
Meeker et al. 2008 Low Low
Meeker et al. 2010 Low
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Table B-17.  Initial Confidence Rating for Molybdenum Health Effects Studies











Zhang et al. 2013 (mouse) Moderate
Zhai et al. 2013 (mouse)




Bersenyi et al. 2008 (rabbit) Very Low
Oral intermediate exposure
Animal studies
Fungwe et al. 1990 (rat) Moderate
Jeter and Davis 1954 (rat, adult) Very Low
Jeter and Davis 1954 (rat, weanling) Very Low
Lyubimov et al. 2004 (rat) High High
Murray et al. 2013 (rat) High
Pandey and Singh 2002 (rat) Moderate
Pandey and Singh 2002 (rat, fertility study) High
Outcome:  Developmental Effects
Human studies
Cross-sectional studies
Vazquez-Salas et al. 2014 Low Low
Shirai et al. 2010 Low
Oral intermediate exposure
Animal studies
Jeter and Davis 1954 (rat, weanling) Very Low
Lyubimov et al. 2004 (rat) High High
Murray et al. 2014 (rat) High
Pandey and Singh 2002 (rat) High
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B.6.2 Adjustment of the Confidence Rating 
The initial confidence rating was then downgraded or upgraded depending on whether there were
substantial issues that would decrease or increase confidence in the body of evidence. The nine properties 
of the body of evidence that were considered are listed below. The summaries of the assessment of the 
confidence in the body of evidence for respiratory, hepatic, renal, alterations in uric acid levels, 
reproductive and developmental effects are presented in Table B-18. If the confidence ratings for a 
particular outcome were based on more than one type of human study, then the highest confidence rating
was used for subsequent analyses.  An overview of the confidence in the body of evidence for all health 
effects associated with molybdenum exposure is presented in Table B-19.
Five properties of the body of evidence were considered to determine whether the confidence rating
should be downgraded:
•	 Risk of bias. Evaluation of whether there is substantial risk of bias across most of the studies 
examining the outcome.  This evaluation used the risk of bias tier groupings for individual studies
examining a particular outcome (Tables B-14, B-15, and B-16).  Below are the criteria used to
determine whether the initial confidence in the body of evidence for each outcome should be
downgraded for risk of bias:
o	 No downgrade if most studies are in the risk of bias first tier
o	 Downgrade one confidence level if most studies are in the risk of bias second tier
o	 Downgrade two confidence levels if most studies are in the risk of bias third tier
•	 Unexplained inconsistency. Evaluation of whether there is inconsistency or large variability in
the magnitude or direction of estimates of effect across studies that cannot be explained.  Below
are the criteria used to determine whether the initial confidence in the body of evidence for each 
outcome should be downgraded for unexplained inconsistency:
o	 No downgrade if there is little inconsistency across studies or if only one study evaluated 
the outcome
o	 Downgrade one confidence level if there is variability across studies in the magnitude or
direction of the effect
o	 Downgrade two confidence levels if there is substantial variability across studies in the 
magnitude or direct of the effect
•	 Indirectness. Evaluation of four factors that can affect the applicability, generalizability, and 
relevance of the studies:
o	 Relevance of the animal model to human health—unless otherwise indicated, studies in
rats, mice, and other mammalian species are considered relevant to humans 
o	 Directness of the end points to the primary health outcome—examples of secondary
outcomes or nonspecific outcomes include organ weight in the absence of histopathology
or clinical chemistry findings in the absence of target tissue effects
o	 Nature of the exposure in human studies and route of administration in animal studies— 
inhalation, oral, and dermal exposure routes are considered relevant unless there are
compelling data to the contrary
o	 Duration of treatment in animal studies and length of time between exposure and
outcome assessment in animal and prospective human studies—this should be considered
on an outcome-specific basis
Below are the criteria used to determine whether the initial confidence in the body of evidence for
each outcome should be downgraded for indirectness:
o	 No downgrade if none of the factors are considered indirect
o	 Downgrade one confidence level if one of the factors is considered indirect
***DRAFT FOR PUBLIC COMMENT***
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o	 Downgrade two confidence levels if two or more of the factors are considered indirect
•	 Imprecision. Evaluation of the narrowness of the effect size estimates and whether the studies 
have adequate statistical power.  Data are considered imprecise when the ratio of the upper to
lower 95% CIs for most studies is ≥10 for tests of ratio measures (e.g., odds ratios) and ≥100 for
absolute measures (e.g., percent control response).  Adequate statistical power is determined if
the study can detect a potentially biologically meaningful difference between groups (20%
change from control response for categorical data or risk ratio of 1.5 for continuous data).  Below
are the criteria used to determine whether the initial confidence in the body of evidence for each 
outcome should be downgraded for imprecision:
o	 No downgrade if there are no serious imprecisions
o	 Downgrade one confidence level for serious imprecisions
o	 Downgrade two confidence levels for very serious imprecisions 
•	 Publication bias. Evaluation of the concern that studies with statistically significant results are 
more likely to be published than studies without statistically significant results.
o	 Downgrade one level of confidence for cases where there is serious concern with
publication bias
Four properties of the body of evidence were considered to determine whether the confidence rating
should be upgraded:
• Large magnitude of effect. Evaluation of whether the magnitude of effect is sufficiently large
so that it is unlikely to have occurred as a result of bias from potential confounding factors.
o	 Upgrade one confidence level if there is evidence of a large magnitude of effect in a few
studies, provided that the studies have an overall low risk of bias and there is no serious
unexplained inconsistency among the studies of similar dose or exposure levels;
confidence can also be upgraded if there is one study examining the outcome, provided 
that the study has an overall low risk of bias
•	 Dose response. Evaluation of the dose-response relationships measured within a study and 
across studies. Below are the criteria used to determine whether the initial confidence in the body
of evidence for each outcome should be upgraded:
o	 Upgrade one confidence level for evidence of a monotonic dose-response gradient
o	 Upgrade one confidence level for evidence of a non-monotonic dose-response gradient
where there is prior knowledge that supports a non-monotonic dose-response and a non-
monotonic dose-response gradient is observed across studies
•	 Plausible confounding or other residual biases. This factor primarily applies to human studies 
and is an evaluation of unmeasured determinants of an outcome such as residual bias towards the 
null (e.g., “healthy worker” effect) or residual bias suggesting a spurious effect (e.g., recall bias).
Below is the criterion used to determine whether the initial confidence in the body of evidence for
each outcome should be upgraded:
o	 Upgrade one confidence level for evidence that residual confounding or bias would 
underestimate an apparent association or treatment effect (i.e., bias toward the null) or 
suggest a spurious effect when results suggest no effect
•	 Consistency in the body of evidence. Evaluation of consistency across animal models and 
species, consistency across independent studies of different human populations and exposure
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MOLYBDENUM B-33
APPENDIX B
scenarios, and consistency across human study types. Below is the criterion used to determine 
whether the initial confidence in the body of evidence for each outcome should be upgraded:
o Upgrade one confidence level if there is a high degree of consistency in the database
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Table B-18. Adjustments to the Initial Confidence in the Body of Evidence
Initial confidence Adjustments to the initial confidence rating Final confidence
Outcome:  Respiratory Effects
Cohort studies Low -1 risk of bias; -1 imprecision Very low
Animal studies High +1 magnitude High
Outcome:  Hepatic Effects
Cross-sectional studies Low -1 risk of bias Very low
Animal studies High -1 indirectness (secondary outcomes); Moderate
Outcome:  Renal Effects
Animal studies High None High
Outcome:  Alterations in Uric Acid Levels
Cross-sectional studies Low -1 risk of bias Very low
Cohort studies Very Low -1 risk of bias Very low
Human controlled exposure studies Low None Low
Animal studies High None High
Outcome:  Reproductive Effects
Cross-sectional studies Low None Low
Animal studies High -1 inconsistency Moderate
Outcome:  Developmental Effects
Cross-sectional studies Low None Low
Animal studies High -1 inconsistency Moderate
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Table B-19.  Confidence in the Body of Evidence for Molybdenum
Confidence in body of evidence
Outcome Human studies Animal studies
Respiratory effects Very low High
Hepatic effects Very low Moderate
Renal effects No data High
Alterations in uric acid levels Low High
Reproductive Effects Low Moderate
Developmental effects Low Moderate
B.7  TRANSLATE CONFIDENCE RATING INTO LEVEL OF EVIDENCE OF HEALTH 
EFFECTS
In the seventh step of the systematic review of the health effects data for molybdenum, the confidence in
the body of evidence for specific outcomes was translated to a level of evidence rating. The level of
evidence rating reflected the confidence in the body of evidence and the direction of the effect (i.e.,
toxicity or no toxicity); route-specific differences were noted. The level of evidence for health effects 
was rated on a five-point scale:  
•	 High level of evidence: High confidence in the body of evidence for an association between 
exposure to the substance and the health outcome
•	 Moderate level of evidence: Moderate confidence in the body of evidence for an association
between exposure to the substance and the health outcome
•	 Low level of evidence: Low confidence in the body of evidence for an association between 
exposure to the substance and the health outcome
•	 Evidence of no health effect: High confidence in the body of evidence that exposure to the
substance is not associated with the health outcome
•	 Inadequate evidence: Low or moderate confidence in the body of evidence that exposure to the
substance is not associated with the health outcome or very low confidence in the body of
evidence for an association between exposure to the substance and the health outcome
A summary of the level of evidence of health effects for molybdenum is presented in Table B-20.
***DRAFT FOR PUBLIC COMMENT***



















    
  
 
    
     






     
     
    
  
 
    
     
     
 
 
   
 
      





   
     
 
   
 
   
     
 
 
    
     
     
    
 
 
      
    
 
 
      















Very low Health effect Inadequate
Hepatic effects Very low Health effect Inadequate
Renal effects No data No data No data
Alterations in uric acid 
levels
Low Health effect Inadequate
Reproductive effects Low Health effect Low




High Health effect High
Hepatic effects Moderate Health effect Moderate
Renal effects High Health effect High
Alterations in uric acid 
levels
High No effect Evidence of no health 
effect
Reproductive effects Moderate Health effect Moderate
Developmental effectsa Moderate Health effect
No health effect
High
Evidence of no health 
effect
aMixed results were found in animal studies reporting developmental effects; three studies reported no effects and 
one study reported an effect.
B.8 INTEGRATE EVIDENCE TO DEVELOP HAZARD IDENTIFICATION CONCLUSIONS
The final step involved the integration of the evidence streams for the human studies and animal studies 
to allow for a determination of hazard identification conclusions.  For health effects, there were four
hazard identification conclusion categories:
•	 Known to be a hazard to humans
•	 Presumed to be a hazard to humans
•	 Suspected to be a hazard to humans
•	 Not classifiable as to the hazard to humans 
The initial hazard identification was based on the highest level of evidence in the human studies and the 
level of evidence in the animal studies; if there were no data for one evidence stream (human or animal),
then the hazard identification was based on the one data stream (equivalent to treating the missing
evidence stream as having low level of evidence). The hazard identification scheme is presented in
Figure B-2 and described below:
•	 Known: A health effect in this category would have:
o	 High level of evidence for health effects in human studies AND a high, moderate, or low
level of evidence in animal studies.
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•	 Presumed: A health effect in this category would have:
o	 Moderate level of evidence in human studies AND high or moderate level of evidence in
animal studies OR
o	 Low level of evidence in human studies AND high level of evidence in animal studies
•	 Suspected: A health effect in this category would have:
o	 Moderate level of evidence in human studies AND low level of evidence in animal
studies OR
o	 Low level of evidence in human studies AND moderate level of evidence in animal
studies
•	 Not classifiable: A health effect in this category would have:
o	 Low level of evidence in human studies AND low level of evidence in animal studies
Other relevant data such as mechanistic or mode-of-action data were considered to raise or lower the level
of the hazard identification conclusion by providing information that supported or opposed biological
plausibility.
Two hazard identification conclusion categories were used when the data indicated that there may be no 
health effect in humans:
•	 Not identified to be a hazard in humans
•	 Inadequate to determine hazard to humans
If the human level of evidence conclusion of no health effect was supported by the animal evidence of no 
health effect, then the hazard identification conclusion category of “not identified” was used.  If the
human or animal level of evidence was considered inadequate, then a hazard identification conclusion 
category of “inadequate” was used.  As with the hazard identification for health effects, the impact of
other relevant data was also considered for no health effect data.  
The hazard identification conclusions for molybdenum are listed below and summarized in Table B-21.
Presumed Health Effects
•	 Respiratory effects following inhalation exposure to molybdenum oxides
o	 Inadequate evidence from studies of molybdenum oxide workers (Ott et al. 2004;
Walravens et al. 1979).
o	 High level of evidence from chronic exposure studies in rats and mice (NTP 1997).
•	 Renal effects
o	 No data in humans.
o	 High level of evidence of histological alterations in kidneys, alterations in renal function,
and/or increased lipid levels in the kidneys in orally exposed rats (Bandyopadhyay et al.
1981; Bompart et al. 1990; Murray et al. 2013; Rana and Kumar 1980c, 1983; Rana et al.
1980).
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Table B-21.  Hazard Identification Conclusions for Molybdenum
Outcome Hazard identification 
Respiratory effects Presumed health effect following inhalation exposure
Hepatic effects Suspected health effect
Renal effects Presumed health effect
Alterations in uric acid levels Not classifiable as a hazard to humans
Reproductive effects Suspected health effect
Developmental effects Not classifiable as a hazard to humans
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Level of evidence for health effects in animal studies
Suspected Presumed
Not Classifiable Suspected Presumed
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o	 Inadequate evidence of increased risk of self-reported liver conditions from a cross-
sectional study (Mendy et al. 2012).
o	 Moderate evidence of increases in clinical chemistry parameters and/or liver lipid levels
in rabbits following acute oral exposure (Bersenyi et al. 2008) or rats exposed orally
exposed to high doses (Rana and Chauhan 2000; Rana and Kumar 1980b, 1980c, 1983;
Rana and Prakash 1986; Rana et al. 1980, 1985).
•	 Reproductive effects
o	 Low level of evidence of male reproductive effects in cross-sectional studies (Lewis and
Meeker 2015; Meeker et al. 2008, 2010).
o	 Moderate level of evidence of male and/or female reproductive effects in orally exposed
rats (Fungwe et al. 1990; Lyubimov et al. 2004; Murray et al. 2013; Pandey and Singh 
2002), mice (Zhai et al. 2013; Zhang et al. 2013), and rabbits (Bersenyi et al. 2008).  
Not Classifiable as a Hazard to Humans
•	 Alterations in uric acid levels
o	 Low evidence of an effect in cross-sectional studies (Koval’skiy et al. 1961; Walravens et
al. 1979).
o	 High confidence in an animal study not finding an effect (Murray et al. 2013).
•	 Developmental effects
o	 Low evidence of an effect in a cross-sectional study.  Two cross-sectional studies 
reported no alterations in newborn body weight (Shirai et al. 2010; Vazquez-Salas et al.
2014); one study reported decreases in psychomotor development indices (Vazquez-Salas 
et al. 2014).
o	 Three studies in rats did not find alterations in resorptions, post-implantation losses, or
fetal body weights (Jeter and Davis 1954; Lyubimov et al. 2004; Murray et al. 2014); the
initial confidence levels for these studies were high, high, and very low.  A fourth study
(initial high confidence level) involving male-only exposure found decreases in number
of live fetuses and fetal body weights (Pandey and Singh 2002).  
o	 The animal studies had different study designs (male only, female only, male and female 
exposure) making a comparison across studies difficult.  Additionally, none of the animal
studies evaluated potential neurodevelopmental effects, which were observed in an 
epidemiology study.  Thus, the available data were not considered adequate for drawing a
conclusion on the potential developmental toxicity of molybdenum in humans.
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C-1MOLYBDENUM
APPENDIX C.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions:
1.	 What effects are known to occur in humans?
2.	 What effects observed in animals are likely to be of concern to humans?
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
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MRLs should help physicians and public health officials determine the safety of a community living near
a hazardous substance emission, given the concentration of a contaminant in air or the estimated daily
dose in water.  MRLs are based largely on toxicological studies in animals and on reports of human 
occupational exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement,
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in
conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.
***DRAFT FOR PUBLIC COMMENT***











   
 
 




   
 
  
      




    
      
   
 
 











    
    
   
  
    
 
 
     
 
     
   
 
 
     






See Sample LSE Table 3-1 (page C-6)
(1)	 Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2)	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable
exposure period within the LSE table and figure.
(3)	 Health Effect. The major categories of health effects included in LSE tables and figures include 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4)	 Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5)	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6)	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen,
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7)	 System.  This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8)	 NOAEL.  A NOAEL is the highest exposure level at which no adverse effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
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(9)	 LOAEL.  A LOAEL is the lowest dose used in the study that caused an adverse health effect.
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile.
(11)	 CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in
experimental or epidemiologic studies.  CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12)	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page C-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health
effects observed within the acute and intermediate exposure periods are illustrated.
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data
exists. The same health effects appear in the LSE table.
(15)	 Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.
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(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).
(19)	 Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
























    
      


































































































































































→	 Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)Exposure 
Less serious Serious (ppm)Key to 	 frequency/ NOAEL
(ppm)figurea Species duration System (ppm)	 Reference
→	 INTERMEDIATE EXPOSURE
5 6 7 8 9 10



























10	 (CEL, lung tumors,
nasal tumors)
10	 (CEL, lung tumors,
hemangiosarcomas)
↓
Nitschke et al. 1981
Wong et al. 1982
NTP 1982
NTP 1982
→	 a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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D-1MOLYBDENUM
APPENDIX D. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software 
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
DOT Department of Transportation
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D-2MOLYBDENUM
APPENDIX D
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg kilokilogram; 1 kilokilogram is equivalent to 1,000 kilograms and 1 metric ton
Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
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D-3MOLYBDENUM
APPENDIX D
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
mt metric ton
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
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OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic 
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
PEL-C permissible exposure limit-ceiling value
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
REL-C recommended exposure level-ceiling value
RfC reference concentration (inhalation)
RfD reference dose (oral)
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase (same as aspartate aminotransferase or AST)
SGPT serum glutamic pyruvic transaminase (same as alanine aminotransferase or ALT)
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TLV-C threshold limit value-ceiling value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
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WHO World Health Organization
> greater than
≥ greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
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